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Bovine tuberculosis (bTB), caused by Mycobacterium bovis imposes a significant financial 
burden on the global cattle industry. Although considerable effort is being spent developing 
vaccines for bTB disease prevention and control, a licensed vaccine for use in cattle has yet 
to emerge. Mycobacterial cell envelope antigens are known to interact with the host immune 
system and contribute to TB pathogenesis.  Thus, a better understanding of the effects of M. 
bovis cell envelope antigens on the bovine immune system will aid the rational development 
of effective bTB vaccines. In this thesis, I first report a comparative analysis of the immune-
stimulatory effects of various fractions of the M. bovis cell envelope on bovine dendritic 
cells (bDCs), which are key immune cells required for TB control by the host. I found that 
the cell surface sugar extract (CSSE) fraction is the least immune-stimulatory suggesting 
that this fraction might contain an immunosuppressive molecule. Given that CSSE fractions 
of the M. tuberculosis complex are enriched in phenolic glycans, including para-hydroxy 
benzoic acid derivatives (p-HBADs), which are known to have immunosuppressive 
properties, I then examined the immunomodulatory effects of p-HBAD-1, the major p-
HBAD made by M. bovis on bDCs. I found that p-HBAD-1 has opposing effects in non-
primed and IFN-γ primed bDCs in vitro. In non-primed bDCs, p-HBAD-I induces a 
tolerogenic response, while a pro-inflammatory response is observed with IFN- primed 
bDCs. These findings suggest that M. bovis p-HBAD-I is an immune-regulatory molecule 
that might have a dual function in bTB pathogenesis. Finally, I successfully prepared 
plasmid constructs required to disrupt the gene encoding a key enzyme involved in p-HBAD 
synthesis in M. bovis. These will be used in future efforts to generate an M. bovis mutant 




I have had the opportunity to know and work with incredible people who have helped me reach 
my academic and professional goals. The work shown in this thesis would not have been 
possible without support from many different individuals to whom I am greatly indebted.  I will 
begin by thanking my supervisors, Drs. Jeffrey Chen and Andrew Potter for tirelessly working 
with me to conceive the ideas that shaped this work and provided valuable insights that allowed 
me to move forward and enriched my experience as a Ph.D. student. I also would like to 
appreciate the effort of all the members of my research committee: Dr. V. Gerdts, Dr. V. Misra, 
Dr. J. Gordon and Dr. E. Jenkins, for their excellent suggestions and inputs throughout my study.  
My laboratory work would not have been successful without the support of Dr. Chen’s lab 
members. Thanks to Ze Lim and Marlene Snider for your help during my entire Ph.D. program, 
especially for your significant contributions to my research work. Thanks to Kylee Drever, Slim 
Zriba, Zoe Sereggela, Beatrice Chung and Niroula Nirajan for supporting me on my laboratory 
work. To VIDO animal care technicians (especially Evans Brock), I appreciate your time and 
effort in helping me collect blood for all my in vitro lab experiments. I also acknowledge Yurij 
Popowych for teaching me and helping me to collect and analyze flow cytometry data. In 
addition, many thanks to Dr. Eoin Scanlan (Trinity College Dublin), who generously provided 
the pure synthetic p-HBAD-1 for my experiments. 
To my daughter (Nnenna Ajaeroh), siblings-especially Dr. John Ihedioha, my parents and 
friends (Tochukwu Eugene), thank you for encouraging and supporting me. Thesis dedicated to 




TABLE OF CONTENTS 
PERMISSION TO USE POST-GRADUATE THESIS……………………………..….i 
ABSTRACT ……………………………………………………………………..………..ii 
ACKNOWLEDGEMENTS……………………………………………………………...iii 
TABLE OF CONTENTS……………………………………………………..….……….iv 
LIST OF TABLES ………………………………………………………………..…...….x 
LIST OF FIGURES…………………………………………………………….…..….....xi 
LIST OF ABBREVIATIONS…………………………………………………..……... xiii 
CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW………………...….1 
1.1 Mycobacteria tuberculosis complex………………………………………….…...…...1 
1.2 Mycobacterium bovis (M. bovis)…………………………………………………...…..1 
1.2.1 Prevalence and financial implication in the cattle industry…………...…....2 
1.2.2 Diagnosis…………………………………………………………….….….3 
1.2.3 Control………………………………………………………...………........4 
1.3 Mycobacterium bovis cell wall antigens…………………………………...……...…..6 
1.3.1 Bovine purified protein derivatives (bPPD)…………………....…….….…8 
1.3.2 Cell wall Lipids (CWL)……………………………..…………….…...…...8 
1.3.3 Cell surface sugar extract (CSSE)………………………..………….…….10 
1.3.4 Phenolic glycoconjugates…………………………………….……...….....10 
1.4 Pathogenesis of Mycobacterium bovis……………………………………...………...12 
1.5 The immune system………………………………………………………..………....15 
1.5.1 Innate immune response against M. bovis……………………..…...…….…...16 
1.5.2 Cell-mediated immune response against M. bovis……………….….….…... 17  
1.6 Innate immune cells………………………………………………………………… 18 
1.6.1 Macrophages………………………………………………………...….... 18 
1.6.1.1 Lung macrophages origin and development…………………..…. 18 
1.6.1.2  Macrophage phenotype and role in mycobacteria infection…...... 19  
1.6.2 Dendritic cell……………………………………………………...…........ 21 
1.6.2.1 Dendritic development and activation………………...…….…... 21 
1.6.2.2 Role of dendritic cell in mycobacterial infection……………........22 
1.6.2.3  Dendritic cells activation markers…………..……………....….....23 
v 
 
 1.6.2.3.1 Antigen-presenting molecules and mycobacterial 
infection………………………….…………………..……..…. .24 
1.6.2.3.2 Co-stimulatory molecules and mycobacterial 
infection……………………………………….……………... 26 
1.6.2.4 Regulatory DCs and effect on the immune response to  
mycobacterial infection……………………………………...…. 27 
1.6.1.4.1  Inhibitory markers expressed by  
regulatory dendritic cells……….………. 29 
1.6.1.4.1.1  Programmed death-ligand 1 and role  
in mycobacterial infection .……………...29 
1.6.1.4.1.2  Indoleamine 2,3-dioxygenase and 
 role in mycobacterial infection.…….….. 30 
1.7 Innate immune receptors…………………………………………………..……... 31 
1.71 Dendritic cell-specific intercellular adhesion molecule 3 grabbing  
nonintegrin (DC-SIGN) receptors……………..…………….…………… 32 
1.71.1 Toll-like receptors………………………………...………...…...33 
1.71.1.1  Toll-like receptor 2……………….…………..……….34 
1.71.1.2  Toll-like receptors 4……………….............……….....35 
1.71.1.3  Toll-like receptor 9………………………..……..…... 36 
1.8 Toll-like receptor signaling………………………………..……………….…... .37 
1.9 Categories of Toll-like receptor agonists…………………….………..….…......38 
1.9.1 Lipopolysaccharide (LPS)……………………..………………..………38 
1.9.2 Flagellin………………..……………………………………………......39 
1.9.3 Polyinosinic-polycytidylic acid (poly I:C)……….…………………... ..39 
1.9.4 Imiquimod and Single stranded-RNA (ssRNA40)……….……….…… 40 
1.9.5 Pam3CSK4………………………………….……..……………........ ...41 
1.9.6 CpG oligodeoxynucleotides (ODN)………………………………...…. 41 
1.10 Immune signaling pathways for cytokine production……………...……..…... 42 
1.10.1 Extracellular signal-regulated kinase  (ERK) signaling 
pathway………………………………………………………….….......42 
1.10.2 Signal transducer and activator of transcription (STAT) signaling 
pathway………………………………………………………..……..... 43 
1.10.3 Nuclear factor-kappa B- signaling pathway………………………...…. 45 
1.11   Role of the cytokine signaling pathway in mycobacterial infection…...............46 
1.12   Cytokines……………………………………………...………………..........…... .47 
1.12.1 Pro-inflammatory cytokines………………………………………..…....48 
1.12.1.1 Interleukin 12 and mycobacterial infection…..…….... 48 




1.12.1.3 Role of interleukin 6 in mycobacterial infection…......50 
1.12.1.4 Role of interleukin 1 in mycobacterial infection…....51 
1.12.1.5 Interferon-gamma (IFN-) and biological   
significance………………………………………………........52 
1.12.2 Anti-inflammatory cytokines…………….…………………….............53 
1.12.2.1 Interleukin 10 and regulation in mycobacterial 
infection…………………………………………………..….... .54 
1.13  Negative regulator of cell signaling…………………..…………….………..... .54 
1.13.1 Suppressor of cytokine signaling and control of mycobacterial 
infection…………………………………………………………….... .55 
1.14  Rationale and major objective ………….……………………………….…….. 56 
CHAPTER 2.  STIMULATION OF BOVINE DENDRITIC CELLS BY M. BOVIS 
CULTURE SUPERNATANT AND SURFACE EXTRACT IS ASSOCIATED WITH 
DECREASED PRO-INFLAMMATORY CYTOKINE RESPONSE...…………….. 58 
HYPOTHESIS………………………………………………………….……………..... 58 
OBJECTIVES…………………………………………………….…………….……......58 
2.1    Introduction……………………………………………………………………...... 59 
2.2 Materials & Methods………………………………………………….……..….....61 
2.2.1  Preparation of M. bovis cell envelope Ag fractions……………………......61 
2.2.1.1  Bovine purified protein derivative (bPPD)..………...….…61 
2.2.1.2 Total cell wall lipid (CWL)…………………………..……61 
2.2.1.3  Cell surface sugar extract (CSSE)…………………..….....61 
2.2.2 Isolation of bovine CD14+ monocytes and culture of monocyte-derived 
 mature DCs……...………………………………………...…………...….62 
2.2.3 In vitro cell culture and treatment…………………….……………..……..63 
2.2.4 ELISA…………………………………………………….………….....… 63 
2.2.5 Western blot analysis……………………………………….…...…….….. 64 
2.2.6 Statistical analysis…………………………………………….…...…..….. 65 
2.3 Results…………………………………………….…………………………........ 66 
2.3.1 Bovine dendritic cells treated with CSSE produce little TNF- and IL-
12………………………………………………………………………... 66 
2.3.2 Cell surface sugar extract-treated bDCs exhibit low phosphorylation of 
ERK……………………………………………..………………………. 68 
2.3.3 Cell surface sugar extract-treated bDCs exhibit low phosphorylation and 
transactivation of the NF- p65 subunit………………….…………... 71 
2.3.4 Treatment of bDCs with CSSE increases SOCs 1 and 3 expression….....74 
vii 
 
2.4 Discussion & conclusion…………………………….…………………….…...… 77 
 
CHAPTER 3. MYCOBACTERIUM BOVIS DERIVED PARAHYDROXYBENZOIC 
ACID DERIVATIVES EXHIBIT A DUAL ROLE IN BOVINE TUBERCULOSIS 




3.2 Materials & Methods……………………………………………………….…......81 
3.2.1 Preparation of M. bovis cell envelope Ag fractions and synthetic p-
HBADs.…………………………………………………………………..81 
3.2.1.1 Bovine purified protein derivatives (bPPD)……..………..81 
3.2.1.2 Total cell wall lipid (CWL)……………..……….……..…81 
3.2.1.3  Parahydroxylbenzoic acid derivatives (p-HBAD-I)…...... 81 
3.2.2 Assessment of p-HBAD-I in M. bovis CSSE using Thin-layer  
chromatography. (TLC)……………………..………………………..….. 82 
3.2.3 Generation of monocyte-derived bovine dendritic cells (bDCs)……........ 82 
3.2.4 In vitro cell culture and treatments……………………….………...…..... 82 
3.2.5 ELISA………………………………..…………………….……….……..83 
3.2.6 Western blotting………………………………………………….…...….. 83 
3.2.7 Statistical analysis…………………………………………….….….....….84 
3.3 Results…………………………………………………...……..………………..… 85 
3.3.1 CSSE fraction of M. bovis contains p-HBAD-1………………………..... 85 
3.3.2 Pure p-HBAD-1 inhibits the production of TNF-α and IL-12 by LPS-,  
bPPD- and CWL-stimulated  bDCs ………………….………………….. 86 
3.3.3  Pure p-HBAD-1 inhibits cell surface TLR 1, 2, 4, 5 and 6-dependent 
signaling in naïve  bDCs stimulated with corresponding TLR agonists…..88 
3.3.4 Pure p-HBAD-1 enhances endosomal TLR 3, 7, 8, and 9-dependent 
signaling in IFN- primed bDCs stimulated with corresponding TLR 
agonists……………………………………………………………….…. 90 
3.3.5 Pure p-HBAD-1 promotes cell surface TLR 4, 5 and 6-dependent signaling 
in IFN- primed   bDCs stimulated with corresponding TLR agonists….. 92 
3.3.6 Pure p-HBAD-1 decreases TLR-2 and 4 expression in LPS-stimulated 
bDCs but not IFN- primed and LPS-stimulated bDCs……………….... 94 
3.3.7 Pure p-HBAD-1 decreases NF-B activation in LPS- and bPPD-stimulated 
bDCs but not IFN- primed and LPS- or bPPD-stimulated 
bDCs…………………………….…………………………….…..…… .96 
3.3.8 Pure p-HBAD-1 increases SOCS 1 and 3 expression in LPS- and bPPD-
viii 
 
stimulated bDCs but not IFN- primed and LPS- or bPPD-stimulated 
bDCs………………………………………………………...………..... ..98 
3.4   Conclusion…………………………………………..……………………………………....100 
CHAPTER 4. p-HBAD-I PROMOTES A TOLEROGENIC PROFILE IN NON-
PRIME bDCs UNLIKE IFN- PRIMED bDCs…………………………………..…..102 
4.1 Introduction…………………………………….…………………………………..102 
4.2 Materials and 
methods……………………………………………….………...……………..….....104 
4.2.1 Generation of monocyte-derived bovine dendritic cells 
(bDCs)…......................................................................................104 
4.2.2  In vitro cell culture and treatments………...…………………. .104 
4.2.3 ELISA……………….…………………………………………..… ..104 
4.2.4 Western blotting…………..………………………….…….........105 
4.2.5 Flowcytometry………………………..…………………….…...106 
4.2.6 Statistical analysis……………………………..………………...107 
4.3 Results……………………………………………………….…………………….... 108 
4.3.1 Pure p-HBAD-1 increases IL-10 production in non-primed unlike   
IFN- primed bDCs stimulated with LPS/bPPD ………….……....108 
4.3.2 Pure p-HBAD-I downregulates the expression of co-stimulatory 
molecules in non-primed bDCs induced by LPS unlike IFN- 
primed…………………………………………………………....109 
4.3.3 Pure p-HBAD-I downregulates the expression of antigen-presenting 
molecules in non-primed bDCs induced by LPS unlike IFN- 
primed…………………………………………………………….…….. 114 
4.3.4 Pure p-HBAD-I downregulates the expression of DC-SIGN in non-
primed bDCs induced by LPS unlike IFN- primed………….....117 
4.4 Conclusion………………………………………..………………………………….119 
CHAPTER 5. GENERATION OF M. BOVIS MUTANT…….……………….….….122 
5.1 Introduction…………………………………………………………………….…..122 
5.1.1 Generation of M. bovis mutant via gene disruption by 
 homologous recombination…………………………………….....….122 
5.1.1.1 Generation and cloning of mutated CPL gene into P2NIL 
vector…………………………………………….…….…...123 
5.1.1.2 Construction of suicide delivery plasmid DNA……………..124 
ix 
 
5.1.1.3 Transform suicide delivery plasmid DNA bearing the mutated 
CPL gene to M. bovis……………….……………………………124 
5.1.1.4 Selection of mutant strain using a 2-step process………….125 
5.1.1.4.1  Single cross over events (SCOs)……….…….….125 
5.1.1.4.2 Double cross over events (DCOs)…………..…....125 
5.2 Materials and Methods...………………….……………………………………..…127 
5.2.1 PCR amplification of CPL gene…………………………..……….…127 
5.2.2 Digestion of vector and insert……………………………..….…....…128 
5.2.3 Ligation of the insert to vector using T4 DNA ligase enzyme..…..….130 
5.2.4 Transformation……………………………………..……….……....…131 
5.2.5 UV irradiation of suicide delivery plasmid  DNA and  
5.2.6 electroporation into electrocompetent M. bovis…………….……..……131 
5.3 Results……………………………….…………..………………………………......133 
5.3.1 Mutated CPL gene of fragment size 2.1kb amplified from pUC19 
vector…………………………………………………………....…....133 
5.3.2 Mutated CPL gene of fragment size 2.1kb amplified from p2NIL  
vector following digestion with HindIII enzyme….………………….133 
5.3.3 Confirmation of p2NIL with mutated CPL gene from 2 positive clones 
 using HindIII and BamHI enzymes……………………………….…134 
5.3.4 Confirmation of pGOAL17 gene cassette of fragment size 6.3kb 
 following digestion with PacI ……………………………………….135 
5.3.5 Confirmation of suicide delivery plasmid DNA construct by digestion  
with   Sal-1 enzyme ………………………………………….………136  
5.3.6 Selection via single cross over events (SCOs)…………………...…. 137 
 
5.4 Conclusion………………………………………..…………………………....…....138 
CHAPTER 6. GENERAL DISCUSSIONS AND CONCLUSIONS…………….……....139 







LIST OF TABLES 
Table 5.1:    Reaction Mixture for PCR setup ……………………………………………… .…127 
Table.5.2: PCR cycling program used to amplify the CPL gene using Phusion  
polymerase………..…………………………………………………………………128 
Table 5. 3:  Set up for double digestion of p2NILvector with mutated CPL gene using BamHI and 
HindIII…………………………………………………………………….………....128 
Table 5. 4:  Set up for single digestion of p2NILvector with mutated CPL gene using HindIII....129 
Table 5. 5:  Set up for single digestion of p2NILvector with mutated CPL gene and pGOAL17 
using PacI…………………………...……………………………………………….129 
Table 5. 6:  Set up for single digestion of suicide delivery plasmid and p2NILvector with mutated 
CPL  gene using Sal1enzyme……………………………………...…………...…...129 
Table 5. 7:  Set up for ligation reaction of mutated CPL gene with p2NIL………………………130 













LIST OF FIGURES 
Figure 1.  1:  Diagrammatic representation of the cell envelope of all members of M. tb complex. 
The plasma membrane, cell wall, and outer capsule are depicted along with their 
comprising biomolecules…………..………………………………………………….7 
Figure 1. 2: Structures of phenolic glycolipid of M. tb (PGL-tb) and structurally related glycans, 
para- hydroxybenzoic acid derivatives I and II (p-HBAD I and p-HBAD II…………12 
Figure 1.  3:  Pathogenesis of bovine TB- modified from Neil et al. 1994…………………………15 
Figure 1.4: Immunogenic and tolerogenic dendritic cell profile. Modified from Marin et al. 
2018………………………………………………………………….……… ….…..29 
 
Figure 2.   1: Low production of IL-12 and TNF- in CSSE simulated bDCs………………..….. 67 
Figure 2.   2: Decreased phosphorylation of ERK protein in CSSE stimulated bDCs………….….70 
Figure 2.   3: Reduced phosphorylation of NF-B in CSSE stimulated bDCs. ……………………73 
Figure 2.   4: Increased expression of SOCS 1 & 3 protein in CSSE stimulated bDCs……………76 
 
Figure 3.   1: TLC showing the presence of p-HBAD-I in M. bovis derived CSSE……………….85 
Figure 3.   2:  Production of IL-12 and TNF- by non-primed bDCs stimulated with LPS and bPPD 
in the presence of various concentrations of p-HBAD-1……………………….…..87 
Figure 3.   3:  Production of IL-12 and TNF- via surface membrane TLR signaling pathway in non-
primed bDCs stimulated with TLR agonist in the presence of p-HBAD-I………...89 
Figure 3.  4:  Production of IL-12 and TNF- via endosomal TLR signaling pathway in IFN--
primed bDCs stimulated with TLR agonist in the presence of p-HBAD-
I……………………………………………………………………………………..91 
Figure 3.  5: Production of IL-12 and TNF- via surface membrane TLR signaling pathway in IFN-
-primed bDCs stimulated with TLR agonist in the presence of p-HBAD-I……….93 
Figure 3:   6: Expression of TLR2 & 4 protein by rIFN- primed and non-primed bDCs stimulated 
with LPS and bPPD in the presence of p-HBAD-1…………………………..…….96 
Figure 3.   7:  Phosphorylation of NFB protein by rIFN- primed and non-primed bDCs stimulated 
 with  LPS and bPPD in the presence of p-HBAD-1……………………….……….97 
Figure  3.  8: Expression of SOCS1 and 3 in non-primed and rIFN- primed bDCs stimulated 
 with LPS and bPPD in the presence of p-HBAD-I…………….……………………99  
 
Figure  4.  1: Production of IL-10 by rIFN- primed and non-primed bDCs stimulated with 
 LPS and bPPD in the presence of p-HBAD-1…………………………………...…109 
Figure 4.  2: p-HBAD-I antagonizes the effects of LPS on bDCs maturation by decreasing  
expression of co-stimulatory molecules………………………………………….….113 
Figure 4.  3: p-HBAD-I antagonizes the effects of LPS on bDCs maturation by decreasing  
expression of antigen-presenting molecules………………………………...….…..116 
Figure 4.  4: Expression of DC-SIGN in non-primed and rIFN- primed bDCS stimulated  
with LPS in the presence of p-HBAD-I……………………………………….…… 118 
 
Figure 5.  1: Steps in amplification of mutated CPL gene………...……………..………………123 
Figure 5.  2: Steps in construction of suicide delivery plasmid DNA……………..…………..…124 
Figure 5.  3: Steps involved in selecting single cross over events (SCOs)……….………...…....125 
Figure 5.   4: Steps involved in selecting double cross over events (SCOs)……………………..126 
xii 
 
Figure 5.  5:  Amplified mutated CPL gene of fragment size 2.1kb …………….………………133 
Figure 5.  6:  Amplified mutated CPL gene from 2 positive clones ……………..………..……..134 
Figure 5. 7: Confirmation of p2NIL with mutated CPL gene from 2 positive clones using  
HindIII and   BamHI enzymes……………………………………………………….135 
Figure 5.  8: Digestion of pGOAL17 and p2NIL construct with Pacl enzyme……………..….…136 
Figure 5.  9: Confirmation of suicide delivery plasmid DNA by digestion with Sal-1 enzyme….137 
 



























Acronym         Definition 
ANOVA Analysis of variance 
ADCC  Antibody-dependent cell-mediated cytotoxicity 
AG  Arabinogalactan  
APC   Antigen presenting cells 
AP-1   Activation protein 1  
BCG  Bacillus Calmette Guerin  
bDCs  Bovine dendritic cells 
BPPD   Bovine purified protein derivatives 
bTB   Bovine TB 
CFP-10   Culture filtrate protein-10 
CW  Cell wall  
CCR  Chemokine receptors 
CPL    Chorismate pyruvate ligase 
CD  Cluster of differentiation   
CLRs  C-type lectin receptors  
CXCL9  Chemokine C-X-C motif ligand 9  
CMI  Cell-mediated immunity 
CWL   Cell wall lipid 
CXCL10 Chemokine C-X-C motif ligand 10  
CSSE  Cell surface sugar extract 
CyAn ADP CyAn Advanced Digital Processing (ADP) 
DAMP               Damage-associated molecular pattern 
DCs   Dendritic cells 
DC-SIGN          Dendritic cell-specific intercellular adhesion molecule grabbing nonintegrin   
DCOs  Double cross over events 
DMSO              Dimethyl Sulfoxide 
DNA                 Deoxyribonucleic Acid 
dNTPs  Deoxyribonucleoside triphosphates  
DPG   Diphosphatidyl glycerol   
Dos-R  Dormancy survival regulator  
ESAT-6  Early secretory antigenic target-6 
EDTA   Ethylene diamine tetra-acetic acid 
ELISA    Enzyme-Linked Immunosorbent Assay 
ERK      Extracellular Signal Regulated Kinase 
E.coli  Escherichia coli 
FACS    Fluorescence Activated Cell Sorting 
FACOLA FCM buffer consisting of 0.03% sodium azide and 0.2% gelatin in PBS pH 7.3 
FBS    Fetal Bovine Serum 
GAS   Interferon gamma activated Site  
gDNA  Genomic deoxyribonucleic acid 
GFP  Green flouresent protein 
GM-CSF Granulocyte Monocyte Colony Stimulating Factor 
GMM   Glucose monomycolate   
IDO  Indoleamine 2,3-dioxygenase 
IFN  Interferon 
IFN-γ   Interferon gamma 
IFN-γR  Interferon Gamma Receptor 
xiv 
 
IGRA  Interferon-gamma  release assays 
IL  Interleukin 
iNOS       Inducible Nitric Oxide Synthase 
IRF3  Interferon regulatory factor-3  
IP-10  IFN-γ-induced protein-10  
IRAK-4 IL-1 receptor-associated kinase-4  
IRF3  Interferon regulatory factor-3  
IKK  Inhibitor of nuclear factor kappa B kinase 
IKB  Inhibitor of nuclear factor kappa B 
JNK     c-Jun Terminal Kinase 
kDa     Kilodaltons 
LM  lipomannan  
LAM   Lipoarabinomannan 
LPS   Lipopolysaccharide 
LBP   LPS binding protein  
LP   Lipoprotein 
M. bovis Mycobacterium bovis 
MIG  Monokine induced by IFN-γ  
M. tb  Mycobacterium tuberculosis 
MAPK  Mitogen-Activated Protein Kinase 
MHC   Major histocompatibility complex 
mRNA  Messenger ribonucleic acid  
MyD88  Myeloid Differentiation Primary Response Protein 88 
MDPs   Macrophage/DC progenitors  
MMG  Mono-mycolyl glycerol  
ManLam mannose-capped lipoarabinomannan 
NFκB     Nuclear Factor κB 
NK   Natural killer  
NKT   Natural killer T-cells 
NLR        NOD-like Receptor  
NO         Nitric Oxide 
OXPHOS  Oxidative phosphorylation  
OL  Outermost capsular layer  
ODN   Oligodeoxynucleotides  
p-HBAD-I  Parahydroxybenzoic acid derivatives -I 
p-HBAD-II  Parahydroxybenzoic acid derivatives -II 
PM   Plasma membrane  
PGE2  Prostaglandin E2 
PAMPs  Pathogen Associated Molecular Patterns 
PG  Peptidoglycan  
PBS   Phosphate Buffered Saline 
PBMC  Peripheral blood mononuclear cell  
PBS  Phosphate buffered saline  
PBST-G PBS-T + 0.5% gelatin  
PBST  PBS + 0.10% Tween 20 
Poly I:C Polyinosinic-polycytidylic acid  
PRR   Pattern Recognition Receptor 
PCR  Polymerase chain reaction   
PD1  Programmed cell death protein 
Poly (I:C)          Polyinosinic-polycytidylic acid  
xv 
 
PNPP  p-Nitrophenyl Phosphate 
PE   Phenylethanolamine   
PE  Phycoerythrin 
PIMs   Mono/di-acylated phosphatidyl inositol  
PDIMs               Phthiocerol dimycocersates  
PAT  Pentacyl trehalose  
PGL  Phenolic glycolipid  
RLR     RIG-like Receptor 
RNI     Reactive Nitrogen Intermediates 
ROS   Reactive Oxygen Species  
RPMI        Rosewell Park Memorial Institute Medium 
RT  Room temperature  
RIPA  Radioimmunoprecipitation 
RNA  Ribonucleic acid 
rIFN-γ-  Recombinant interferon-gamma 
SDP  Suicide delivery plasmid 
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SH2  Src Homology 2 
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TAE  Tris base+ acetic acid +EDTA 
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TAG  Triacyl glycerol  
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CHAPTER 1. Introduction and literature review 
1.1 Mycobacteria tuberculosis complex 
The Mycobacterium tuberculosis complex (MTBC) consists of  M. tuberculosis (causative 
agent of human tuberculosis), Mycobacterium bovis (M. bovis), M. bovis Bacillus 
Calmette-Guérin (live attenuated TB vaccine strain), Mycobacterium microti, 
Mycobacterium africanum, Mycobacterium canetti and Mycobacterium caprae [1]. 
Although some species have 99.9% similarity in nucleotide sequences, they have different 
abilities to induce macrophage cell death [2]. M. tuberculosis is 99.95 % genetically 
identical to M. bovis [2, 3]. Genetic analysis showed that M. bovis lacks certain trehalose-
containing glycolipids on its cell wall, which could affect the virulence and adaptability 
within the host cells. The loss of some of these trehalose-containing glycolipids was related 
to distortion of the surface-exposed acyltrehaloses signaling system [4, 5]. The reduction 
of this signaling system in M. bovis has been linked to less virulence in humans [5].  
1.2 Mycobacterium bovis  
Mycobacterium bovis is a slow-growing, facultative intracellular, aerobic, and Gram-
positive bacterium. It is the causative agent of bovine tuberculosis (bTB). Despite cattle 
being the preferred host for M. bovis,  it can also infect and cause disease in humans and 
other animals such as swine, bison, and cervids (deer and elk) [6]. Indeed as a zoonotic 
disease, bTB is recognized as a major hindrance to global efforts to eradicate TB by the 
year 2030 [7]. Thus, the human TB burden cannot be decreased without controlling bTB 
in animal reservoirs. High-risk individuals are those in direct contact with infected animals, 
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such as farmers and veterinarians [8]. The most frequent route of transmitting the disease 
is through inhalation of aerosols containing bacilli, and risk exposure is highest in the 
enclosed areas [9]. Other methods of contracting the disease are drinking unpasteurized 
milk products from an infected cow, direct contact with the excreta of infected animals, 
and sharing common water or feed sources [9].  Clinically the disease is characterized by 
debilitating conditions, cough, decreased milk production, and labored breathing.  
1.2.1 Prevalence and financial implication in the cattle industry 
Based on the report from the Worldwide Animal Health Information Database of OIE [10], 
an estimate of 91 out of 182 countries publicized the existence of bTB infection in cattle 
between 2015–2017.  Widespread bTB has been reported in Central and South America, 
Middle East countries and some parts of Asia [10]. An estimated 30 countries in Africa 
have also reported the presence of bTB. 
 In most developed countries, bTB has been successfully controlled by applying test-and-
slaughter schemes, milk pasteurization and meat inspection in abattoirs [10]. However, in 
some developed countries (Ireland, UK, New Zealand), eradication of bTB is challenging 
despite the implementation of extensive control [11, 12]. In these countries, elimination of 
bTB is challenging in wildlife (source of infection) when compared to domestic animals 
resulting in inadequate eradication of the disease [13]. Despite the low prevalence in 
developed countries, the costs of bTB are primarily associated with trade barriers for live 
animals. Also, the financial costs of executing compulsory bTB control programs are high 
[14]. Other costs can negatively impact consumer trust, adverse market reactions, the 
farming industry, and the country’s reputation.  
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In most developing countries, eliminating bTB remains a problem where the 
implementation of preventive measures is non-existent [15]. In countries with endemic 
disease, bTB threatens their national economies by reducing productivity and affecting 
animal product international trade [16]. Also, the costs of bTB are primarily associated 
with losses in livestock production, including lower meat/milk production and a high 
mortality rate [17].  
1.2.2 Diagnosis  
The diagnosis of bTB is based on clinical ante-mortem and post-mortem tests [18]. The 
principal ante-mortem tests for bTB diagnosis are immune-based assays to detect cell-
mediated immune (CMI) response. This includes tuberculin skin tests (TST) and 
interferon-gamma release assays (IGRAs) [19]. Commercially available IGRAs for cattle 
use include the Bovigam assay and the BIO-RAD bovine interferon-gamma ELISA Kit 
[20, 21]. In addition to IFN-γ, other biomarkers of CMI responses have emerged as 
potential TB tests for humans and cattle. These include interleukin-1β (IL-1β), interleukin-
2 (IL-2), chemokine C-X-C motif ligand 9 (CXCL9), chemokine C-X-C motif ligand 10 
(CXCL10), also known as IFN-γ-induced protein-10 (IP-10), tumor necrosis factor-alpha 
(TNF-α), nitric oxide (NO), interleukin-17 (IL-17), and interleukin-22 (IL-22)[22]. 
Recently, a whole blood culture system was used for evaluation of antigen-specific 
cytokine/chemokine gene and protein expression, and data obtained further confirm that 
CXCL9, CXCL10, IL-21, IL-13, and several acute-phase cytokines may serve as 
diagnostic host biomarkers of M. bovis infection in cattle [22].  
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The synchronous presence of infection in the herd of Mycobacterium avium subsp.  
paratuberculosis or non-pathogenic environmental mycobacteria [23], or co-infection with 
Fasciola hepatica [24], may compromise specificity and sensitivity values, thus affecting 
the reliability of diagnostic tools. Additionally, M. bovis infection is not detectable in 
animals with a depressed cell-mediated immune response [25]. Therefore, gross analysis 
of the carcass at slaughterhouses during post-motem inspection allows the confirmation of 
bTB in herd test reactors and provides additional data concerning infected animals that 
have not reacted in field tests.  
During post-mortem diagnosis, all cattle intended for human consumption are exposed to 
routine meat inspection. Carcasses are assessed for typical gross and histopathological 
lesions resulting from bTB in naturally infected animals [26-28]. Gross pathology of bTB 
manifests as a chronic inflammatory disease with the formation of a granulomatous lesion 
affecting lungs, lymph node, intestines, liver and spleen [27]. These granulomatous lesions 
are characterized by different sizes, superficially or deeply located, caseous or calcified 
nodules bulging from the mucous or serous surface. The tissue analysis procedure via 
histopathology is as follows: paraffin-embedded, formalized tissues are finely sectioned 
and stained with Haematoxylin/Eosin and Ziehl Neelsen stains. 
1.2.3 Control 
Considering the zoonotic potential of bTB and its economic impact on animal production, 
many industrialized countries established specific eradication programs, which aimed to 
control the infection in susceptible animal hosts, thus reducing the risk for human infection 
[29, 30]. Several countries adopt bTB control programs, which constitute ‘tuberculin test 
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and slaughter’ to control the bovine disease [29].  However, the incidence of bTB continues 
to increase (due to the presence of M. bovis wildlife reservoir) despite the use of test and 
slaughter control policy, highlighting the urgent need for a better control strategy [31]. An 
effective strategy for bTB control could involve cattle vaccination combined with a highly 
specific and sensitive diagnostic test that discriminates M. bovis-infected from vaccinated 
cattle. The ideal bTB vaccine would induce protective immunity without tuberculin skin 
test reactivity [32, 33].  
So far, the only vaccine available for humans and bTB is the live attenuated Bacille 
Calmette Guerin (BCG) [34]. BCG derived from the serial passage of M. bovis confer 
protection against mycobacteria via the induction of Th1 responses [35-37].  Though BCG 
remains the standard against which the efficacy of any novel vaccine is judged, it is unlikely 
to fulfill the criteria defined for an ideal cattle vaccine. A reason for this is because  BCG 
vaccination to control bTB can also sensitize cattle to the tuberculin skin test. That way, 
vaccinated cattle respond positively to the skin test [38]. The tuberculin test primary 
antigenic target is bPPD antigen, and it is present in both M. bovis and BCG vaccines [38]. 
This challenge can be overcome by applying a diagnostic antigen whose genes are lacking 
from the BCG genome.  Thus, antigens whose genes are expressed by M. bovis but are 
lacking in environmental mycobacteria or BCG constitute candidates for diagnostic 
antigens that are more specific and better defined than PPD. This candidate antigenic target 
can help differentiate the BCG vaccine from M. bovis infection [38]. Primary antigenic 
targets (ESAT-6 and CFP-10) encoded by genes located on the RD1 region of the M. bovis 
genome but deleted from the BCG genome have been shown to discriminate between 
vaccinated and infected cattle successfully [39].  
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Other challenges incurred using BCG as a vaccine in cattle are due to a high degree of 
variability in the ability of BCG to protect against infection with M. bovis as demonstrated 
in field trials and challenge cattle experiments [40]. The variability in protection is 
associated with different BCG strains (with variable genetic content) exhibiting different 
protective efficacies [41]. Therefore, developing a new vaccine or boosting the 
immunogenicity of BCG as well as identifying candidate diagnostic antigens that can 
differentiate M. bovis infected and BCG vaccinated cattle is vital for bTB control. Many 
vaccine development approaches, such as MTBVAC (live attenuated vaccine), subunit, 
and modified BCG vaccines, are currently being explored for safer and more efficacious 
TB vaccines than BCG. These approaches have been successful in developing a large 
number of vaccine candidates included in the TB vaccine pipeline and are at different 
stages of clinical trials in humans[42] 
1.3 Mycobacterium bovis cell wall antigens 
The unique cell envelope of all members of M. bovis consists of three major layers: the 
plasma membrane (PM), the cell wall (CW), and the outermost capsular layer (OL) [43]. 
This thick multilayer cell envelope is highly hydrophobic with a very low cellular 
permeability. Therefore, it acts as a barrier against many classes of hydrophilic 
antibacterial drugs and chemotherapeutic agents. This has been implicated in the 
mycobacteria's ability to develop resistance to several anti-tubercular drugs [44]. The 
plasma membrane appears similar in structure to that of other bacteria, and it is composed 
of an asymmetrical bilayer of phospholipids decorated with glycoproteins and 
transmembrane proteins. Surrounding the plasma membrane is the cell wall consisting of 
7 
 
two segments: a lower segment of peptidoglycan (PG), which is covalently linked to the 
arabinogalactan (AG) layer [43]. The AG layer consists of galactofuranose, 
oligosaccharides and arabinofuranose, esterified to mycolic acids [43]. Lastly, the upper 
segment of the cell wall is made up of intercalating glycolipids and waxes [43]. 
Collectively, the cell wall surface is studded with various proteins, glycoproteins and 
glycolipids [45]. These cell envelope antigens exert a robust immunomodulatory effect 
because they are the first to interact with host immune cells.  
 
Figure 1.1: Diagrammatic representation of the cell envelope of all members of M. tb complex. The 






1.3.1 Bovine purified protein derivatives (bPPD) 
The first purified protein derivatives were developed by Florence B. Seibert in the US in 
1934 [47].  Bovine purified protein derivatives contain a complex mixture of proteins, 
including the antigens ESAT-6 and CFP10, which are the antigens used in the M. tb specific 
IFN- release assays [48]. The primary eradication program for bTB involves the ability to 
diagnose and identify affected animals correctly. Thus, the eradication of M. bovis is 
dependent on the “test and slaughter” program, where cattle are consistently tested using 
the tuberculin skin test, which utilizes purified protein derivatives derived from M. bovis, 
and reacting animals are slaughtered [49]. Bovine purified protein derivatives in the skin 
test lack specificity as some of its antigenic components are present in non-pathogenic 
environmental mycobacteria and BCG. 
The injection of bPPD induces inflammation resulting in a delayed-type of hypersensitivity 
response in TB-infected animals.  The “delayed” response occurs within 3 days following 
exposure to antigen. Previous studies have reported that CD4+, CD8+, and γδ T cells are 
the primary T-cell subsets responding to bPPD stimulation in cattle experimentally infected 
with M. bovis [50]. Consistent with data obtained from cattle experimentally infected with 
M. bovis, another study reported a Th1 cytokine profile in response to bPPD stimulation in 
cattle naturally infected with M. bovis [51].  
1.3.2 Cell wall lipids (CWL) 
Many CWL has been implicated in the virulence of mycobacteria. These CWL consist of 
a complex mixture of polar, apolar lipids and glycolipids. The identified polar lipids 
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include diphosphatidyl glycerol (DPG), glucose monomycolate (GMM), 
phenylethanolamine (PE), and mono/di-acylated phosphatidyl inositol mannosides (PIMs) 
[52]. In contrast, the apolar Lipids consist of phthiocerol dimycocersates (PDIMs), 
trehalose dimycolate (TDM) and trehalose monomycolate (TMM), pentacyl trehalose 
(PAT), triacyl glycerol (TAG), phenolic glycolipid (PGL), and mono-mycolyl glycerol 
(MMG) [52]. These mycobacterial CWL are well known to regulate the function of a 
variety of innate immune cells [52-54]. Recent studies demonstrated that polar lipid 
fractions can alter the cytokine profile of bovine macrophages and DCs [52]. Furthermore, 
exposure of bovine APCs to polar lipids hinders antigen presentation by down-regulating 
MHC-II and other co-stimulatory molecules [52]. Thus, these data demonstrate that 
pathogenic mycobacterial polar lipids can block the ability of antigen-presenting cells to 
induce an appropriate immune response to an invading pathogen. 
Similar to polar lipids, apolar lipids such as TDM  have been reported to promote a 
tolerogenic phenotype in bone marrow-derived murine DCs activated with mycobacterial 
antigens and Toll-like receptor agonists, resulting in low expression of DCs activation 
makers and altered cytokine production [55].  Moreover, PGL expression is associated with 
increased mycobacterial virulence by downregulating host phagocyte inflammatory 
responses [56, 57]. In addition, PGL-1 and PGL-tuberculosis produced by the clinical 
isolates of M. tb block TLR2 agonist-driven activation NF-B and cytokine production 
[58], as well as decreased TRIF dependent TLR4 signaling in macrophages resulting in 
limited pro-inflammatory and bactericidal responses [59]. Collectively, these studies 
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suggest that CWL contributes to the pathogenicity of mycobacteria by blocking the 
generation of robust innate immune responses. 
1.3.3 Cell surface sugar extract (CSSE) 
Mycobacterial-derived CSSE fractions, enriched in glycolipids and glycans, play 
prominent roles in the evasion of host immune responses [46, 60]. For example, 
Phosphatidylinositol mannosides derived from M. tuberculosis have been shown to inhibit 
LPS activation of human DCs by reducing the up-regulation of MHC II molecules and pro-
inflammatory cytokine production [61]. Moreover, M. tuberculosis-derived LM reportedly 
blocks the biosynthesis of TNF-α in human macrophages by destabilizing TNF mRNA 
transcripts, thereby allowing M. tuberculosis to evade host immune response and 
potentially increase its virulence [62]. Furthermore, ManLAM has been shown to block 
IL-12 production by human DCs previously stimulated with LPS [63] and inhibit LPS-
induced DCs maturation [64]. Recently, it was reported that Di-O-Acyl-trehalose promotes 
a tolerogenic phenotype in bone marrow-derived murine DCs activated with mycobacterial 
antigens, resulting in low expression of DCs activation markers and altered cytokine 
production [55]. These studies suggest that CSSE fraction contributes to host evasion by 
mycobacteria.  
1.3.4 Phenolic glycoconjugates 
Phenolic glycoconjugates belong to CSSE antigenic class, and it consists of phenolic 
glycolipid (PGL) and structurally related parahydroxybenzoic acid derivatives (p-
HBADs). Both share the same glycosylated aromatic nucleus. The aromatic core is derived 
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from the methyl ester of p-hydroxybenzoic acid (p-HBA) and synthesis of both p-HBADs 
and PGL is thought to proceed from p-hydroxybenzoic acid [65]. The glycosyl moieties in 
p-HBADs are identical to mycoside B in PGL-tb, and display potent immunomodulatory 
activities [65]. While few mycobacterial clinical isolates synthesize PGL, p-HBADs are 
secreted by all mycobacteria strains [65, 66]. It has been shown that M. bovis and BCG 
produce only p-HBAD-I (monosaccharide), while M.tb generates both p-HBAD-I and II 
(trisaccharide) (Stadthagen et al., 2005). Moreover, Scanlan et al. reported the chemical 
synthesis of p-HBADs, accompanied by biological studies on the immunological effects of 
the molecules on immune cells [65]. They showed that the synthesis of p-HBADs involves 
chorismate pyruvate lyase enzyme during host infection and is released in culture filtrates 
[67]. The immune-modulatory role of p-HBADs has been studied in mycobacteria [68]. 
Previous studies have shown that M.tb mutant defective in the synthesis of p-HBAD-I and 
II promote a more robust inflammatory response than wild-type strains [68]. Furthermore, 
in vitro studies with mouse splenocytes and bone marrow-derived macrophages showed 
that p-HBAD-I and II derived from M. tuberculosis strain can suppress host immune 
response and enhance TB pathogenesis [69].  A recent report demonstrates that M. 
tuberculosis derived p-HBAD-I and related structures affect acute macrophage activation 
by inhibition of pro-inflammatory response and reduction of bactericidal nitric oxide 
production following BCG vaccination [70]. Thus, this indicates that the presence of p-




Figure 1.2: Structures of phenolic glycolipid of M. tb (PGL-tb) and structurally related glycans, para-
hydroxybenzoic acid derivatives I and II (p-HBAD I and p-HBAD II) [46]. 
 
1.4 Pathogenesis of Mycobacterium bovis  
 Infection is initiated following inhalation of a droplet containing bacilli of size ranging 
between 1-5μm in diameter [71]. Inhaled bacilli avoid the bronchi's defense mechanism 
and penetrate the terminal alveoli, where they are recognized and phagocytized by resident 
alveolar macrophages [71]. Bacterial components are detected by host receptors expressed 
on alveolar macrophages and other immune cells via Toll-like receptors (TLRs), 




 During the first ten days of infection with M. bovis, alveolar macrophages switch towards 
an M2 phenotype with an anti-inflammatory response, which enables bacilli to manipulate 
host immune responses to favor their survival [74]. Towards the end of ten days post-
infection, infected alveolar macrophages transmigrate from the alveolar space to the lung 
interstitium via the help of cytokine released by alveolar epithelial cells. In the interstitium, 
infected alveolar macrophages release chemokines and cytokines, which attract monocytes 
and other inflammatory cells. During the acute phase of infection, signals from M. bovis 
infection polarize interstitial macrophages to the M1 phenotype. Switch over of M2 
macrophages to M1 phenotype is accompanied by aerobic glycolysis resulting in enhanced 
pro-inflammatory response, subsequent elimination of non-virulent mycobacteria, and 
formation of primary TB lesion [74].  
However, virulent M. bovis evade interstitial macrophage microbicidal mechanisms via its 
virulence factor known as ESAT- 6, resulting in the induction of adaptive immune 
response. DCs mediate induction of adaptive immune response against mycobacterial 
infection.  Infected DCs migrate to the regional lymph node and prime T-cells by up-
regulation of chemokine receptor 7 (CCR7) (Worbs, Hammerschmidt [75]. Depending on 
the host immune response, primed T-cells and other immune cells accumulate at the 
infection site resulting in total clearance of infection or granuloma formation.  Though 
immunocompetent hosts clear off the bacteria. However, in the case of 
immunocompromised hosts, virulent bacilli capable of surviving escape killing and persist 
in the chronic phase [76].  Thus, the host protects itself by switching from host resistance 
to host tolerance by the formation of granuloma. The granuloma wall off tubercle bacilli 
from the rest of the lung tissue, thereby limiting the spread of bacteria and provides a 
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microenvironment for interactions among macrophages and other immune cells as well as 
cytokines produced by these cells.   
 Two distinct types of granulomatous lesions exist (chronic and necrotic granulomas) 
depending on the host immune response [77]. Histopathological studies have demonstrated 
that the classic chronic granuloma comprises epithelial macrophages, neutrophils, and 
other immune cells surrounded by fibroblasts [78]. The chronic granuloma with neutral pH 
consists of dead macrophages and other immune cells with non-replicating M. bovis 
residing inside macrophages in the hypoxic center [78]. The necrotic granuloma with acidic 
pH possesses actively replicating bacilli surrounded by immune cells [79]. Infected cattle 
with chronic or necrotic granuloma manifest signs of latent or active infection, 
respectively. While latently infected cattle show no sign and rarely transmit diseases, 
actively infected animals show signs and transmit the disease to both immunocompetent 
and immunocompromised cattle. Thus, the establishment of both latent or active TB 





Figure 1.3: Pathogenesis of bovine TB- modified from Neil et al. 1994 [80] 
1.5 The Immune System 
The immune system protects the host via a highly regulated network of cells and molecules, 
which work synergistically. Upon encountering a threat, the immune system responds with 
diverse mechanisms to control the threat. The immune system is split up into two separate 
arms, the innate and the adaptive immune system [81]. While innate immune cells respond 
quickly to invading pathogens, adaptive immune cells exhibit a delayed response and form 
immunological memory [82]. It is established that both innate and acquired immune 
defenses are involved in defending the host against M. bovis infections and vary depending 
on the host species, the virulence of an M. bovis strain, and host genetics [83]. 
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1.5.1 Innate immune response to M. bovis 
Alveolar macrophage (AM) is a subset of tissue-resident macrophages that reside within 
the lung airspace and play crucial roles in lung homeostasis, surfactant metabolism, and 
tissue repair [84]. Alveolar macrophages are the first cell type to encounter M. bovis. In 
mice, a productive M. tuberculosis infection starts with an infection of AM that resides in 
the lung alveoli [85]. Depleting AM prior to infection reduces the bacterial burden in the 
lungs and increases survival, suggesting that AM forms a replicative niche early after 
infection [86]. The reverse is seen in the growth-restrictive environment within M1 
interstitial macrophages. In addition to eliciting inflammatory cytokine in interstitial 
macrophages, pathogen recognition by innate immune cells triggers a cascade of cellular 
events such as phagocytosis, autophagy, apoptosis, and induction of adaptive immunity. 
All these cellular events contribute to the elimination of invading pathogens [87]. 
During phagocytosis, various host cell receptors are involved in the uptake of M. bovis by 
macrophages [88]. Ultimately, the fusion of mycobacteria-containing phagosomes with 
lysosomes results in bacterial killing. The importance of IFN-γ during M. tuberculosis 
infection has been attributed to its ability to activate microbicidal mechanisms of 
macrophages, most notably via the production of reactive oxygen species (ROS) or reactive 
nitrogen species (RNS) and expression of the enzyme inducible nitric oxide synthase 
(iNOS) [89]. iNOS catalyzes the production of the bactericidal/static radical NO, which is 





1.5.2 Cell-mediated immune response against M. bovis infection 
Cell-mediated immunity activates phagocytes, antigen-specific cytotoxic T-lymphocytes, 
and the release of various cytokines in response to an antigen. Although innate immune 
responses eliminate invading pathogens by the induction of adaptive immunity, dendritic 
cells recruited to the site of mycobacterial infection mediate this effector function. These 
dendritic cells bridge innate and adaptive immunity, traveling from sites of infection and 
inflammation to secondary lymphoid tissues for activation of T-cells. Antibody-based 
depletion of CD11c+ cells, which transiently eliminates both classical and monocyte-
derived DCs, results in defective CD4 T-cell priming and increased susceptibility to M. tb 
infection, demonstrating the importance of  CD4 T-cells and  DCs for host defense [91].  
The accumulation of IFN- producing Th1 cells at the inflammatory site mediate protective 
immunity by activating mycobacteria-infected macrophages. Although it is assumed that 
IFN- producing CD4 T-cells are required for induction of protective immunity, however, 
it has been reported that IFN- is not a reliable correlate of TB protection because IFN-γ 
levels poorly correlate with TB protection  [92]. Recently, the induction of polyfunctional 
lung tissue-resident memory CD4 T-cells (CD4+TRM) responses has been established to 
protect against mycobacterial infection [93, 94]. The protective response of CD4+TRM 
cells against mycobacterial infection is partly based on reports demonstrating their 





1.6 Innate immune cells  
The innate immune cells develop from the bone marrow-derived multipotent hematopoietic 
stem cells [95]. The establishment of mycobacterial infection depends on its early 
interaction with host innate immune cells, such as natural killer (NK) cells, neutrophils, 
and phagocytes  (monocytes, macrophages, and dendritic cells) [96]. These innate immune 
cells express various pattern recognition receptors (PRRs) such as Toll-like receptors 
(TLRs), Nod-like receptors (NLRs), and C-type lectin receptors (CLRs). All these 
receptors play a role in pathogen recognition, uptake of mycobacteria, and initiation of 
intracellular signaling events that result in antimicrobial function [97]. Thus, the innate 
immune cells, signaling pathways, and cellular functions that are involved in the early 
phases of M. bovis infection are crucial in limiting disease and serve as potent regulators 
of antigen-specific adaptive immunity 
1.6.1 Macrophages  
1.6.1.1  Lung macrophages origin and development  
The lung consists of two main types of macrophages that reside in different anatomical 
compartments: interstitial and alveolar macrophages [98]. Macrophages are classified 
based on their origin as either derived from fetal/embryonic precursors that primarily self‐
renew or from adult blood monocytes that evolve from hematopoietic stem and progenitor 
cells (HSPCs) in the bone marrow [99]. Earlier studies on mice have demonstrated that 
alveolar macrophages are predominantly of embryonic origin in a steady-state, as they are 
nurtured and sustained independently of circulating monocyte [100]. Specifically, mouse 
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alveolar macrophages evolve from fetal monocytes that seed into the lung and differentiate 
after birth into mature alveolar macrophages under the influence of GM‐CSF, TGF‐β, and 
PPAR [101, 102]. 
In contrast, interstitial macrophages have a mixed origin, originating from blood and lung 
monocytes in mice with a minor early contribution from yolk sac macrophages [103]. The 
mixed origin may relate to distinct populations of interstitial macrophages that occupy 
specific niches in the lung. The monocytic origin of interstitial lung macrophages may 
explain why their energy metabolism relies on glycolysis, whereas alveolar macrophages 
mainly use fatty acid oxidation [74]  
1.6.1.2 Macrophage phenotypes and role in mycobacterial infection 
Through the process of polarization, macrophages can change their phenotypic and 
functional profiles [104]. Macrophage polarization is the process by which macrophages 
respond to stimuli from the local microenvironment and acquire a specific functional 
phenotype. Based on the secretion of certain specific cytokines and switch in cell 
metabolism, naïve macrophages (M0) can polarize to either classical/pro-inflammatory 
(M1) or alternative/anti-inflammatory (M2) phenotype [105, 106].  
The  M1 phenotype is obtained following exposure to a pathogenic molecule or cytokines 
(tumor necrosis factor-/Interferon-gamma) [107].  Thus, M1 phenotypes are associated 
with an increase in aerobic glycolysis, which is essential for the optimal production of pro-
inflammatory cytokines and suppresses the anti-inflammatory cytokine, resulting in 
reduced bacterial load. The mediators of host metabolism  such as hypoxia-inducible 
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factor-1 (HIF-1), glucose transporters (Glut-1), and mammalian target of rapamycin 
(mTOR)) enhance induction of the glycolytic enzymes and metabolic shift to aerobic 
glycolysis [108]. The M1 macrophages are critical in host defense, and the mediators they 
produce can lead to host-tissue damage. Hence, their activation must be tightly controlled.  
However, M2 macrophages are induced upon exposure to IL-10/IL-14/IL-13 or TGF-b.  In 
vitro treatment of macrophages with IL-4 and IL13 (alternative activation) results in the 
failure of antigen presentation to T-cells, and therefore minimal cytokines are produced 
from these macrophages. Alternatively, activated macrophages are also less efficient in 
producing toxic oxygen/ nitrogen radicals and killing of intracellular pathogens than 
classically activated macrophages [109]. The M2 macrophages depend on oxidative 
phosphorylation (OXPHOS) and fatty acid oxidation (FAO) for energy generation. This 
phenotype is associated with enhanced fatty acid metabolism [110]. The accumulated lipid 
serves as a nutrient for bacterial growth and survival by down-modulation of immune 
responses via anti-inflammatory cytokine release [110]. Other signaling proteins associated 
with M2 polarization include a signal transducer and activator of transcription 6 (STAT 6), 
GATA binding protein (GATA 3), suppressor of cytokine signaling (SOCs 1& 3) and 
arginase 1[111]. All these molecules regulate the anti-inflammatory profile of M2 






1.6.2 Dendritic cells 
1.6.2.1 Dendritic cells development and activation 
Dendritic cells, so named because of their distinctive dendritic processes, are professional 
antigen-presenting cells localize in tissues that are in communication with the skin and 
mucosal surfaces [112]. Dendritic cells are infrequent and are not abundantly distributed 
within the tissues as macrophages [113]. Like other phagocytes, DCs develop from 
macrophage/DCs progenitors (MDPs) in the bone marrow [114]. Four primary stages of 
DC development have been identified, including bone marrow progenitors, circulating 
precursor DCs, and tissue-resident immature or mature DCs. Precursor DCs patrol and 
circulate in the blood before populating peripheral tissues (e.g., the lungs) and lymphoid 
tissues. Granulocyte monocyte colony-stimulating factor (GM-CSF) and interleukin 4 (IL-
4) can induce DCs differentiation from precursors cells [115].  
Dendritic cells are described as either immature or mature based on their phenotypic 
characteristics and function. In steady-state, DCs are immature and are characterized by 
the high capacity to capture antigens, low expression of activation markers, and decreased 
secretion of cytokines [116]. Following exposure to an antigen, immature DCs undergo 
transformational changes and become mature DCs, which is associated with changes in 
their phenotypic and functional characteristics [117]. Inflammatory stimuli, such as 
lipopolysaccharide (LPS) and TNF-α can also facilitate DCs maturation [118].  Mature 
DCs lack the capability of antigen uptake. However, they are known for antigen 
presentation and have a higher capacity for activating naïve T-cells to initiate adaptive 
immune responses [119]. Thus maturation of DCs results in upregulation of major 
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histocompatibility complex (MHC) molecules [120], co-stimulatory molecules (CD40, 
CD80, and CD86),  lymph node-homing chemokines (CCR7), and increased production of 
pro-inflammatory cytokines required for T-cell activation [119].  
The pro-inflammatory cytokines produced by the mature DCs polarize T-cell response into 
different types of cell-mediated immunity [121]. Thus, according to the allergen sources, 
with pro-inflammatory cytokines and participation of costimulatory signals, DCs induce 
the polarization and differentiation of distinct types of T-cell responses that align well with 
different classes of pathogens (e.g., Th1, Th2, Th17, or regulatory T cells).  Interleukin 12 
(IL-12) production by DCs is crucial for the differentiation of naïve T-cells into Th1 cells 
that produce IFN-, an important cytokine needed to control mycobacterial infection [122]. 
In contrast, lack of IL-12 production by DCs results in Th2 response and susceptibility to 
mycobacterial infection [123]. 
1.6.2.2 Role of DCs in mycobacteria infection 
Pathogen-associated molecular patterns (PAMPs) induce an inflammatory response 
initiated via pattern recognition receptors (PRRs) expressed on dendritic cells [121]. The 
early wave of proinflammatory cytokines and chemokines released by DCs inhibits 
pathogen spread and prime T-cells to eradicate the invading pathogen [121]. For the early 
pro‐inflammatory response, activation of DCs is triggered by PRR signals. These signals 
transform resting DCs into strong antigen‐presenting cells capable of boosting the 
expansion and differentiation of naive pathogen‐specific T-cells to effector T-cells [121, 
124]. Following infection, DCs are required for induction of the cell-mediated immune 
response by promoting the dissemination of mycobacteria and its antigen from the infection 
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site to the local draining lymph node [125]. Chemokine homing receptors (CCR7 and 
CCR8) expressed on monocyte-derived DCs promote migration from lung tissue into the 
local draining lymph nodes [126, 127]. Following transportation of mycobacteria to 
draining lymph node by myeloid DCs, only tissue-resident DCs presents antigen and prime 
CD4 T-cells in the lymph node [128, 129].  Within the granuloma, the role of DCs varies 
depending on the stage of infection. DCs within acute granulomas upregulate the 
expression of costimulatory molecules, promote priming of naïve T-cells, and reactivation 
of newly arrived IFN- producing Th1 cells  [129].  However, DCs in chronic lesions 
promote latent TB infection by inducing a high level of PD-L1 expression and do not 
support the reactivation of newly recruited T-cells, thereby decreasing protective T-cell 
responses, thus acting as a shield that facilitates mycobacterium survival [128]. Although 
mycobacteria infect both macrophages and DCs, infected DCs lack the ability to control 
mycobacteria efficiently as macrophages [130, 131]. This suggests that infected DCs, may 
serve as a long-term reservoir for mycobacteria, thereby promoting their survival within 
the granuloma during chronic infection. The DCs shield may explain why mycobacteria 
adapt for long-term survival in granulomatous lesions. 
1.6.2.3 DC activation markers 
The full activation of T-cells requires two signals. The primary signal is mediated by 
antigen-presenting molecules, while the secondary signal is provided through 
costimulatory molecules. The up-regulation of antigen-presenting and costimulatory 




1.6.2.3.1 Antigen-presenting molecules (MHCI and II) and mycobacterial infection 
Mature DCs express high levels of MHC I and II molecules. The class II transactivator 
(CIITA) is a master regulator of MHC gene expression. It induces de novo transcription of 
MHC class II genes and enhances constitutive MHC class I gene expression [132]. The 
role of MHC molecules is to bind pathogen-derived peptide fragments and display them 
on the cell surface for detection by the appropriate T-cells via T-cell receptors [133].  
Dendritic cells are highly efficient at antigen presentation and adaptive immune cell 
activation due to their ability to determine if the antigen is endogenous or exogenous [134]. 
To communicate with CD8 T-cells,  MHC-I presents endogenous peptides to CD8 T-cells 
by the classical pathway via the endoplasmic reticulum (ER) and the transporter associated 
with antigen processing (TAP) complex [135]. The classical TAP-dependent MHC-I 
pathway is critical in host defense against M. tuberculosis [136]. In addition, mice lacking 
β2-microglobulin (β2m), a component of the MHC-I chain, cannot stably present antigens 
on the surfaces of their cells. Recent studies using β2m knockout (KO) mice have shown 
that MHC-I plays a vital role in host defense against several intracellular bacterial 
pathogens, including M. tuberculosis and Listeria monocytogenes [135, 136]. Furthermore, 
the evidence that M. tuberculosis infection induces severe disease and a significant 
reduction of CD8 T-cells in MHC-I-deficient β2 m−/− mice indicates that MHC-I-restricted 
antigen-specific CD8 T-cells are crucial for host defense against M. tb infection. 
Also, DCs are the only antigen-presenting cells with the unique ability to undergo cross-
presentation and display exogenous antigens on MHC-I molecules to activate CD8 T-cells 
[137]. The intracellular pathway for DCs cross-presentation is still under debate. However, 
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two pathways proposed for the cross-presentation of exogenous antigens are the cytosolic 
and vacuolar pathways [138].  In the cytosolic pathway, an exogenous antigen undergoes 
phagocytosis and is transported to the phagosome, followed by exportation to the cytosol, 
where it is degraded to a peptide by the proteasome [139].  From there, the antigenic peptide 
can be re-imported into the phagosome (phagosomal loading) or transported to the ER (ER 
loading) for MHC-I loading and cell-surface antigen presentation [140].  In the vacuolar 
pathway, exogenous antigens undergo phagocytosis followed by transportation to the 
phagosome for degradation.  The antigenic peptides are loaded on the MHC class I 
molecule in the phagosome then transported to the cell surface for antigen presentation 
[141].  
In contrast to MHC-I molecules, MHC-II molecules are present only on the surfaces of 
antigen-presenting cells, such as dendritic cells, B-cells, and macrophages. MHC-II 
molecules are transmembrane αβ heterodimers, and they present exogenous antigens from 
phagocytosed compounds to CD4 T-cells, which is critical for the expansion and function 
of CD4 T-cells during host immune responses [137, 142]. In vitro exposure to M. 
tuberculosis or its lipoproteins drives DCs maturation and the increased expression of co-
stimulatory and MHC class II molecules [143, 144]. Despite the proposal that TLR 
stimulation increases DCs antigen presentation, a mycobacterial infection might interfere 
with MHC-II antigen processing and the presentation of M. tuberculosis antigens by DCs. 
For instance,  ManLAM derived from M. tuberculosis is a DC-SIGN ligand, which inhibits 
DCs maturation [145]. In addition, Some in vitro studies indicate that infection of DCs 
with M. bovis BCG ultimately leads to loss of MHC-II molecules, making DCs another 
possible niche for immune evasion by mycobacteria [124]. Furthermore, in vivo infection 
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of lung DCs after aerosol administration of GFP-expressing M. bovis BCG led to poor 
expression of MHC-II molecules relative to expression in uninfected DCs from the same 
lung [146]. 
1.6.2.3.2 Costimulatory molecules (CD40, CD80 and CD86) and mycobacterial 
infection 
The ligands CD80 and CD86 are predominantly expressed on APCs, such as B cells, 
dendritic cells, macrophages, and monocytes. The expression of these molecules is 
upregulated in response to inflammatory stimuli. However, the timing and pattern of 
expression of these molecules differ. While CD86 is expressed at moderate levels at steady-
state and upregulated rapidly in response to inflammatory stimuli, CD80 is found at low 
levels in the absence of inflammation and is upregulated more slowly than CD86 after 
activation [147]. Also, CD86 is expressed as a monomer, while CD80 is a dimer with 
stronger binding affinities than CD86 to CD28. CD28 was one of the first costimulatory 
molecules to be identified and is a surface protein expressed on T-cells. Engagement of  
CD28 with CD80  and CD86 provides a second signal required for optimal T-cell activation 
and differentiation [148]. Antigen presentation to T-cells in the absence of costimulation 
can lead to clonal T-cell anergy[149]. 
Several studies demonstrated the role of mycobacteria in downregulating the expression of 
co-stimulatory molecules on APCs [128, 150]. A recent study, albeit for BCG, shows that 
MHC-II, CD80, CD86, and CD40 are down-regulated during the chronic phase of infection 
[128]. The down-modulation of CD80/CD86 in the chronic phase of infection suggests that 
mycobacteria may exploit this pathway to anergize the T-cells.  Another study reported 
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that the expression of costimulatory and MHC II molecules are downregulated in 
macrophages infected with fluorescent reporter bacteria [128, 146]. In addition, it has been 
shown that cell wall lipid trehalose 6, 6′-dimycolate (TDM) of M. tuberculosis inhibits the 
expression of costimulatory molecules on the surface of the macrophages [151]. The 
importance of CD80/CD86 in controlling mycobacterial infection was further 
demonstrated in CD80/CD86 double knockout mice [152]. In contrast, others suggested 
the augmentation of costimulatory molecules upon infection [153]. This discrepancy may 
be primarily dependent on the strain, system, or time-point of the study. 
1.6.2.4 Regulatory DCs and effect on the immune response to mycobacterial infection 
The immune system exists in equilibrium between tolerance and effective inflammatory 
responses. Recent findings suggest that innate immune cells (in particular DCs) are 
essential players in the induction of effective immunity and tolerance [154]. Immunogenic 
DCs mediate effective innate and adaptive immunity primarily due to their remarkable 
capacity to process and present antigens through major histocompatibility complexes to T-
cells [155]. Unlike immunogenic DCs, regulatory DCs can induce tolerance resulting in T-
cell anergy and deletion [156].  Several factors including DCs phenotype, antigen detection 
receptors, DCs maturation state, and exposure to microbial and soluble inflammatory 
factors, play a crucial role in the induction of regulatory DCs [157-160]. Soluble 
inflammatory factors such as TGFβ, IL-10, or PGE2 are the key players in the induction of 
regulatory DCs by inhibiting the upregulation of DCs activation markers [161, 162]. 
 Regulatory DCs can be characterized by the combination of surface marker expression 
(PD-L1, PD-L2, B7-H3, B7-H4, CD103, ILT3/4) and cytokine (IL-10, IL-1, TGF-) 
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production [163]. Other immunoregulatory factors produced by regulatory DCs include 
indoleamine 2,3 dioxygenase (IDO), arginase I and inducible nitric oxide synthase (iNOS) 
[163]. In addition, regulatory DCs express a normal level of MHC-II, while expression of 
the costimulatory molecules is low or deficient [164-166]. By the lack of costimulatory 
molecules, regulatory DCs are not fitted to provide T-cells with the necessary signal two 
required for full T-cell activation.  
Considering the prolonged coevolution of the tubercle bacilli with humans, the bacillus has 
evolved the capacity to persist in the host tissue in a dormant state. This ability primarily 
depends on cell wall glycolipids, which target antigen-presenting cells, thereby dampening 
effective T-cell immunity [61, 167]. A recent study demonstrated that mycobacterial 
glycolipid Di-O-acyl trehalose induces a tolerogenic phenotype in DCs by altering DCs 
maturation, leading to the expansion of regulatory T-cells [55]. In a murine model, 
regulatory DCs in chronic mycobacterial granulomas block protective T-cell response via 
the PD-1:PD-L signaling pathway, thereby promoting prolonged survival of bacteria [128]. 
This suggests that the regulatory DCs contributes to the induction of immune tolerance and 




  Figure 1.4: Immunogenic and tolerogenic DC profile. Modified from Marin et al. 2018 [168] 
1.6.2.4.1 Inhibitory markers expressed by regulatory DCs 
1.6.2.4.1.1 P     mme   e th     n  1 (P   1)  n     e  n my     te      n e t  n 
Two major PD-1 ligands exist namely PD-L1 and PD-L2, and they differ in their affinities 
for PD-1.  PD-L2 exhibits a stronger affinity for PD-1 as compared to PD-L1 [169]. While 
expression PD-L2 is inducible in fewer cell types (mainly antigen-presenting cells), PD-
L1 is broadly or constitutively expressed on hematopoietic and non-hematopoietic cells 
[170]. The inflammatory cytokines control the expression of PD-L1 and PD-L2.  In 
particular, PD-L1 expression on APCs is up-regulated following stimulation with IFN-γ 
and toll-like receptor ligands [171, 172]. Studies have shown that DCs can suppress T-cell 
responses by providing inhibitory signal via binding of PDL-1 on DCs with the PD-1 
molecules expressed on T- cells  [173]. Thus, the PD1/PDL-1 pathway is a key signaling 
pathway that terminates immune responses resulting in immune tolerance [174]. The PD-
1/PD-L pathway produces inhibitory signals that control both central and peripheral T-cell 
tolerance. Also, it has been demonstrated that the PD-1/PD-L pathway controls peripheral 
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T-cell tolerance by limiting the activation, expansion, and function of self-reactive T-cells 
[175]. The elimination of PD-L1/PD-I signaling pathway results in the breakdown of 
tolerance and promotes autoimmunity. 
 
In mycobacterial infection, CD4+ T cells exert strong cytokine production at the initial 
stage of infection, but these robust cytokine responses are diminished during the later stage 
of infection  [176, 177]. This suggests that an antigen-specific T-cell response is suppressed 
by some inhibitory mechanism, thereby allowing mycobacteria persistence in the host.  The 
PD-1/PD-L1 signaling pathway has been reported to impair the protective Th1 immune 
response in the later stage of infection with M.bovis bacillus Calmette–Guérin resulting in 
bacteria persistence in host tissue [178]. A recent study further confirms that M. 
tuberculosis antigens suppress Th1 immune response and facilitate lung cancer metastasis 
via the PD-1/PDL-1 signaling pathway [179]. This indicates that the PD-1/PD-L1 signaling 
pathway blockade may benefit patients with M .tb or other chronic infections. 
 
1.6.2.4.1.2  In   e m ne 2,3    xy en se  n     e  n my     te      n e t  n 
Indolamine-2,3-dioxygenase (IDO2) is a cytosolic immune-regulatory enzyme that plays 
a role in immunological tolerance [180]. The IDO2 oxidizes/converts the essential amino 
acid (tryptophan) to kynurenine (Kyn) by cleaving the 2,3-double bond of the indole ring 
[181]. The absence of tryptophan due to catabolism by IDO2 prevents T-cell proliferation 
due to starvation. Thus, T-cells are highly sensitive to a low concentration of tryptophan 
resulting in cell cycle arrest [182]. The IDO2 enzyme expressed in various tissues and 
antigen-presenting cells (DCs and macrophages) become up-regulated in response to 
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inflammation (specifically bacterial lipopolysaccharides and cytokines such as IFN-γ) 
[183].  It has been demonstrated that human dendritic cells expressing IDO2 are capable 
of blocking T-cell proliferation, suppress effector T-cells, and promote differentiation of 
naïve T-cells to regulatory T-cells  [184-186].  The expression and activation of IDO2 
create a local immunosuppressive micro-environment that promotes pathogen survival 
[187].  The role of IDO2 in immune regulation is observed in various disease states such 
as autoimmune disorders, tolerance in transplantation, and response to infection.  
Expression and activation of IDO2 have been demonstrated in both mice and non-human 
primates with mycobacterial infection [188]. In mice, enhanced activation of  IDO2  has 
been linked to poor TB outcomes [189]. In non-human primates, IDO2 induction in the 
granuloma is associated with active TB disease [190]. In humans exposed to M. 
tuberculosis, significant IDO expression levels have been reported [191, 192]. This 
evidence from both human and animal studies indicates that high expression of IDO2 in 
the granuloma compromises T-cell function, thereby supporting mycobacterial 
proliferation and survival [188, 190]. Blocking the expression and activity of IDO2 via 
gene silencing plays a role in reducing pathogen burden, minimize TB pathology and 
enhance host survival [188]. In addition, the inhibition of IDO2 is associated with the 
restoration of T-cell proliferation and functions [188]. These findings indicate that IDO2 
activation plays a vital role in M. tuberculosis pathogenesis  
1.7 Innate immune receptors 
Sensing and recognition of pathogens by the innate immune system is mediated by a 
number of germline-encoded receptors, which detect pathogen-associated molecular 
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patterns (PAMPs) released by the invading pathogens. The receptors involved in detecting 
these structures are called pattern recognition receptors (PRRs), expressed on the cell 
surfaces of innate immune cells [193]. PRRs are broadly divided into two: Transmembrane 
proteins (Toll-like receptors and C-type receptors) and cytoplasmic proteins (Retinoic acid-
inducible gene I-like receptors and NOD-like receptors) [193, 194]. The detection of 
PAMPs by PRRs induces an inflammatory response, resulting in a rapid innate immune 
response. In addition, the signal from the activated receptors plays a crucial role in the 
expression of costimulatory and MHC molecules on professional antigen-presenting cells, 
resulting in the generation of an effective immune response against pathogens. 
1.7.1 Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin 
(DC-SIGN) receptors 
DC-SIGN is mainly expressed on immature DCs, macrophages and karyocytes, and is one 
of a few lectin-like receptors involved in initiating signaling cascades after binding ligands 
[195]. The expression of DC-SIGN is mainly induced by IL-4 [196].  As with other lectin-
like receptors, DC-SIGN can successfully direct foreign antigens to late 
endosomal/lysosomal compartments for efficient processing and presentation to T-cells, 
specifically CD4 T-cells [197], and in some cases naïve and memory CD8 T-cells [198].  
Active participation of DCs to peripheral tolerance depends on how DCs sense or detect 
foreign antigens. For instance, DCs activation via Toll-like receptors (mainly TLR-4 and 
TLR-2) induces an immunogenic response. In contrast, DC-SIGN (lectin-like receptors) 
favor tolerogenic DCs that produce anti-inflammatory factors and activate regulatory T-
cells [159]. Many pathogens exploit DC-SIGN binding to evade host immune response.  
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The DC-SIGN has been identified and characterized as a key receptor for M. tuberculosis 
in human DCs and alveolar macrophages [160, 199]. This lectin-like receptor is capable of 
sensing mycobacterial-derived mannose-containing molecules such as mannose-capped 
LAM (Man-LAM), lipomannan (LM), arabinomannan, glycoproteins, PIMs, and α-glucan. 
Thus, M. tuberculosis utilizes its ability to interact with DC-SIGN to evade immune 
detection [200]. For instance, the activation of dendritic cells by ManLAM via DC-SIGN 
impairs maturation and induces the anti-inflammatory cytokine IL-10 [160]. In this 
manner, the bacillus prevents the proper activation of DCs, given that IL-10 inhibits the 
expression of co-stimulatory molecules and the production of IL-12, which are essential 
for the activation of Th1 cells.  A recent study showed that macrophages found in 
tuberculous pulmonary lesions of non-human primates express DC-SIGN, which enable 
M. tb to parasitize macrophages, and also turn off the pro-inflammatory response in these 
cells to prevent potential immunopathology [200]. Therefore, mycobacteria target DC-
SIGN to infect DCs and shift the Th1- versus Th2 cell balance towards Th2 in favor of the 
pathogen's persistence.  
1.7.2 Toll-like receptors (TLRs)  
TLRs are members of the type-1 transmembrane receptor family that are evolutionarily 
conserved proteins among vertebrates and invertebrates [201]. It belongs to one of the most 
essential and functionally characterized pattern recognition receptors playing a crucial role 
in innate immunity [202]. TLRs, named after the Drosophila melanogaster toll protein, are 
membrane-bound sensors present on cell plasma membranes and endosomes [203]. 
Prototypical TLR proteins are structurally characterized by two major domains, namely- 
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an extracellular domain that contains hydrophobic tandem leucine-rich repeat (mediates 
the recognition of pathogen molecular patterns) and the cytoplasmic tail that contains a 
highly conserved region called the Toll/IL-1 receptor (TIR) signaling domain, required for 
signal transduction [204]. 
The TLR family is highly expressed in immune-responsive tissue such as macrophages, 
dendritic cells, spleen cells, and cells of the tissues exposed to the external environment 
such as lungs and the gastrointestinal tract [205]. They recognize PAMPs, which are highly 
expressed by microbial pathogens or danger-associated molecular patterns (DAMP) [206]. 
Upon binding PAMPs, TLRs activate the NF-κB signaling pathway and induce the 
transcription of pro-inflammatory genes [204]. During mycobacterial infection, there is 
evidence that mycobacterial components are detected by TLR2, TLR4 and TLR9 [207] 
1.7.2.1 Toll-like receptor 2 (TLR2) 
TLR2 signaling is induced by forming a heterodimer with its coreceptors (TLR1 or TLR6) 
which increases the diverseness of molecules detected by the receptor [208]. Following 
ligand stimulation, TLR2 heterodimers initiate a MyD88-dependent intracellular signaling 
cascade [209]. This signaling pathway induces nuclear translocation of nuclear factor-
kappa B (NF-B) to activate gene transcription and subsequent cytokine production [210]. 
The signaling cascade also induces mitogen-activated protein kinases (MAPKs) that can 
promote transcription of inflammatory genes via activation protein 1 (AP-1) [210, 211].  
A growing number of studies have shown that TLR2 is involved in macrophages/DCs 
recognition and responses to a variety of mycobacterial cell wall glycolipids such as 
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lipoarabinomannan (LAM), phosphatidylinositol mannoside (PIM), Lipomannan (LM), 
Trehalose 6,6'-dimycolate (TDM) [88, 207, 212]. Aside lipoglycan binding, TLR2 also 
recognizes glycoprotein present or secreted from the mycobacterial cell wall. One of these 
glycoproteins is the 19 kDa mycobacterial lipoprotein [213, 214]. In addition to 
mycobacterial cell wall glycolipids and lipoproteins, secreted proteins such as ESAT-6 and 
TB10.4 induce pro-inflammatory cytokine production in a cell line via TLR2 signaling 
[215, 216]. Furthermore, recent findings indicate that M. bovis-derived protein activates 
the NF-κB pathway via TLR2 in macrophage cell lines [217]. Thus, the broad ligand 
specificity of TLR2 indicates a crucial role for TLR2 activation in eradicating 
mycobacterial infection. 
1.7.2.2 Toll-like receptor 4 (TLR4) 
As a complex glycoprotein, TLR4 structurally has both extracellular domains containing 
leucine-rich repeats (LRRs) and the intracellular TIR domain. The LRRs play a role in 
ligand detection resulting in activation of TRIF- or MYD88-dependent intracellular 
signaling cascades [218]. TLR4 is known for recognizing gram-negative bacteria-derived 
lipopolysaccharide (LPS) [219]. In the serum, LPS first binds to LPS binding protein (LBP) 
[220, 221]. LBP catalysis the transfer of LPS to CD14 receptor. CD14 receptor is a co-
receptor for TLR4, and it is a membrane-bound pattern recognition receptor that primarily 
recognizes LPS [222]. However, CD14 lacks an intracellular domain and thus is incapable 
of transducing cytoplasmic signals [223]. To compensate for the limitation of intracellular 
signal transduction, CD14 interacts with TLR4 to recognize LPS. The complex (LPS-
CD14-MD-2 proteins) formed associate with the extracellular domain of TLR4 to initiate 
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intracellular signaling events that lead to inflammatory cytokine production [224]. MD-2, 
also known as Lymphocyte antigen 96, is a molecule that confers LPS responsiveness on 
TLR4. The binding of LPS/MD-2/CD14 complex to TLR4 leads to TLR4 dimerization and 
conformational changes in the TIR domain interface. This enhances the recruitment of 
adaptor proteins that binds to the intracellular TIR-domain [225]. TLR4 activation triggers 
two intracellular signaling pathways: myeloid differentiation factor 88 (MyD88)-
dependent and independent pathways.  
 In M. tuberculosis, TLR4 recognizes cell wall lipids, glycoproteins, and secreted proteins 
as TLR2. Similar to TLR2, Lipomanan induces the production of pro-inflammatory 
cytokines in macrophages in a TRL4-dependent manner [226]. Thus, whereas some M. 
tuberculosis strains activate mainly TLR2, others also activate TLR4, resulting in different 
cytokine profiles [227] 
1.7.2.3 Toll-like receptor 9 (TLR9)  
Synthetic CpG-DNA derived from bacterial DNA activates innate immune cells such as 
macrophages and DCs via its specific receptor TLR9 localized on the phagosomal 
membrane [228]. Mice lacking TLR9 are highly susceptible to a low-dose aerosol M. tb 
infection than wild-type controls [229]. Furthermore, IL-12p40 production is abolished in 
TLR2/TLR9−/− cells infected with M. tuberculosis, indicating a synergistic effect of TLR2 
and TLR9 activation in cytokine production [229]. Aside from TLR2 and 4 recognizing 




1.8 TLR signaling  
The binding of TLRs to its ligands activates specific downstream  intracellular signaling 
cascades that initiate host defense response [231]. The interaction of  PAMPs with TLR 
results in the production of pro-inflammatory cytokines and type 1 interferon [232]. 
Signaling via TLR depends on the type of stimulus, the TLR stimulated, and the 
downstream adaptor molecule recruited to the TIR domain [233]. Thus, TLR signaling 
involves two distinct pathways: the MyD88-dependent pathway (employed by all TLRs 
apart from TLR3 resulting in the generation of inflammatory cytokine) and TRIF-
dependent pathway (utilized by TLR3 and 4 leading to interferon regulatory factor-3 
(IRF3) transcription factor activation and subsequent increase of genes encoding type 1 
interferons (IFNs) and costimulatory molecules) [234]. Following activation of MyD88,  
IL-1 receptor-associated kinase-4 (IRAK-4) are recruited through the death domains to 
TLR4. The recruited IRAK4 binds to its receptor complex leading to activation of IRAK1, 
thereby inducing the kinase activity of IRAK1[235].  The phosphorylated IRAK1  
dissociates and binds to tumor necrosis factor receptor-associated factor-6 (TRAF6) 
through 3 major conserved binding domains [236, 237]. The downstream signaling of the 
TNF receptor superfamily is mediated by TRAF6 [237].  The complex formed by IRAK1 
and TRAF6 dissociates from the TLR4 receptor cytoplasmic domain and later form a 
complex with three adapter molecules, which are TAK1-binding protein 1, 2 and 3 (TAB1, 
TAB2 and TAB3) and transforming growth factor-β activated kinase 1 (TAK1). Also, 
TRAF6 phosphorylation leads to activation of MKK and IKK complex resulting in the 
subsequent phosphorylation of NF-B and MAP kinases.  
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1.9 Categories of Toll-like receptor agonists 
PAMPs are agonists of PRRs expressed by innate immune cells. Immune system 
stimulation via TLRs activates innate immune cells and promotes inflammatory responses, 
which are critical for host protective mechanisms [238]. As such TLRs recognize 
lipopolysaccharide (LPS), Single stranded-RNA (ssRNA40), flagellin and CpG 
oligodeoxynucleotides to initiate intracellular signaling events that result in the activation 
of a variety of proinflammatory immune responses [239]. Due to the ability of TLR 
agonists to activate the immune system, promising approaches to control infectious disease 
involve regulation of the host’s innate immune cells using agonists that bind to its receptor 
and execute an agonist function. Because of TLR agonist immunostimulatory activity, TLR 
agonists are being utilized as cancer immunotherapeutics and vaccine adjuvants. 
1.9.1 Lipopolysaccharide (LPS) - (a TLR4 agonist)  
Multiplication of the gram-negative bacteria within the host results in the release of LPS 
into the circulation.  Lipopolysaccharide, a proinflammatory endotoxin is a component of 
the outer membrane of Gram-negative bacteria that robustly activates different circulating 
cell types [240]. Dendritic cells and macrophages, which are LPS-responsive cells, get 
activated following the interaction of LPS with circulating LPS-binding protein and CD14 
[241]. It has been demonstrated that LPS triggers the induction of NF-κB-dependent 
proinflammatory mediators such as interleukin-12 (IL-12), tumor necrosis factor-α (TNF-




1.9.2 Flagellin - (a TLR5 agonist) 
Flagellin, a major component of bacterial flagella, is a virulence factor detected by the 
innate immune system [244]. It has been reported that mammalian TLR5 senses bacterial 
flagellin from both gram-negative and gram-positive bacteria resulting in the activation of 
the receptor and subsequent phosphorylation of the NF-κB signaling events [245]. There 
is growing evidence suggesting that Salmonella flagellin is a potent inducer of pro-
inflammatory cytokines in monocytes following interaction between flagellin and the 
surface receptor localize on innate immune cells [244, 246]. Also, flagellin is known as a 
potent adjuvant. The adjuvant activity depends on the ability of flagellin to induce the 
production of proinflammatory responses in both innate and non-immune cells, which is 
essential for the activation of adaptive immune responses [247, 248]. Dendritic cells are 
among the innate immune cells activated by flagellin and depending on the type of DCs 
involved, the flagellin-DCs interaction is either direct or indirect. Thus, myeloid-derived 
DCs directly respond to flagellin via TLR5, unlike the indirect response of splenic DCs to 
flagellin [249].  
1.9.3 Polyinosinic-polycytidylic acid-Poly (I:C) - (a TLR3 agonist) 
Viral proteins and nucleic acids activate TLRs to induce the production of chemokines, 
cytokines, and IFNs. Poly (I:C) is a synthetic analog of double-stranded RNA, which serves 
as a molecular pattern associated with cells infected with RNA virus [250]. Both viral 
double-stranded RNA and its analog poly (I:C) are potent inducers of type I IFNs (IFN-α 
and -β), which are the key cytokines in antiviral host defense. Induction of type I IFNs by 
poly (I:C) occurs via activation of  TLR-3, resulting in the protection of mice and rhesus 
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monkeys from viral infection [251, 252]. Furthermore, TLR3 recognizes dsRNA and 
resultant signal transduction activates the nuclear factor-kappaB (NF-κB), resulting in pro-
inflammatory cytokine production [253]. Unlike other TLRs, TLR3 mRNA expression is 
restricted to DCs subsets and intestinal epithelial cells fibroblasts [254].  Only CD11c+ DC  
subset was shown to respond to poly (I:C), while plasmacytoid DC are stimulated by 
immunostimulatory bacterial DNA (CpG DNA) through TLR9 [255]. 
1.9.4 Imiquimod and Single stranded-RNA (ssRNA40) - (a TLR7 agonist) 
Imiquimod (an immune response modifier) activates innate and adaptive immune 
responses by binding to TLR7, with subsequent activation NF-B resulting in cytokine 
release [256]. Imiquimod exposure causes activation of immune cells to produce antiviral 
cytokines, particularly IFN-α,  TNF-α, and interleukin (IL)-12, IL-10, IL-1, IL-6, and IL-
8 [257].  Imiquimod also triggers IFN- production via T-cell stimulation, thereby 
promoting cell-mediated immunity [258]. IFN-γ released stimulates cytotoxic T 
lymphocytes, which is essential in the clearance of virally infected cells [259]. Thus, 
besides its anti-viral activity, imiquimod causes apoptosis of skin cancer cells, implicating 
its anti-tumoral activity [260]. The ability of Imiquimod to induce Interferon-alpha and 
other cytokines explains its acute antiviral and antitumor effects. Single-stranded RNA 
(ssRNA) is also known as the natural ligand of endosomal localized TLR7 [261, 262]. 
Influenza virus-derived ssRNA has been demonstrated to induce the production of 




1.9.5 Pam3CSK4 – (a TLR2 agonist) 
Pam3CSK4 (Pam3CysSerLys4), is a synthetic triacylated lipopeptide (LP) that mimics 
bacterial lipopeptides [264]. Detection of Pam3CSK4 is mediated by TLR2, which 
synergizes with TLR1 via the cytoplasmic domain, triggers the signaling events resulting 
in activation of NF-κB [265]. Pam3CSK4 promotes Th1 responses, thereby serving as a 
beneficial antiallergic effect on allergic rhinitis [266]. Thus, the binding of TLR2 by its 
agonist Pam3CSK4 decreased allergic inflammation and skewed Th2 response toward Th1 
response. This suggests that activation of TLR2 by Pam3CSK4 activates the antigen-
presenting cells to produce cytokines such as IL-12, which induces IFN- producing Th1 
response, resulting in impaired Th2 cell differentiation and weakened eosinophilic airways 
inflammation. Other studies demonstrated that PAM3CSK4 instruct or bias the commitment 
of haematopoietic stem cells to favour myeloid cell, which correlate to the selective 
upregulation of transcription factors known to facilitate myeloid commitment [267]. This 
suggest that TLR2 agonists can shift the developing lineage committed progenitors to 
enhance the generation of effector cells associated with innate immune system. 
1.9.6 CpG oligodeoxynucleotides (ODN) - (a TLR9 agonist) 
Synthetic CpG ODN is the ligand for TLR9, and activation occurs via endosomal uptake 
of CpG ODN by TLR9 [268]. Following TLR9 activation, two different TLR9 signaling 
cascades occur namely- IFNα and NF-κB signaling pathway. Interaction of  TLR9 and 
CpG ODNs stimulate the innate immune system through direct and indirect induction of 
IFNs, chemokines, and pro-inflammatory cytokines [269]. Innate immune cells such as 
plasmacytoid DCs and natural killer cells are efficiently activated by CpG ODNs. 
42 
 
Furthermore, CpG ODNs stimulate the B-cell arm of the adaptive immune system, 
resulting in antibody production and the activation of antibody-dependent cell-mediated 
cytotoxicity (ADCC) [269]. This suggests that the overall immune responses induced by 
CpG ODNs should be beneficial for controlling numerous diseases where robust innate 
and adaptive immune responses serve as a requirement.  
CpG ODNs activation of the immune system has been shown to have a broad range of 
benefits.  For instance, CpG ODNs serve as a vaccine adjuvant and also treat viral, 
bacterial, and parasitic diseases [269]. Furthermore, the antitumor activity of CpG ODNs 
has also been demonstrated in a mouse model [269]. Therefore, CpG ODNs represent 
targeted immune-modulatory drugs with a broad range of potential applications.  
1.10 Immune signaling pathways for cytokine production 
The primary signaling pathways known to induce cytokine production in immune cells 
include the mitogen-activated protein kinase pathway (MAPKs), JAK-STAT and NF-κB 
pathway. MAPKs and STATs are cytoplasmic proteins that play a critical role in immune 
regulation, cytokine production and inflammatory response [270, 271]. Hence, the 
activation of MAPKs, STAT and NF-κB pathways initiate a cascade of intracellular 
signaling events resulting in the expression of various pro-inflammatory genes. 
1.10.1 Extracellular signal-regulated kinases (ERK) pathway 
Mitogen-activated protein kinases are highly conserved group of serine/threonine protein 
kinases that mediate intracellular signaling events required to accomplish various 
fundamental cellular processes like differentiation,  proliferation, apoptosis, motility, stress 
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response and survival [272, 273]. Conventional MAPKs consist of extracellular signal-
regulated kinase 1/2 (ERK1/2), p38 MAPKs, c-Jun amino-terminal kinase (JNK), and Big 
MAPKs (BMK) [273, 274].  
ERK is the first mammalian MAPKs to be characterized and exhibit different isoforms 
from ERK1-ERK8, but ERK 1and ERK2 are the most important among them. The two 
phosphorylation sites (tyrosine and threonine) are phosphorylated in order to activate the 
ERK1/2 signaling cascade, which occurs exclusively through MEK1 and MEK2 [275]. 
ERK1/2 shares 83% amino acid sequence identity, and they are highly conserved 
throughout eukaryotic cells. The ERK1/2 is primarily activated by the cell surface receptor 
enzyme (receptor tyrosine kinases), and they respond to various extracellular stimuli, 
including mitogens, cytokines, growth factors, bacterial products and environmental 
stressors [276]. Following stimulation,  ERK1/2 phosphorylates different substrates in 
many cellular locations, resulting in the induction of ERK1/2 dependent cellular processes 
[277]. 
1.10.2 Signal transducer and activator of transcription (STAT) signaling pathway  
The biological effects of IFN- are manifested via its interaction with the IFN- receptor 
complex localizes on the cells. The heterodimeric receptor complex consists of a ligand-
binding alpha subunit (IFNGR1) and a signal-transducing beta subunit (IFNGR2). There 
is higher affinity binding of IFN-γ to IFNGR1 when compared with IFNGR2. The 
interaction between the receptor and ligand initiates a signaling event that subsequently 
induces host protective immune responses [278]. IFN-γ binding crosslinks IFNGR1 and 
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IFNGR2 and phosphorylates Janus Kinases (JAK1 and JAK2). The inactive cytosolic 
transcription factor STAT1 becomes phosphorylated by the activated JAKs [279].  
All STATs have seven well-defined domains, including an N-terminal conserved domain 
and a C-terminal transactivation domain. The amino-terminal region prevents the 
dimerization of STATs in their inactive state [280]. SH2 domain is critical for recruiting 
STATs to activate receptor complexes and interaction with Janus (JAK) and Src kinases. 
It is the most conserved domain among STATs, and it plays a vital role in STAT signaling 
by facilitating homodimerization and heterodimerization, which are crucial for nuclear 
localization and DNA binding activities [281]. In an inactive or unstimulated cell, STATs 
are inactive and exists in an unphosphorylated state in the cytoplasm. Receptor tyrosine 
phosphorylation occurs upon cytokine stimulation and serves as a docking site for STATs 
through the SH2 domains leading to the reorientation of STAT proteins resulting in 
homodimerization or heterodimerization. Once phosphorylated, the dimerized STATs 
translocate to the nucleus and bind to specific regulatory sequences to activate or repress 
transcription of target genes. Although the classical JAK-STAT pathway is usually 
initiated by tyrosine phosphorylation, most vertebrate STATs also contain a second 
phosphorylation site, which is a serine, and serine phosphorylation also regulates STAT 
transcriptional activities [282]. STAT1 phosphorylation occurs at Tyr701, resulting in 
STAT1 dimerization, nuclear translocation and DNA binding. STAT1 can also be 
phosphorylated at serine (ser727) and serine phosphorylation is required for the maximal 
induction of STAT1 mediated gene activation. Phosphorylated STAT1 translocate to the 
nucleus and binds to GAS (gamma activated sequences) elements in the promoter region 
and mediates protective immunity by transcription of IFN-γ associated genes. Activated 
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STAT1 phosphorylation subsequently activates T-bet transcription factor, representing the 
onset of T-cell polarization to Th1 subset [283]. Recruitment of additional transcription 
factor Runx3, which utilizes IFN-γ promoter as its binding site, induces IFN-γ expression 
and simultaneous silencing of the IL-4 gene [284]. Hence, IFN-γ plays a crucial role in 
maintaining T-bet expression and suppresses the capability of Th1 cells to produce  IL-4 
[273]. 
1.10.3 Nuclear factor-kappa B (NF-B) signaling pathway 
The NF-κB protein represents Rel family, and it is associated with five structurally related 
members, which include RelA (p65), C-Rel, RelB, p105 (NF-B1) and p100 (NF-B2) 
[285]. Members of NF-B are characterized by the presence of Rel homology domain 
(RHD), which is essential for binding to cognate DNA elements.  The phosphorylation of 
NF-κB consists of two major signaling pathways, namely- the canonical and noncanonical 
pathways [286]. In contrast to the canonical NF-κB signaling pathway, which responds to 
various ligands of pattern-recognition receptors (PRRs), cytokine receptors, T-cell receptor 
as well as  TNF receptor superfamily members [287],  the non-canonical NF-κB pathway 
only responds to a specific group of stimuli such as ligands of a subset of TNF receptor 
superfamily members [286]. 
Under homeostatic conditions, the inactive NF-B is localized in the cytoplasm due to its 
interaction with IKB proteins. The binding of IKB proteins to inactive NF-B inhibits its 
nuclear translocation, resulting in cytoplasmic confinement. However, following TLR 
stimulation with a pathogenic molecule or cytokine, the ensuing signal transduction results 
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in NF-B activation [288]. This is achieved via the inducible degradation of IKB by 
activated IKK, resulting in nuclear translocation of canonical NF-B [289]. The primary 
role of NF-κB is the mediation of pro-inflammatory gene induction in innate immune cells 
and the regulation of T-cells effector function [290]. In addition, it has been reported that 
NF-κB regulates the activation of inflammasomes [291]. 
1.11 Role of signaling pathways in mycobacterial infection 
M. tuberculosis-complex PAMPs bind various PRRs expressed on innate immune cells 
resulting in the activation of different signaling pathways [292, 293]. Although 
mycobacteria infection leads to profound production of proinflammatory cytokines, the 
intracellular signaling pathways leading to the production of these cytokines are well 
studied. An increasing number of studies have revealed the role of MAPKs, STAT and NF-
kB family proteins in mycobacteria-induced proinflammatory cytokine production [294-
297]. However, there are inconsistent reports on the role of these proteins in mycobacteria-
induced cytokine production. One study shows that TLR2-ERK signaling in M. tuberculosis-
infected macrophages drives anti-inflammatory responses and inhibits Th1 polarization of 
responding T-cells [298]. In addition,  M. tuberculosis uses the TLR2-ERK signaling 
pathway in macrophages to facilitate its intracellular survival and prevent efficient 
elimination by antigen-specific IFN-γ-producing T-cells [299]. 
 In contrast, protective immune responses in seen in studies where activation of p38 and 
ERK mediates IFN-γ production from T-cell in response to M. tuberculosis infection, a 
defective pathway in patients with TB [300]. Also, Jung et al. revealed that ESAT6 directly 
induces IL-6 production in macrophages by activating STAT3 [301]. Furthermore, M. 
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tuberculosis induces the expression of proinflammatory and regulatory cytokines in human 
monocytes infected with M. tuberculosis via NF-κB and MAPK dependent mechanisms 
[302].  A recent study reported that M. tuberculosis activation of MAPKs and  NF-B via 
the TLR4 dependent pathway is critical in producing pro-inflammatory cytokines in DCs 
[303]. To date, no study has addressed the role of ERK and NF-B proteins in pro-
inflammatory cytokine production following stimulation of bDCs with M. bovis cell 
surface antigen.  In studies II and III, I addressed this gap in knowledge and provided strong 
evidence to show that ERK and NF-B proteins play a critical role in M. bovis-induced 
proinflammatory cytokine production in DCs 
1.12 Cytokines 
Cytokines are water-soluble proteins and glycoproteins produced by hematopoietic and 
non-hematopoietic cells to influence the activity of other cells [304]. They are critical in 
regulating immune cells by mediating cell to cell communication through autocrine and 
paracrine pathways. In a homeostatic condition, cytokine production is limited. However, 
with infectious conditions, cytokine induction is in response to the causative agent [305].  
Interaction of M. tuberculosis ligands with the receptors on innate immune cells causes cell 
activation and cytokine production, modulating innate and adaptive immune response to 
M. tuberculosis [306]. It has been reported that cytokines produced in response to a 
pathogen could be beneficial or harmful to the host [307]. Thus, the production of cytokines 
in response to M. tuberculosis infection is not always helpful to the host protection, instead 
some of these immune modulators promote pathogen survival [308]. Therefore following 
M. tuberculosis infection, two major groups of cytokines are released, namely 
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proinflammatory cytokines (beneficial to the host) and anti-inflammatory cytokines 
(harmful to the host). 
1.12.1 Proinflammatory Cytokines 
Proinflammatory cytokines are usually released by innate immune and non-immune cells 
following exposure to a pathogenic molecule. These cytokines promote both local and 
systemic inflammatory responses, and severe inflammatory response due to excessive 
generation of these cytokines results in tissue damage [307]. After encountering M. 
tuberculosis antigen by immune cells, several pro-inflammatory cytokines (IL-12, IL-1, 
TNF, IL-6,  IL-23, and IL-18) are produced, which control mycobacterial infection by 
induction of  Th1 immunity [309]. 
1.12.1.1 Interleukin 12 (IL-12) and control of mycobacterial infection 
Interleukin 12 is a pro-inflammatory cytokine composed of two subunits (p35 and p40 
subunits). While p35 is constitutively expressed at a low level, however the expression of 
p40 is induced with microbial stimulation [310]. The co-expression of these two subunits 
within a cell is required to produce a bioactive IL12p70 cytokine.  Production of IL-12 
following infection is critical for the induction of IFN- producing Th1 responses against 
intracellular pathogens. Hence, the binding of IL-12 to its receptor expressed on naïve CD4 
T-cells induces intracellular signaling cascades leading to activation and differentiation of 
naïve CD4 T-cells to IFN- producing Th1 subset [310]. Furthermore, IL-12 inhibits the 
polarization of Th2 and associated cytokines (IL-4 and IL-10). 
It has been reported that microbial stimuli are not potent enough to induce the production 
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of bioactive IL-12 cytokine. Thus, secondary signals in the form of CD40-CD40 ligand 
interaction are required to promote the production of bioactive IL-12 [310-312]. During 
IL-12 signaling, communication between cells occurs via CD40-CD40L interaction and 
this interaction is bi-directional, which allows signaling to both APCs and T-cells [313]. 
Thus, aside from CD40-CD40L interaction resulting in increased production of bioactive 
IL-12 from APCs, the interaction of CD40-CD40L also induce T-cell proliferation and 
IFN-γ production [313].  
Following M. tuberculosis infection, IL-12 produced by DCs synergizes with IL-18 to 
induce IFN- production from Th1 subset, which is essential for host protection against M. 
tuberculosis infection [314]. It has been revealed that IL-12-deficient mice are highly 
susceptible to M. tuberculosis infection [315]. Mutations in IL-12 and its receptor have 
also been demonstrated in individuals suffering from mycobacterial disease due to the 
attenuated production of IFN- [316]. This suggests that IL-12 protects the host against 
mycobacterial infection via induction of IFN-, thereby serving as a link between adaptive 
and innate host immune responses [317]. 
1.12.1.2 Tumor necrosis factor-alpha (TNF-) and mycobacterial infection 
Tumor necrosis factor-alpha glycoprotein is another proinflammatory cytokine produced 
by phagocytic cells. There are two isoforms of TNFs, namely TNF- and TNF-. Both 
TNF- and TNF- induce an immune response by binding to surface receptors TNFR1 and 
TNFR2, respectively. In homeostatic conditions, TNF- detection is rare. However, 




In mycobacterial infections, TNF- plays a significant role in protecting the host [319]. 
TNF- is the primary cytokine that maintains granuloma containing the infectious foci, 
thereby preventing dissemination [320]. In a mouse model, TNF- is essential in protecting 
the host from developing active TB by containment of latent infection within granuloma 
[320]. Mice lacking either TNF- production or its receptor are highly susceptible to M. 
tuberculosis infection [321]. In addition, mice lacking TNF- receptors or treated with an 
anti-TNF antibody are at high risk of infection with mycobacteria [322]. It has been shown 
that the neutralization of TNF- activity during latent TB infection triggers TB reactivation 
in  C57BL/6 mice resulting in host tissue damage and death [320].  Other studies also 
reported that TNF- signaling blockage increases mortality in zebrafish infected with M. 
marinum due to increased intracellular bacterial growth [323]. These findings indicate that 
TNF- is required for maintaining the integrity of granuloma structure, thereby inhibiting 
bacterial dissemination.  
1.12.1.3 Role of interleukin 6 (IL-6) in mycobacterial infection 
IL-6 is a multifunctional cytokine. IL-6, together with TNF-αand IL-1β, initiates early pro-
inflammatory responses [324]. Mice studies demonstrated that IL-6 might play multiple 
roles and contribute positively and negatively to host defense against M. tuberculosis 
infection. It has been shown that IL-6 plays a vital role in protection against murine M. 
tuberculosis infection [325] due to the influence of the CD4+ T cells response [326]. M. 
tuberculosis-infected IL-6-deficient animals show an impaired Th1 response and increased 
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bacterial loads, indicating a requirement for IL-6 in host resistance to M. tuberculosis 
infection [325, 327].  
In contrast, IL-6 is also associated with the pathogenesis of many chronic inflammatory 
diseases, including tuberculosis [328, 329]. For instance,  IL-6 secreted by M. tuberculosis-
infected macrophages suppresses the responses of uninfected macrophages to IFN-γ, 
resulting in increased proliferation of bacteria [330]. To understand which cellular process 
induced by IFN-γ is actually counteracted by IL-6, Dutta et al. studied the role of IL-6 on 
IFN-γ induced autophagy formation in virulent M. tuberculosis infection. They observed 
that  IL-6 inhibits both IFN-γ and starvation-induced autophagy in M. tuberculosis-infected 
macrophages [331]. Further studies revealed that increased levels of IL-6 in the lungs, 
along with increased levels of IL-1β, is significantly correlated with tuberculosis 
progression in genetically susceptible mice [328]. The downregulation of IL-6R expression 
on CD4 T-cells in patients with active pulmonary TB is associated with decreased Th17 
phenotype response, suggesting a role for IL-6 in the progression of TB in humans [332].  
1.12.1.4 Role of interleukin 1 beta (IL-1) in mycobacterial infection 
The pro-inflammatory cytokine IL-1β is a key mediator of inflammation and plays a vital 
role in the host's resistance to M. tuberculosis infections [333]. IL-1β directly kills M. 
tuberculosis in murine and human macrophages and promotes the recruitment of anti-
microbial effector molecules. The role played by IL-1β in host resistance has been 
demonstrated by the significantly reduced survival of IL-1β-/- or IL1R-/- mice following 
mycobacterial infection [334-336]. The increased susceptibility of mice lacking critical 
mediators of IL-1 signaling suggests that the initial production of IL-1 upon M. 
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tuberculosis infection is essential for establishing protective immune responses necessary 
for disease control [337].  
In contrast, IL-1 has been implicated in TB disease severity. Production of IL-1 is 
regulated after the onset of adaptive immunity via multiple mechanisms, including IFNγ 
production, which acts via the induction of nitric oxide synthase 2 (NOS2) [338, 339]. In 
susceptible mice, persistent IL-1 signaling can contribute to the accumulation of disease-
promoting neutrophils, and genetic variants that result in higher IL-1β production are 
associated with increased disease severity and neutrophil accumulation in humans [339, 
340].   This suggests that IL-1 blocking may ameliorate inflammation-induced tissue 
damage and improve the treatment outcome in TB infected hosts. 
1.12.1.5 Interferon-gamma (IFN-) and biological significance in mycobacterial 
infection 
Interferon-gamma is the primary subtype of type 2 IFNs, and it is established as a 
macrophage activating factor due to its role in activating macrophage physiologic 
activities. IFN- production is mainly by Th1 subset of CD4 T-cells, cytotoxic CD8 T-
cells,  NK cells and NKT cells [341, 342]. Also, it can be produced by DCs, macrophages, 
and B-cells [343]. IFN- has been demonstrated to have numerous immunomodulatory 
functions such as inflammatory activity and regulation of macrophage intracellular 
microbicidal effect [343]. Some of the immunomodulatory effects of IFN- on 
macrophages include induction of cytokine and nitric oxide production, which facilitates 
the killing of intracellular bacteria [344]. In addition, IFN-γ reverts the blockage of 
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phagosome-lysosome fusion caused by M. tuberculosis as part of its survival mechanism, 
as well as induction of autophagy to promote clearance of M. tuberculosis [345]. 
Furthermore, IFN-γ boosts human macrophage apoptosis in a NO-dependent manner [346].  
Several studies showed that IFN-γ orchestrates the induction of cellular immunity, which 
is the hallmark of TB infection.  Thus, IFN- induces the expression of antigen-presenting 
molecules on DCs, thereby increasing antigen presentation and induction of protective host 
immune response.  It has been demonstrated that a non-functional IFN-γ or IFN-γR 
signaling pathway enhances host susceptibility to less virulent strains. Also, dysfunctional 
IFN-γR promotes disseminated infection in children vaccinated with BCG [347]. Knock-
out mice lacking IFN-γ exhibit increased mycobacterial growth and developed necrotic 
granulomas [348]. The increased mycobacterial burden and host susceptibility are related 
to dampened cell-mediated immunity and poor expression of nitric oxide synthase 2 
(NOS2) [349].  
1.12.2 Anti-inflammatory cytokines 
Anti-inflammatory cytokines are the immune modulators that control pro-inflammatory 
cytokine induction, thereby inhibiting the inflammatory process [350]. These cytokines 
exhibit their immunomodulatory role by blocking the proinflammatory cytokine 
production or by interfering with their biological effects [350]. Thus, over-production of 
anti-inflammatory cytokines may compromise host protection induced by the 
proinflammatory cytokines. The three major anti-inflammatory cytokines secreted by 
immune cells include interleukin 4 (IL-4), interleukin 10 (IL-10), and transforming growth 
beta (TGF-) [350]. 
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1.12.2.1 Interleukin 10 and regulation of mycobacterial infection  
Interleukin 10  is a well-established anti-inflammatory cytokine produced by different 
immune cells [351].  It blocks immunopathology emanating from excessive activity of DCs 
and Th1 cells by down-regulating the production of IL-12 and TNF- [351]. Excessive IL-
10 production blocks the pro-inflammatory response to mycobacterial infection [352], 
which aids in pathogen escape. Production of IL-10 also supports mycobacterial survival 
by inhibiting CD4 T-cell responses and antigen presentation by mycobacteria-infected DCs 
[353]. Thus, DCs transportation of mycobacterial antigens to the draining lymph nodes was 
shown to be blocked by IL-10 [354]. Moreover,  IL-10 inhibits DCs mediated T-cell 
differentiation and recruitment of Th1 cells to the lungs of mice infected with M. 
tuberculosis [355]. Within the granuloma, IL-10 blocks phagosome maturation and IFN- 
mediated macrophage activation, resulting in impaired secretion of both ROIs and RNIs, 
required for mycobacterial killing [356]. In peripheral blood mononuclear cells isolated 
from TB patients, increased T-cell proliferation and IFN- production was observed 
following antibody neutralization of endogenous IL-10 [357]. These observations suggest 
that IL-10 favors mycobacterial infection by downregulating host Th1 immune responses. 
1.13 Negative regulators of cell signaling 
Several molecules negatively regulate cytokine signaling via various mechanisms to inhibit 
generation of excessive immune responses that result in host tissue pathology and 
autoimmunity. The key molecules involved in these signaling pathways are the primary 
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targets of negative regulators. Activation of the cytokine signaling pathways is blocked by 
the suppressor of cytokine signaling (SOCs) protein [358]. 
1.13.1 Suppressor of cytokine signaling (SOCs) and control of mycobacterial 
infection 
Suppressor of cytokine signaling (SOCs) proteins are the negative regulator of cytokine 
signaling [358, 359]. Eight members of SOCs proteins (CIS and SOCs1-7) have been 
reported in mammals [358]. Overexpression studies have demonstrated that SOCs1 and 3 
possess the same inhibitory role on various cytokine signaling [358]. Thus, SOCs1 and 3 
have been reported as inhibitors of tyrosine phosphorylation and nuclear translocation of 
STAT1 following IFN- stimulation. In contrast to SOCs1, which show robust inhibitory 
activity to IFN- signaling due to its higher affinity to Jak2, SOCs 3 exhibit less inhibitory 
activity because of its higher affinity for Tyk2. Hence, this indicates that SOCs1 and 3 are 
the primary inhibitors of IFN- mediated Jak /STAT signaling pathways.  
In addition to IFN- signaling, the initial step involved in TLR signaling is blocked by 
SOCs1 in macrophages [360]. SOCs protein has utilized several mechanisms to block TLR 
signaling pathways. For instance, SOCs inhibit TLR signaling by targeting IL-1 receptor-
associated kinase 1 (IRAK1) via its SH2 domain [361].  Also, SOCs1 causes proteasomal 
degradation of Mal, leading to inhibition of TLR/Mal-dependent NF-κB activation [362]. 
Furthermore, SOCs protein has been shown to regulate TLR-induced NF-κB activation by 




Bacterial pathogens exploit SOCs 1 and 3 proteins to manipulate cytokine receptor 
signaling and thereby influence infection outcomes as a strategy of evading host immune 
defenses [363]. This suggests that pathogens can induce SOCS1 and SOCS3 to evade 
deleterious host immune responses. Recent studies have reported that SOCs1 and 3 were 
elevated in active TB patients and contributed to the down-modulation of Th1-mediated 
IFN-γ responses [364]. Also, SOCs1 were reported to support mycobacterial growth in 
macrophages by inhibiting the secretion of IFN-γ production by T-cells in response to IL-
12 [365]. Additionally, SOCS3 induced by PPE18 inhibited NF-κB activation by 
diminishing the phosphorylation of IκBα [366].  In general,  the induction of SOCs1 and 3 
by mycobacteria results in the blockage of the pro-inflammatory response required for 
effective TB control [367]. 
1.14 Rationale and major objective 
Although numerous efforts have gone into studying the TB pathogenesis in the context of 
M. tuberculosis, it is still unclear the role and mechanism of M. bovis derive cell envelope 
antigens in bTB pathogenesis. From the above literature review, it is evident that the 
interaction between the M. tuberculosis-derived cell envelope antigens with the host innate 
immune cells is essential in determining the outcome of infection. However, there are gaps 
in knowledge, including how M. bovis-derived cell envelope antigens inhibit DCs 
maturation and how these antigens block the induction of protective Th1 immune response. 
Therefore, we sought to assess bovine dendritic (bDCs) activation upon treatment with M. 
bovis-derived cell surface protein, lipid and glycan antigens. We focused on bDCs because 
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they are key professional antigen-presenting cells that upon activation, can prime and direct 

















CHAPTER 2. Stimulation of bovine dendritic cells by Mycobacterium bovis cell 
surface sugar extract is associated with decreased pro-inflammatory cytokine 
response 
(Innate Immunity 2020, Vol. 26(6) 537–546 DOI: 10.1177/1753425920929759) 
HYPOTHESIS   
Distinct antigenic components of M. bovis cell envelope induces differential pro-
inflammatory responses in bovine innate immune cells  
OBJECTIVES  
The primary objective is to use a functional biological assay to compare the stimulatory 
effects of bPPD, CWL and CSSE on bDCs in vitro.  
1. Determine the production of pro-inflammatory cytokines (IL-12 & TNF-a) following 
treatment of bDCs with bPPD, CWL and CSSE using ELISA.  
2. Assess for the phosphorylation of MAPKs (ERK) and NF-B in bDCs following 
treatment of bDCs with bPPD, CWL and CSSE using Western blot. 
3. Investigate the expression of SOCs protein following treatment with bPPD, CWL and 








While considerable effort is being spent in the research and development of vaccines for 
bTB disease prevention and control, a licensed vaccine for use in cattle has yet to emerge. 
The live attenuated M. bovis bacillus Calmette-Guerin (BCG) vaccine that is used to 
immunize people has been shown to confer protection in cattle [370, 371]. However, BCG 
is not used in cattle because the tuberculin skin test routinely used to diagnose bTB in the 
field does not distinguish BCG-vaccinated animals from M. bovis-infected animals [372]. 
Therefore, a better understanding of the effects of M. bovis cell surface antigens on the 
bovine immune system will help in the development of bTB vaccine. 
 
Members of the M.tb-complex, which include M. tuberculosis - the human-adapted agent 
of TB and M. bovis, have on their cell surfaces a complex mixture of proteins, polar and 
apolar lipids, glycolipids and glycans with diverse biological properties [373-375]. These 
biomolecules play crucial roles in host-pathogen interactions and TB immunopathogenesis 
[61, 374-377]. Earlier studies reported that M. bovis-derived cell wall polar lipids compared 
to apolar lipids differentially stimulate proinflammatory responses in bovine monocyte-
derived dendritic cells [52]. Thus, M. bovis antigens separated into fractions may be a 
useful approach to identify immunostimulatory antigens from non-stimulatory antigens. 
There is no information on the effects of distinct M. bovis-derived protein, lipid and glycan-
enriched fractions on bovine immune cells to the best of our knowledge. In this study, the 
effects of three different types of M. bovis cell envelope fractions - purified protein 
derivative (bPPD) [378], total cell wall lipid (CWL) [379, 380], and cell surface sugar 
extract (CSSE) [65, 381] on bDCs activation was determined. We found that M. bovis 
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CSSE-treated bDCs exhibited little to no activation. The CWL fraction meanwhile induced 
more activation of bDCs than CSSE but less than bPPD and the lipopolysaccharide (LPS) 
control. Furthermore, the muted response of CSSE was found to be associated with 
decreased extracellular signal-regulated kinase (ERK) and nuclear factor kappa-B (NF-
κB) activation, and increased expression of suppressors of cytokine signaling 1 and 3 
(SOCS1 and 3). These observations taken together suggests that the M. bovis CSSE fraction 



















2.2 Materials and Methods 
2.2.1 Preparation or source of M. bovis cell envelope antigen fractions 
2.2.1.1 Bovine purified protein derivative (bPPD) was purchased from Prionics AG 
(ThermoFisher Scientific Inc.). The production of bPPD, which is a purified mixture of 
proteins prepared from the culture filtrate of heat-killed M. bovis grown in a synthetic 
medium is described elsewhere [378]. bPPD was diluted in PBS before use and the same 
batch of bPPD was used for cell stimulation throughout the entire study. 
 
2.2.1.2 Total cell wall lipid (CWL) from M. bovis was obtained commercially from BEI 
resources (https://www.beiresources.org/). The production of total CWL, which is a 
complex mixture of polar and apolar lipids and glycolipids has been described elsewhere 
[379, 380]. Briefly, M. bovis AF2122/97 was grown in glycerol-alanine-salts medium to 
late-log phase, pelleted and washed with phosphate-buffered saline (PBS), gamma-
irradiated and lyophilized. Total lipids were then extracted from the dried cells with 
chloroform/methanol (2:1). Water-soluble molecules were then removed from the organic 
extract by biphasic partitioning in water. The organic phase enriched with total CWL was 
collected, dried and weighed. Before use, the CWL was resuspended in ethanol and diluted 
further in PBS before use. The same batch of CWL was used for cell stimulation throughout 
the entire study. 
 
2.2.1.3 Cell surface sugar extract (CSSE), which has been shown to contain a complex 
mix of extracellular glycans and glycolipids, was enriched from the culture filtrates of M. 
bovis AF2122/97 grown in Sautons liquid media [65, 381, 382]. CSSE was extracted and 
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purified from M. bovis grown in our lab. Briefly, to 0.8 volumes of cell-free M. bovis 
culture filtrate, 2 volumes of methanol and 1 volume of chloroform were added to yield a 
homogenous single-phase mixture and incubated overnight at room temperature. To this 
mixture, water/chloroform (1:1) was added and after 30 minutes, the organic phase was 
allowed to partition from the aqueous phase and recovered. After washing with 0.9% NaCl, 
the organic phase containing CSSE was recovered, dried and weighed. Before use, the 
CSSE was resuspended in ethanol and diluted further in PBS before use. The same batch 
of CSSE was used for cell stimulation throughout the entire study. 
 
2.2.2 Isolation of bovine CD14+ monocytes and culture of monocyte-derived mature 
dendritic cells (bDCs) 
Blood was collected from healthy cattle in 60-mL syringes containing 7.5% 
ethylenediaminetetraacetic acid (EDTA). Peripheral blood mononuclear cells (PBMCs) 
were obtained from these blood samples using the Ficoll (GE Healthcare Bioscience) 
method of isolation[383]. CD14+ monocytes were isolated from PBMCs by positive 
selection using MACs columns (Miltenyi Biotec Inc.). Mature bovine dendritic cells 
(bDCs) were subsequently derived from CD14+ monocytes after culturing in a complete 
RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum and 
HEPES (Hyclone Laboratories Inc.), 2-mercaptoethanol (Sigma-Aldrich), recombinant 
bovine GM-CSF at 100 ng/mL (Biorad) and recombinant bovine IL-4 at 50 ng/mL (Biorad) 
for 6 days as previously described[384]. bDCs were assessed by flow cytometry and the 




2.2.3 In vitro cell culture and treatment 
Bovine dendritic cells were incubated in serum-free RPMI 1640 culture medium for 24 h.  
The serum-free medium was then replaced with 1 mL of complete medium containing 
either E.coli derived  LPS (1 µg/mL; Sigma-Aldrich), bPPD (1 µg/mL), CWL (1 µg/mL), 
and CSSE (1 or 10 µg/mL as indicated). In all experiments, the treated cells were incubated 
overnight at 37oC, 5% CO2, before supernatant collection. Untreated cells (culture medium 
only) served as negative control. Culture supernatants were collected for analysis of 
cytokine using ELISA. In a different experiment, treated bDCs were lysed with RIPA lysis 
buffer containing protease inhibitors at 5, 15, 30, 60, 120 and 240 minutes following media 
removal. The resulting cell lysate was used for Western blot analysis. 
 
2.2.4 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assays were performed to determine the concentrations of 
IL-12 and TNF-α in bDC supernatants. Briefly, high-binding Immulon-2 (Thermofisher 
Scientific Inc.) ELISA plates and Maxisorp (Thermofisher Scientific Inc.) ELISA plates 
were respectively coated with bovine-specific TNF-α monoclonal antibodies produced in-
house and bovine-specific IL-12 monoclonal antibodies (AbD Serotec)[385] in coating 
buffer (Sodium carbonate, sodium bicarbonate and distilled water at pH 9.6), and incubated 
overnight at 4oC. Following incubation, the plates were washed 5 times with wash buffer 
(Tris buffered Saline containing 0.05% Tween-20 (TBST), pH 7.4) and blocked for 1 hr at 
room temperature. 200 µl/well of 0.1% gelatin (Sigma-Aldrich) and 0.1% casein (Sigma-
Aldrich) was used for both TNF-α and IL-12 blocking respectively. The micro-well plates 
were rinsed 5 times with wash buffer, and appropriately diluted recombinant IL-12 and 
64 
 
TNF-α standards were titrated in a 2-fold dilution to generate the standard curve. Samples 
were added undiluted (100 µL/well) and incubated at room temperature for 2 hrs. 
Thereafter, the plates were washed 5 times with washing buffer and 100 µL of biotinylated 
detection antibody at 4 µg/mL was added to all wells. After 1 hr incubation at room 
temperature, the plates were washed 5 times and 100 µL of streptavidin at (1/5000 dilution) 
was added to the wells and also incubated for 1hr. Then, 100 µL of p-Nitrophenyl 
Phosphate (PNPP) (1 mg/mL) was added to all the wells and incubated for 1 hr at room 
temperature.  Plates were read at 405 nm using Spectra Max plus microplate reader 
(Molecular Devices).  
 
2.2.5 Western blot analysis.  
Protein concentrations of lysates from bDCs treated with LPS, bPPD, CWL and CSSE 
were determined using Bicinchoninic acid assay (Thermofisher Scientific Inc.). 15 µg of 
total protein were loaded in each lane and resolved by SDS-polyacrylamide gel 
electrophoresis. Following electrophoresis, the protein bands were transferred to a 
nitrocellulose membrane using the iBlot 2 dry blotting system (Thermofisher Scientific 
Inc.). The membranes were blocked with 5 % powdered skimmed milk in Tris Buffered 
Saline (TBS) and incubated for 1 hour at room temperature. Thereafter, the membranes 
were incubated overnight with primary antibodies diluted in TBS supplemented with 5% 
bovine serum albumin and 0.05% Tween 20 (TBST). Immunoblotting of total and 
phosphorylated ERK, total and phosphorylated NF-κB (p65 subunit), SOCS1 and 3, and 
β-actin was performed as described previously[386]. The antibodies used were: anti-
p44/42 MAPK (ERK1/2) rabbit monoclonal antibody (clone 137F5) and anti-phospho-
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p44/42 (ERK1/2) (Thr202/Tyr204) rabbit monoclonal antibody XP® (clone D13.14.4E) 
(Cell Signaling Technology), anti-NF-κB p65 rabbit mAb (clone C22B4) and anti-
phospho-NF-κB p65 (Ser536) rabbit mAb (clone D13.14.4E) (Cell Signaling Technology), 
anti-SOCS1 (middle region) rabbit polyclonal antibody (Antibodies-online.com), anti-
SOCS3 (Internal) rabbit polyclonal antibody (LSBio), and anti-β-actin mouse monoclonal 
antibody (clone mAbcam 8226) (Abcam). After washing with TBST, the membranes were 
incubated for 1 hr at room temperature with Alexa Fluor® conjugated secondary antibody, 
at a dilution of 1:10000 in antibody dilution buffer. Signals were acquired using LI-COR 
imaging system (LI-COR Biosciences). Densitometry was performed using the band 
analysis tools of the Image Lab software version (LI-COR Biosciences). 
 
2.2.6 Statistical analysis. 
Cytokine data are presented as means ± standard error of means while densitometry data 
are presented as means ± standard error of the mean. A one-way ANOVA was used to 
compare differences in cytokine production using GraphPad Prism software. Significance 










2.3 Resu ts 
2.3.1 Bovine dendritic cells treated with CSSE produce little IL-12 and TNF-α.  
Antigen-presenting cells (APCs) like macrophages and dendritic cells produce the pro-
inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin 12 (IL-12) in 
response to infection with members of the M. tb-complex[387, 388]. In turn, both TNF-α 
and IL-12 help trigger naïve T-cells to mediate a Th1 response critical for controlling 
intracellular pathogens like mycobacteria [369, 389]. Here we assessed the production of 
TNF-α and IL-12 by bovine dendritic cells (bDCs) upon treatment with 1 µg/mL each of 
M. bovis-derived bPPD, CWL and CSSE, with LPS serving as a positive control. Relative 
to no treatment, LPS at 1 µg/mL was found to induce the strongest response, followed by 
bPPD and CWL which were also at 1 µg/mL (Figure 2.1A and B). CSSE at 1 µg/mL 
induced very little to no production of TNF-α and IL-12 (data not shown). Strikingly, even 
when the concentration of CSSE was increased to 10 µg/mL, it failed to induce appreciably 
higher TNF-α and IL-12 compared to no treatment (Figure 2.1A and B). These results show 
that M. bovis-derived bPPD is best at stimulating bDCs followed by CWL, while CSSE is 













































Figure 2.1: Low production of IL-12 and TNF- in CSSE simulated bDCs.  
Bovine dendritic cells were stimulated in vitro with bPPD (1 µg/mL), CWL (1 µg/mL) and CSSE (10 µg/mL) 
for 24 hr and the production of TNF-α (A) and IL-12 (B) were determined by ELISA. In all experiments, 
LPS (1 µg/mL) and unstimulated cells served as positive and negative control, respectively. Results are 
presented as mean +/- SEM of replicate wells and are representative of 3 independent experiments (**, p 






2.3.2 CSSE treated bDCs exhibit low phosphorylation ERK  
The pro-inflammatory response in APCs is mediated by signal-transduction events 
involving multiple cytoplasmic proteins known as mitogen-activated protein kinases 
(MAPKs)[390]. Activation of a MAPK protein called extracellular signal-regulated kinase 
(ERK) via phosphorylation plays a key role in pro-inflammatory cytokine production in 
response to products of bacterial origin such as LPS[386, 390]. Therefore, we sought to 
examine the phosphorylation of ERK in bDCs treated with bPPD (at 1 µg/mL), CWL (at 1 
µg/mL) and CSSE (at 10 µg/mL), with LPS (at 1 µg/mL) serving as positive control. LPS 
consistently induced phosphorylation of total ERK within 5 minutes post-addition, which 
decreased thereafter (Figure 2.2A to F). bPPD, on the other hand, induced phosphorylation 
of total ERK later at 15 minutes post-addition, and subsided shortly thereafter (Figure 2.2A 
and B). CWL treatment induced phosphorylation in ERK to the same level as LPS by 5 
minutes post-addition but maintained the same rate of phosphorylation longer than LPS 
treatment which had waned after 5 minutes, before also decreasing (Figure 2.2C and D). 
In contrast, CSSE induced less phosphorylation of total ERK throughout the duration of 
the experiment (Figure 2.2E and F). These results show ERK in CSSE-treated bDCs is 
poorly phosphorylated and activated and is consistent with the poor induction of pro-




















































Figure 2.2: Decreased phosphorylation of ERK protein in CSSE stimulated bDCs. Bovine dendritic 
cells were stimulated in vitro with bPPD (1 µg/mL), CWL (1 µg/mL) and CSSE (10 µg/mL) and lysate were 
collected at different indicated times. Total cell lysate were assessed for phosphorylation ERK protein (A, C 
& E) by Western blot using appropriate primary and secondary antibodies. The same blots were stripped and 
re-probed with antibodies against -actin, then used as loading controls. LPS (1 µg/mL) served as positive 
control. The ratios of phosphorylated ERK to their respective total proteins were calculated by densitometry 
and plotted as bar graphs (B, D & F).  Results are presented as mean +/- SEM of replicate wells and are 







2.3.3 CSSE t e te    Cs exhibit low phosphorylation  n  t  ns  t   t  n    NF κB 
p65 subunit 
The multi-subunit NF-κB protein is a master transcriptional regulator that plays a vital role 
in immune activation[391, 392]. Moreover, transactivation of the p65 subunit of NF-κB by 
phosphorylation has been shown to upregulate pro-inflammatory gene expression in 
APCs[386, 391]. Therefore we also sought to assess the phosphorylation status of the NF-
κB p65 subunit over time in bDCs upon treatment with bPPD (at 1 µg/mL), CWL (at 1 
µg/mL) and CSSE (at 10 µg/mL), with LPS (at 1 µg/mL) treatment serving as positive 
control. LPS induced phosphorylation of total NF-κB p65 by 5 minutes post-addition and 
stayed at those levels for the entire duration of the experiment (Figure 2.3A to F). bPPD 
also induced phosphorylation of total NF-κB p65 within 5 minutes post-addition and with 
these levels remaining constant for the duration of the experiment (Figure 2.3A and B). 
Phosphorylation of NF-κB p65 upon treatment with CWL appeared to be more variable 
with total NF-κB p65 being phosphorylated within 15 minutes post-addition followed by a 
drop for the next 45 minutes before an increase of total NF-κB p65 by 120 minutes post-
addition (Figure 2.3C and D). In striking contrast, CSSE treatment does not induce 
phosphorylation of total NF-κB p65 for the entire experimental duration (Figure 2.3E and 
F). These results clearly show that NF-κB p65 in CSSE-treated bDCs are poorly 
phosphorylated and activated. The results of these experiments are also consistent with the 
poor phosphorylation of ERK and the low production of pro-inflammatory cytokines by 












































































Figure 2.3:  Reduced phosphorylation of NF-B in CSSE stimulated bDCs.  
Bovine dendritic cells were stimulated in vitro with bPPD (1 µg/mL), CWL (1 µg/mL) or CSSE (10 µg/mL) 
and the lysate was collected at different indicated times. The total cell lysate was assessed for phosphorylation 
NF-κB protein (A, C & E) by Western blot using appropriate primary and secondary antibodies. The same 
blots were stripped and re-probed with antibodies against -actin, then used as loading controls. LPS (1 
µg/mL) served as positive control. The ratios of phosphorylated NF-κB to their respective total proteins were 
calculated by densitometry and plotted as bar graphs (B, D & F).  Results are presented as mean +/- SEM of 






2.3.4 Treatment of bDCs with CSSE up-regulates SOCS 1 and 3 expression. 
 Our results suggest CSSE is a poor inducer of inflammation in bDCs. However, to 
determine whether this fraction simply lacks sufficient amounts of the bacterial products 
needed to activate pro-inflammatory responses or if it contains immunomodulatory 
biomolecules that actually suppress activation of pro-inflammatory responses in bDCs, we 
decided to look at the status of negative regulators of inflammation like the suppressor of 
cytokine signaling (SOCS) proteins. SOCS proteins prevent hyper-inflammation following 
interaction with microbial products and thus play a key role in ensuring an appropriate and 
balanced immune response[393]. Moreover, SOCS proteins exert their regulatory effects 
by blocking pro-inflammatory signal transduction through a negative feedback loop to 
control the activation of immune cells as well as cytokine production[394]. Specifically, 
the initial steps of TLR signaling in macrophages are inhibited by SOCS 1, while other 
studies have implicated SOCS 1 and 3 in the blockage of NF-κB p65 activation [395, 396]. 
In light of the poor activation of NF-κB observed in CSSE-treated bDCs, we assessed the 
expression of SOCS 1 and 3 in bDCs treated with either LPS or CSSE. We found that by 
5 minutes post-addition, CSSE caused an increase in the expression of SOCS 1 (Figure 
2.4A and B). In contrast, the expression of SOCS 1 was not increased substantially in LPS-
treated bDCs (Figure 2.4A and B). SOCS 3 expression was increased in CSSE-treated 
bDCs by 5 minutes post-addition (Figure 2.4C and D). However, LPS appeared to induce 
less SOCS 3 expression for the duration of the experiment (Figure 2.4C and D). These 
results clearly show that CSSE treatment increases SOCS 1 and 3 expression and may 















































































Figure 2.4: Increased expression of SOCS 1 & 3 protein in CSSE stimulated bDCs. Bovine dendritic 
cells were stimulated in vitro with bPPD (1 µg/mL), CWL (1 µg/mL) and CSSE (10 µg/mL) and lysate were 
collected at different indicated times. Total cell lysate was assessed for phosphorylation SOCS 1 and 3 
proteins (A & B) by Western blot using appropriate primary and secondary antibodies. The same blots were 
stripped with stripping buffer and re-probed with antibodies against -actin, then used as loading controls. 
LPS (1 µg/mL) served as a positive control. The ratios of expressed SOCS 1and 3 to their respective total 
proteins were calculated by densitometry and plotted as bar graphs (C & D).  Results are presented as mean 








2.4 Discussion & Conclusion  
During mycobacterial infection, pro-inflammatory cytokines like TNF-α and IL-12 
produced by DCs help drive the induction of Th1 immunity [368, 369]. However, 
numerous studies show that pathogenic mycobacteria can modulate pro-inflammatory 
signaling in macrophages and dendritic cells, thus enabling the bacterium to survive and 
persist within its host [61, 374-377]. Given that distinct lipidic components of the M. bovis 
cell surface appear to induce differential pro-inflammatory responses in bovine innate 
immune cells [52], the purpose of this study was to perform a direct head-to-head 
comparison of the effect of three different types of M. bovis cell envelope fractions on 
bDCs in order to help determine which of these might be suitable bTB vaccine components.   
We found that unlike bPPD, M. bovis-derived CWL and CSSE are relatively poor inducers 
of TNF-α and IL-12 production by bDCs, with the latter being the poorest of them all. 
Further analysis revealed that the activation of ERK and NF-κB in CSSE-treated bDCs 
were significantly reduced, suggesting that the meagre production and secretion of TNF-α 
and IL-12 may be due to reduced activation of the ERK/NF-κB signaling pathway. 
Alternatively, it is conceivable that decreased phosphorylation of ERK protein directly or 
indirectly affects phosphorylation of NF-κB. It is also possible that CSSE inhibits 
phosphorylation of NF-κB by directly blocking the ability of the inhibitor of Kappa B 
kinase (IKK) complex to degrade the inhibitor of Kappa B (IkB) proteins, thus preventing 
the activation and translocation of NF-κB to the nucleus. Further studies to delineate the 
mechanisms by which CSSE affects NF-κB phosphorylation in dendritic cells are 
warranted. 
Previous studies have shown that SOCS 1 suppresses dendritic cell maturation and 
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functions to prevent the development of systemic autoimmunity [397, 398]. Most 
importantly, pathogenic mycobacteria have been reported to induce the expression of 
SOCS 1 and 3 proteins as part of their virulence strategy [399, 400].  As such, we 
hypothesized that SOCS 1 and 3 might be involved in blocking IL-12 and TNF-α 
production in CSSE-treated bDCs. Indeed, we found CSSE treatment increased the 
expression of SOCS 1 and SOCS 3 proteins in bDCS. As such, the CSSE-mediated hypo-
activation of ERK and NF-κB and concomitant lack of TNF-α and IL-12 production may 
also be due to increased expression of SOCs 1 and 3 proteins.  
Components of  CWL and CSSE fractions, especially lipids, glycolipids, and glycans, play 
prominent roles in the evasion of host immune responses by pathogenic mycobacteria [60, 
61, 373-377]. While there is overwhelming evidence that many individual mycobacterial 
glycolipids and glycans exhibit immunomodulatory properties, their overall effect on the 
host immune system when immunostimulatory mycobacterial antigens are also present, 
remain to be ascertained and warrant further study. Nonetheless, based on our data, we 
speculate that the M. bovis-derived CSSE fraction and perhaps even the CWL fraction, 
albeit to a lesser extent, are enriched with immunosuppressive glycolipids and/or glycans 
that contribute to the overall survival and proliferation of the bacteria within its host. We 
further speculate that the mycobacterial products in these fractions would probably be 
detrimental to include or have present in any next-generation TB vaccine preparations.  
In conclusion, our study shows that the M. bovis-derived CSSE fraction is a very poor 
immune stimulator. Furthermore, our data suggest that this fraction contains molecules that 





 In chapter 2, I showed the M. bovis culture supernatant and surface extract (CSSE) is poor 
at stimulating bDCs. Given that the CSSE is enriched in polysaccharides, phenolic 
glycolipids and glycans, I hypothesized that one or more of these molecules might actually 
be anti-inflammatory and contribute to the virulence of the TB bacillus. Indeed, previous 
studies have demonstrated that the M. tuberculosis-complex CSSE is particularly enriched 
in a family of phenolic glycans called para-hydroxybenzoic acid derivatives (p-HBADs), 
and these have been shown to regulate cytokine production by suppressing host 
inflammatory response [68, 69]. In addition, a recent report demonstrated that pure 
synthetic-HBADs affect acute macrophage activation by inhibition of pro-inflammatory 
response and reduction of bactericidal nitric oxide production following BCG vaccination 
[70]. This indicates that p-HBAD-1 and related molecules could be undermining the innate 
immune responses and explain why CSSE is a poor inducer of inflammation in bDCs.  In 
this chapter, I sought to address this possibility and examine in detail the 










CHAPTER 3. Mycobacterium bovis parahydroxybenzoic acid derivatives (p-HBADs) 




It is known that M. tuberculosis -complex CSSE is enriched in p-HBADs, with M. bovis 
and BCG producing only p-HBAD-I, while M. tuberculosis generates both p-HBAD-I and 
II [46, 65]. In chapter 2, we observed that the M. bovis-derived cell surface sugar extract 
(CSSE) fraction exhibit a less immune-stimulatory effect on bDCs. Based on these results 
and given that the CSSE fraction of M. tuberculosis is enriched in p-HBADs which exhibit 
immunosuppressive properties in innate and adaptive immune cells [46]. In this chapter, I 
assessed the effect of M. bovis derived p-HBAD-I on bDCs stimulated with either 
lipopolysaccharide or bovine purified protein derivative.  Result shows that the effect of p-
HBAD-I in non-primed and IFN-γ primed bDCs varies. In non-primed bDCs, p-HBAD-I 
exhibits a tolerogenic response by blocking the production of pro-inflammatory cytokines. 
In contrast, the reversal effect was observed with IFN- primed bDCs, in which p-HBAD-
I induces an immunogenic response resulting in increased pro-inflammatory cytokine 
production. These data suggest that M. bovis-derived p-HBAD-I is an immune-regulatory 






3.2 Materials and Methods 
3.2.1 Preparation or source of M. bovis cell envelope antigen fractions 
3.2.1.1 Bovine purified protein derivatives (bPPD) and total cell wall lipid (CWL)- As 
previously mentioned in the materials and methods section in chapter 2,  bPPD was 
obtained from Prionics AG (Thermofisher Scientific Inc.). Similarly, CWL was acquired 
from BEI resources (https://www.beiresources.org/). The same batch of bPPD and CWL 
was used throughout the entire experiment 
3.2.1.2  Parahydroxylbenzoic acid derivatives (p-HBAD-1)- were extracted from the 
culture filtrate of M. bovis cultured in Sautons liquid media using as previously described 
[382]. Specifically, 2 volumes of CH3OH and 1 volume of CHCl3 were used to extract pure 
p-HBAD-1. The chemical synthesis of p-HBAD-1 is described elsewhere [69]. The 
synthesized p-HBAD-1 was analyzed after resolving by thin-layer-chromatography (TLC) 
using CHCl3/CH3OH/H2O (90:10:1), and the structure of synthetic p-HBAD-I was 
confirmed using NMRI and mass spectrometer. For confirmation of p-HBAD-1 structure 
using mass spectrometry, it was performed using a Voyager DE-STR MALDI-TOF 
instrument equipped with a pulse nitrogen laser emitting at 337 nm. Briefly, samples were 
directly applied onto the sample plate and then allowed to crystallize at room temperature. 
Samples were analyzed in the Reflector mode using an extraction delay time set at 100 ns 






3.2.2 Assessment of p-HBAD-1 in M. bovis CSSE using Thin-layer chromatography 
(TLC) 
M. bovis and M. bovis BCG-derived CSSE were extracted from the culture filtrate using a 
previously established protocol [382]. Determination of the presence of p-HBAD-1 was 
done by comparing extracted M. bovis CSSE with pure synthetic p-HBAD-I using Thin-
layer chromatography [67]. The presence of p-HBAD-1 in M. bovis CSSE was identified 
by visual detection using a short wavelength U  lamp and alpha-naphthol spray [69]. 
3.2.3 Generation of monocyte-derived bDCs. 
The generation of monocyte-derived bDCs has been previously described in the material 
and methods section of chapter 2. Briefly,  isolation of CD14+ monocytes from PBMCs 
was done via positive selection using MACs columns (Miltenyi Biotec Inc.) [401]. 
Immature bDCs were differentiated from CD14+ monocytes using recombinant bovine 
GM-CSF (100 ng/mL; Biorad) and IL-4 as previously described (50 ng/mL; Biorad) [402].  
 
3.2.4 In vitro cell culture and treatment 
Monocyte-derived bDCs were cultured and treated as previously described in the material 
and methods section of chapter 2. Briefly, stimulation of differentiated bDCs suspended in 
complete RPMI medium was done either with LPS (1 µg/mL; Sigma Aldrich), bPPD (1 
µg/mL), CWL (1 µg/mL) or one of several TLR agonists (Pam3CSK4 -10 µg/mL; HKLM-
109 cells/mL; LPS-100 µg/mL; Flagellin -10 µg/mL; synthetic lipopeptide (FSL-1)-10 
µg/mL; ODN-100 µg/mL; Poly I. C-500 µg/mL; Poly I. C [LMW]-500 µg/mL; 
Imiquimod-25 µg/mL; SSRNA-25 µg/mL (each from Invitrogen) in the presence or 
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absence of p-HBAD-I (200 μM; generously provided by Professor Eoin Scanlan, Trinity 
College Dublin, Dublin, Ireland). For IFN- primed bDCs, cells were first primed with 
recombinant bovine IFN- (rIFN-) (100 ng/mL; Sigma Aldrich Co.) for 2 h before 
stimulation in the presence and absence of p-HBAD-I.  In all experiments, LPS-treated and 
untreated cells served as the positive and negative controls, respectively. The controls, as 
well as stimulated cells, were incubated overnight at 37oC before supernatant collection.  
The concentrations of IL-12 and TNF-α (Sigma Aldrich) in the culture supernatants were 
determined by sandwich enzyme-linked immunosorbent assay (ELISA) as briefly 
described below. Following removal of culture media, treated bDCs were lysed at 5, 15, 
30, 60, 120 and 240 minutes with a combination of RIPA lysis buffer and protease 
inhibitors (Sigma- Aldrich). Cell lysate obtained was used for Western blot analysis. 
 
3.2.5 Enzyme-linked immunosorbent assay (ELISA) 
Assessment of the cytokine (IL-12 and TNF-α) concentration in bDCs supernatant was 
done using in-house antibodies by ELISA as was previously stated in the materials and 
methods section of chapter 2.  
 
3.2.6 Western blotting  
Activation of NF-B p65, expression of TLR2/4 and SOCS1/3 was determined by Western 
blot as previously described in materials and method section of chapter 2, albeit with slight 
modification. Briefly, overnight incubation of membranes with primary antibodies diluted 
in antibody dilution buffer (TBS supplemented with 5% bovine serum albumin and 0.05% 
Tween 20 (TBST) were done. The antibodies used were: anti-NF-κB p65 rabbit mAb 
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(clone C22B4) and anti-phospho-NF-κB p65 (Ser536) rabbit mAb (clone D13.14.4E) 
(from Cell Signaling Technology), human anti-bovine TLR 2 and 4 (Clone 12542) (from 
Cedarlane), anti- SOCS1 (middle region) rabbit polyclonal antibody (from Antibodies-
online.com), anti-SOCS3 (Internal) rabbit polyclonal antibody (from LSBio and anti-β-
actin mouse monoclonal antibody (clone mAbcam 8226). After washing with TBST, the 
membranes were incubated for 1 h at room temperature with Alexa Fluor® conjugated 
secondary antibody, at a dilution of 1:10000 in antibody dilution buffer. Signals were 
acquired using LI-COR imaging system (LI-COR Biosciences). Densitometry was 
performed using the band analysis tools of the Image Lab software version (LI-COR 
Biosciences). 
3.2.7 Statistical analysis. 
Cytokine and densitometry data are presented as Mean ±SEM. Both one-way and two-way 
ANOVA was used to compare differences in cytokine production. Significance was 












3.3.1 CSSE fraction of M. bovis and BCG contains p-HBAD-1 
In chapter 2, we showed that M. bovis-derived cell CSSE fraction exhibit less immune-
stimulatory effect on bovine dendritic cells (bDCs). We therefore speculated that the CSSE 
fraction might be enriched with molecules like p-HBAD-1 that possess 
immunosuppressive properties, and contribute to the survival and proliferation of the 
bacteria within its host. Indeed, analysis of M. bovis CSSE by thin-layer chromatography 









Figure 3.1: TLC showing the presence of p-HBAD-I in M. bovis derived CSSE. The arrow indicates the 











3.3.2 Pure p-HBAD-1 inhibits the production of TNF-α  n  I -12 by LPS-, bPPD- 
and CWL-stimulated bovine bDCs   in a dose-dependent manner 
Various cytokines elicited by DCs during the innate phase of activation play a crucial role 
in deciding the outcome of mycobacterial infection. As reported by Hickman et al., IL-12 
and TNF-α are pivotal for the induction of optimal Th1 responses against invading 
pathogens, including mycobacteria [403]. Earlier studies showed that pure synthetic p-
HBADs suppressed the production of IL-12 and TNF- in mouse macrophages stimulated 
with irradiated M. tuberculosis [69, 404]. However, the effect of M. bovis CSSE on bDCs 
had not been determined. To address this, the effect of different concentrations of synthetic 
p-HBAD-1 on IL-12 and TNF- production was determined following overnight 
incubation with LPS, bPPD or CWL. The result obtained was compared to LPS positive 
control. Relative to no treatment, the induction of IL-12 and TNF- was most potent in 
cells treated with 1 µg/mL of LPS (positive control). Likewise, treatment of bDCs with 
bPPD and CWL also led to the induction of these cytokines, albeit to a lesser extent than 
LPS (Figs. 3.2A to F). Interestingly, co-treatment of increasing concentrations of p-HBAD-
1 with each of these three different antigen preparations significantly abrogated production 
of IL-12 (Figs. 3.2A to C) and TNF-  (Figs. 3.2D to F) in a dose-dependent manner. These 





Figure 3.2: Production of IL-12 and TNF- by non-primed bDCs stimulated with LPS and bPPD in 
the presence of various concentrations of p-HBAD-1. Bovine dendritic cells were stimulated with LPS (1 
µg/mL), bPPD (1 µg/mL), CWL (1 µg/mL) in the presence of various concentrations of p-HBAD-1 (200, 
400 & 800 μM/mL) overnight and the production of IL-12 (A, B & C) and TNF-α (D, E & F) were 
determined by ELISA. In all experiments, LPS (1 µg/mL) and untreated cells served as a positive and 
negative control, respectively. Results are presented as mean (+/- standard error of mean) of signals from 
replicate wells and represent 3 independent experiments (*p <0.0001).  
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3.3.3 Pure p-HBAD-1 inhibits cell surface TLR 1, 2, 4, 5 and 6-dependent signaling in 
naïve bovine bDCs stimulated with corresponding TLR agonists 
Following the recognition of microbial components by TLRs, intracellular TLR signaling 
pathways get activated, resulting in cytokine production [405]. In addition, TLR agonists 
(a synthetic analog of microbial components) have been reported to initiate an intracellular 
signaling event that results in the activation of a variety of proinflammatory immune 
responses [239]. Therefore, to determine the precise TLRs signaling pathways that p-
HBAD-1 targets to mediate its inhibitory effect, TLR-specific agonists were used to 
activate bDCs in the absence and presence of p-HBAD-I and cytokine production was 
assessed by ELISA. 
 Results showed that TLR agonists (Pam3CSK4, HKLM, LPS, Flagellin, synthetic 
lipopeptide-FSL-1) specific to surface membrane TLR (1, 2, 4, 5 and 6) exhibit their 
agonistic effects by inducing IL-12 and TNF- production in bDCs. However, in the 
presence of p-HBAD-1, the production of these cytokines via surface membrane TLRs-
dependent pathway was significantly suppressed (Figs. 3.3A and B).  Given that binding 
of ligands to surface membrane TLR stimulates specific intracellular downstream signaling 
cascades that initiate host defense responses,   this data suggests that p-HBAD-1 targets 
multiple surface membrane TLR signaling pathways to inhibit cytokine production. 
Alternatively, there might be a common and shared downstream point in surface TLR 
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Figure 3.3: Production of IL-12 and TNF- via surface membrane TLR signaling pathway in non-
primed bDCs stimulated with TLR agonist in the presence of p-HBAD-1. Bovine dendritic cells were 
stimulated with surface membrane TLR agonist in the presence and absence of p-HBAD-1 (200 μM/mL), 
following overnight incubation, the production of IL-12 (A) and TNF- (B) were determined by ELISA. In 
all experiments, untreated cells served as a negative control. Results are presented as mean (+/- SEM) of 







3.3.4 Pure p-HBAD-1 enhances endosomal TLR 3, 7, 8, and 9-dependent signaling in 
IFN- primed bDCs stimulated with corresponding TLR agonists 
To determine if other TLRs signaling pathways are inhibited by p-HBAD-1, endosomal 
TLR agonists (ODN, Poly I. C, Imiquimod, ssRNA) were used to activate bDCs in the 
absence and presence of p-HBAD-1, and cytokine production was determined.  However, 
IFN-γ priming is a requirement for endosomal TLR signaling [406]. Moreover, IFN- 
produced by T-cells has a combined effect with TLR ligation to enhance DCs activation 
and function [406]. Accordingly, bDCs were primed with rIFN- for 2 h before incubation 
with endosomal TLRs agonists in the absence and presence of p-HBAD-1, and cytokine 
production following overnight incubation was assessed and compared ELISA. In the 
absence of p-HBAD-I, endosomal TLR agonists stimulate IFN- primed bDCs to produce 
IL-12 and TNF-. Interestingly, when p-HBAD-1 was added, it induced a robust increase 




























Figure 3.4: Production of IL-12 and TNF- via endosomal TLR signaling pathway in IFN--primed 
bDCs stimulated with TLR agonist in the presence and absence of p-HBAD-I. Bovine dendritic cells 
were primed with rIFN- (100 ng/mL) for 2 h before stimulation with endosomal TLR agonist in the presence 
and absence of p-HBAD-I (200 μM/mL), following overnight incubation, the production of IL-12 and TNF-
 (A & B) were determined by ELISA. In all experiments, untreated cells served as a negative control. 
Results are presented as mean (+/- SEM) of signal from replicate wells and represent three independent 



















































































































































































































3.3.5 Pure p-HBAD-1 promotes cell surface TLR 4, 5 and 6-dependent signaling in 
IFN- primed bDCs stimulated with corresponding TLR agonists 
Based on the results with IFN- primed bDCs with respect to endosomal TLR signaling, in 
the effect of IFN- priming on surface membrane TLR signaling was also investigated. As 
was done with endosomal TLRs agonists, bDCs were primed with rIFN-γ for 2 h before 
incubating with surface membrane TLR agonists in the presence and absence of p-HBAD-
1, and the production of IL-12 and TNF- was assessed. Consistent with cytokine 
induction with endosomal dependent signaling pathway, result showed increased 
production of IL-12 and TNF- in IFN- primed bDCs treated with surface membrane TLR 
agonist in the absence of p-HBAD-I. However, a slight increase in these cytokines was 
observed in the presence of p-HBAD-1 (Fig. 3.5A and B). Considering that IFN- priming 
promotes DCs response to TLR ligands, these data collectively suggest that with IFN- 
primed bDCs, the inhibitory effect of p-HBAD-1 on TLRs signaling pathway and 


































































































































































Figure 3.5: Production of IL-12 and TNF- via surface membrane TLR signaling pathway in IFN--
primed bDCs stimulated with TLR agonist in the presence of p-HBAD-1. Bovine dendritic cells were 
primed with rIFN- (100 ng/mL) for 2 h before stimulation with surface membrane TLR agonist in the 
presence and absence of p-HBAD-I (200 μM/mL). Following overnight incubation, the production of IL-12 
and TNF- (A & B) were determined by ELISA. In all experiments, untreated cells served as a negative 
control. Results are presented as mean (+/- SEM) of signal from replicate wells and are representative of 3 





3.3.6 Pure p-HBAD-1 decreases TLR-2 and 4 expression in LPS-stimulated bDCs but 
not IFN- primed and LPS-stimulated bDCs 
Studies by others have shown that mycobacterial antigens can activate DCs maturation via 
ligation with TLRs, in particular TLR2 and TLR4 [407]. Given that priming of bDCs with 
IFN- appears to block the inhibitory effect of p-HBAD-1 on pro-inflammatory cytokine 
production via TLR signaling pathways, I decided to examine the expression of TLR2 and 
4 in non-primed and IFN- primed bDCs stimulated with LPS or bPPD.  
Indeed, exposure of both IFN- primed and non-primed bDCs to LPS or bPPD in the 
presence of p-HBAD-1 resulted in comparable induction of TLR2 expression at earlier 
time points (5-30 mins) (Figs. 3.6A to D). However, at later time points (30-240 mins), the 
up-regulation of TLR2 expression was suppressed by p-HBAD-1 in non-primed bDCs after 
30 and 60 mins post-stimulation with LPS or bPPD, respectively (Figs. 3.6E to H). 
Interestingly, p-HBAD-1 potentiated LPS or bPPD-induced up-regulation of TLR2 
expression in IFN- primed bDCs (Figs. 3.6 E to H).  
Assessment of TLR4 revealed a similar pattern of receptor expression in IFN- primed and 
non-primed bDCs. LPS or bPPD-induced TLR4 expression level remains strongly up-
regulated in IFN- primed bDCs during the later time point.  However, in non-primed 
bDCs,  p-HBAD-1 suppressed TLR4 expression post-stimulation with LPS or bPPD 
(Fig.3.6 I to L). Given that M. tuberculosis activated TLR2 and 4 promotes immunogenic 
response[408]. Therefore, the decreased production of pro-inflammatory cytokines in non-
primed bDCs following LPS or bPPD stimulation is related to the reduced expression of 








Figure 3.6: Expression of TLR2 & 4 protein by rIFN- primed and non-primed bDCs stimulated with 
LPS and bPPD in the presence of p-HBAD-1. Bovine dendritic cells were primed with rIFN-g for 2 h 
before stimulation with LPS (1 µg/mL) or bPPD (1 µg/mL) in the presence of p-HBAD-I (200 μM/mL). The 
cell lysate was collected at different time points and assessed for expression of TLR2 & 4 protein by Western 
blot, and the result obtained were compared with non-primed bDCs (A, B, E, F, I & J). The same blots were 
stripped with stripping buffer and re-probed with antibodies against -actin, then used as loading controls. 
The percentage of expressed TLR2 relative to -actin was calculated by densitometry and plotted as bar 
graphs (C D, G, H, K & L).  Results are presented as mean (± SEMs) of 3 different blots. 
 
 
3.3.7 Pu e p HB   1 decreases  PS/ PP   n u e    t   t  n    NF B    te n in 
n n    me    Cs un  ke  n IFN     me    Cs. 
 
NF-κB (p65 subunit) is a key transcription factor involved in the expression of pro-
inflammatory genes, such as those encoding IL-12, TNF-α, IL-1β [409]. Previous studies 
demonstrated that  M. tuberculosis induces proinflammatory cytokines in human DCs by 
activation of NF-κB  [302]. To examine the effects of p-HBAD-1 on the activation of NF-
B in unprimed and primed bDCs stimulated with either LPS or bPPD, its phosphorylation 
was assessed by Western blot. Consistent with cytokine analysis data, p-HBAD-I was 
found to dampen LPS or bPPD-induced NF-B activation in non-primed bDCs. In contrast, 
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p-HBAD-I was found to augment LPS or bPPD mediated phosphorylation of NF-B in 
IFN- primed cells (Fig. 3.7A and B). Given that NF-B signaling plays a role in pro-
inflammatory cytokine production, these results suggest that suppression of IL-12 and 
TNF- by p-HBAD-1 in non-primed bDCs may be driven by its inhibition of NF-B 
phosphorylation and consequently of its activation. 
 
Figure 3.7:  Phosphorylation of NFB protein by rIFN- primed and non-primed bDCs stimulated 
with LPS or bPPD in the presence of p-HBAD-1. Bovine dendritic cells were primed with rIFN- (100 
ng/mL) for 2 h before stimulation with LPS (1 µg/mL) or bPPD (1 µg/mL) in the presence of p-HBAD-1 
(200 μM/mL). Cell lysate were collected after 1h and assessed for both phosphorylated and total NF-B (A) 
by Western blot, and the result generated was compared with non-primed bDCs. The same blots were stripped 
with stripping buffer and re-probed with antibodies against -actin, then used as loading controls. The 
percentage of phosphorylated NF-B relative to -actin was calculated by densitometry and plotted as bar 





3.3.8 Pure p-HBAD-1 up-regulates SOCs1 and 3 expressions in non-primed bDCs 
stimulated with LPS or bPPD unlike in IFN- primed  
To maintain a balanced inflammatory response following interaction with PAMPs, the 
TLR and IFN- signaling pathway is controlled by inhibitors of cytokine signaling known 
as  SOCs proteins, which provides a negative-feedback loop to inhibit cytokine signal 
transduction [410, 411]. The first step involved in TLR signaling has been reported to be 
blocked by SOCs1 in macrophages [107].  Mycobacteria are known to survive in the host 
by up-regulating SOCs1and 3 protein expression, resulting in the manipulation of cytokine 
responses, especially IFN-γ that is required in the resolution of mycobacterial infections  
[399, 400]. Therefore, we investigated whether p-HBAD-1 affects the expression of SOCs1 
and 3 in non-primed bDCs.  
Results showed that in non-primed bDCs treated either with LPS or bPPD, p-HBAD-1 up-
regulates SOCs1 expression during the early treatment period. However, the reverse was 
seen in IFN- primed bDCs (Fig. 3.8A to D). Increased SOCs3 expression by p-HBAD-1 
in non-primed bDCs was maintained during the entire treatment period with LPS, but an 
increased expression of SOCs3 was only seen after 5 mins of stimulation of non-primed 
bDCs with bPPD. Interestingly, down-regulation of SOCs 1 and 3 in IFN- primed bDCs 
treated with LPS or bPPD during the entire treatment period were observed (Fig. 3.8A to 
H). Since SOCs 1 and 3 play a major role in cytokine inhibition, these results suggest that 
the suppressive effect of p-HBAD-1 in pro-inflammatory cytokine production may also be 





Figure 3.8:  Expression of SOCS1 and 3 in non-primed and rIFN- primed bDCs stimulated with LPS 
or bPPD in the presence of p-HBAD-1.  Bovine dendritic cells were primed with rIFN-(100 ng/mL) for 2 
h before stimulation with LPS (1 µg/mL) and bPPD (1 µg/mL) in the presence of p-HBAD-1 (200 μM/mL). 
Cell lysate was collected at different time points and assessed for expression of SOCS1 (A & B) and SOCS3 
(E & F) by Western blot, and result generated was compared with non-primed bDCs. The same blots were 
stripped with stripping buffer and re-probed with antibodies against -actin, then used as loading controls. 
The percentage of expressed SOCs 1 and 3 relative to -actin was calculated by densitometry and plotted as 




Since we have shown that M. bovis-derived CSSE is a poor immune stimulator of bDCs. 
In this chapter, we confirm the presence of p-HBAD-1 in CSSE and analyze the effect of 
M. bovis derived p-HBAD-1 on bDCs pro-inflammatory response. Using controlled 
conditions, we showed that the effect of p-HBAD-1 in non-primed and IFN- primed bDCs 
varies. In non-primed bDCs, we observed that p-HBAD-1 is capable of blocking the 
functional phenotype of bDCs by reducing the production of pro-inflammatory cytokines 
(IL-12 and TNF-α) induced by either LPS or bPPD. Furthermore, we propose that the 
molecular mechanism by which p-HBAD-1 mediates its immunosuppressive effect in non-
primed bDCs depends on the regulatory effect of SOCs1/3 protein expression.  
Interestingly, these effects were reversed in IFN- primed bDCs, resulting in an increased 
pro-inflammatory response. These observations are consistent with previous studies, which 
showed that M. tuberculosis-derived p-HBADs suppress pro-inflammatory response in 
macrophages stimulated with LPS or irradiated M. tuberculosis [68, 70]. However, the only 
difference is that the effect of p-HBAD-1 in  IFN- primed cells was not assessed in 
previous studies. In summary, our study suggests that p-HBAD-I plays a dual role in 
inducing immunosuppressive and immunostimulatory responses in non-primed and IFN- 







We have shown in chapter 3 that the effect of p-HBAD-1 in non-primed and IFN-γ primed 
bDCs varies. In non-primed bDCs, p-HBAD-1 blocked the inflammatory response by 
decreasing pro-inflammatory cytokine production (IL-12 and TNF- ). Previous studies 
have shown that p-HBADs from M. tuberculosis can suppress host immune response in a 
mouse model and promote M.tb virulence [68, 69]. Furthermore, a recent report showed 
that M. tuberculosis derived p-HBAD-1 and related structures affect early macrophage 
activation by blocking pro-inflammatory response following BCG vaccination [70]. This 
suggests that the presence of p-HBAD-1 and related molecules could be undermining the 
host's protective innate immune response, perhaps by promoting a tolerogenic profile in 
DCs. In this chapter, we sought to investigate the tolerogenic effect of M. bovis derived p-









CH PTER 4.  Pu e p HB   1    m tes   t  e   en         e  n n n    me    Cs 
t e te  w th  PS     PP  
4.1. Introduction 
The immune system exists in equilibrium between tolerance and effective inflammatory 
responses. Recent findings suggest that innate immune cells (in particular DCs) are 
essential players in the induction of effective immunity and tolerance [412]. Immunogenic 
DCs mediate effective innate and adaptive immunity primarily due to their remarkable 
capacity to process and present antigens through major histocompatibility complexes 
(MHC) to naïve T-cells [316]. Unlike immunogenic DCs, regulatory DCs can induce 
tolerance resulting in T-cell anergy and deletion. Regulatory/tolerogenic DCs are 
characterized by the production of immunoregulatory factors (IL-10, IL-1, TGF-, IDO, 
arginase I and iNOS) and a decrease in the production of pro-inflammatory cytokines 
[163]. Considering the prolonged coevolution of tubercle bacilli with humans, the tubercle 
bacillus has evolved the capacity to persist in the host tissue in a dormant state. This ability 
primarily depends on cell wall glycolipids, which target antigen-presenting cells, thereby 
dampening effective T cell immunity [413]. A recent study demonstrated that 
mycobacterial glycolipid Di-O-acyl trehalose induces a tolerogenic phenotype in DCs by 
altering DCs maturation, leading to the expansion of regulatory T- cells [55]. In non-primed 
bDCs treated with cell wall antigens, we have shown that M. bovis derived p-HBAD-1 
suppresses pro-inflammatory response, and the reverse was seen in IFN- primed bDCs.  
This inhibitory effect in non-primed bDCs could be related to IL- 10 production, which 
exerts negative feedback inhibition. Given that IL-10 is a major characteristic of 
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tolerogenic DCs, we hypothesize that p-HBAD-1 might be inducing a tolerogenic profile 
in non-primed bDCs by upregulating the production of IL-10. Thus, the tolerogenic effect 
of p-HBAD-1 on LPS or bPPD treated IFN- primed and non-primed bDCs was assessed 
by checking for production of IL-10, expression of DCs activation markers and DC-SIGN 
receptor.  Results show that the effect of p-HBAD-1 in non-primed and IFN-γ primed bDCs 
varies. p-HBAD-1 induces a tolerogenic phenotype in non-primed bDCs activated with 
either LPS or bPPD by undermining DCs co-stimulatory molecules' expression and 
increasing the expression of DC-SIGN. In addition, the production of IL-10 was 
upregulated. However, in interferon-gamma primed bDCs, the tolerogenic phenotype was 
suppressed. These findings taken together suggest that M. bovis-derived p-HBAD-1 might 












4.2 Materials and methods 
4.2.1 Generation of monocyte-derived bDCs 
As previously described in materials and methods in chapter 2, generation of bDCs from 
CD14+ monocytes was done using recombinant bovine GM-CSF at 100 ng/mL (Biorad) 
and IL-4 at 50 ng/mL (Biorad) [384]. bDCs were assessed by flow cytometry and the 
expression of DC-specific marker CD206 was found to be greater than 97%.  
4.2.2 In vitro cell culture and treatments 
Monocyte-derived bDCs were cultured as previously stated in the material and methods 
section of chapter 2, although with a slight alteration. Briefly, the stimulation of 
differentiated bDCs suspended in complete RPMI medium was done with LPS (1 µg/mL) 
in the absence or presence of p-HBAD-I (200 μM; Eoin Scanlan Lab, Trinity College 
Dublin). For IFN- primed bDCs, cells were first primed with recombinant IFN- (rIFN-) 
(100 ng/mL; Sigma Aldrich Co.) for 2 h before stimulation in the presence and absence of 
p-HBAD-1. The stimulated cells were incubated overnight at 37oC before harvesting cells 
for flow cytometry staining.  Following removal of culture media, treated bDCs were lysed 
at 5, 30 and 60 minutes with a combination of RIPA lysis buffer and protease inhibitors 
(Sigma- Aldrich). Cell lysate obtained was used for Western blot analysis. 
 
4.2.3 Enzyme-linked immunosorbent assay (ELISA) 
The concentration of IL-10 in bDCs supernatant was determined by Enzyme-linked 
immunosorbent assays as previously described in the materials and methods section in 
chapter 2, but with slight modification. Briefly, high-binding Immulon-2 (Thermofisher 
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Scientific Inc.) ELISA plates and Maxisorp (Thermofisher Scientific Inc.) ELISA plates 
were respectively coated with bovine-specific IL-10 monoclonal antibodies produced in-
house in coating buffer (Sodium carbonate, sodium bicarbonate and distilled water at pH 
9.6), and incubated overnight at 4oC. Following incubation, the plates were washed 5 times 
with wash buffer (Tris buffered Saline containing 0.05% Tween-20 (TBST), pH 7.4) and 
blocked for 1 hr at room temperature. 200 µl/well of 0.1% gelatin (Sigma-Aldrich) was 
used for IL-10 blocking. The micro-well plates were rinsed 5 times with wash buffer, and 
appropriately diluted recombinant IL-10 standards were titrated in a 2-fold dilution to 
generate the standard curve. Samples were added undiluted (100 µL/well) and incubated 
at room temperature for 2 hrs. Thereafter, the plates were washed 5 times with washing 
buffer and 100 µL of biotinylated detection antibody at 4 µg/mL was added to all wells. 
After 1 hr incubation at room temperature, the plates were washed 5 times and 100 µL of 
streptavidin at (1/5000 dilution) was added to the wells and also incubated for 1hr. Then, 
100 µL of p-Nitrophenyl Phosphate (PNPP) (1 mg/mL) was added to all the wells and 
incubated for 1 hr at room temperature.  Plates were read at 405 nm using Spectra Max 
plus microplate reader (Molecular Devices).  
 
4.2.4 Western blotting  
The expression of DC-SIGN was determined by Western blot as previously described in 
the materials and methods section in chapter 2, albeit with slight modification. Briefly, 
overnight incubation of membranes with primary antibodies diluted in antibody dilution 
buffer (TBS supplemented with 5% bovine serum albumin and 0.05% Tween 20 (TBST) 
were done.   Also, immunoblotting of β-actin was performed. After washing with TBST, 
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the membranes were incubated for 1 h at room temperature with Alexa Fluor® conjugated 
secondary antibody, at a dilution of 1:10000 in antibody dilution buffer. Signals were 
acquired using LI-COR imaging system (LI-COR Biosciences). Densitometry was 
performed using the band analysis tools of the Image Lab software version (LI-COR 
Biosciences). 
4.2.5 Flow cytometry 
Bovine DCs were harvested using cold PBS (Thermofisher Scientific, USA) and 
centrifuged at 1200 rpm for 5 min. The supernatant was removed, pellet suspended at 5 
x105 cells in100 µl of FACOLA and bovine serum for 15 mins at 4 degrees. Cells were 
washed with PBS at 400g for 3 mins and stained with fluorochrome-labeled antibodies 
against the following molecules: CD80, CD86, CD40, MHCI and MHCII (Biorad, 
Canada). After 30 mins incubation on ice, the cells were re-suspended and washed in 300 
µl PBS and fixed in 2% paraformaldehyde. PE-labeled CD14 (marker of monocyte) 
monoclonal antibody (Biorad, Canada) was used to assess monocyte purity, while APC-
labelled CD206 (marker of DCs) monoclonal antibody (Biolegend, USA) was used to 
assess the DCs markers.   Flow cytometry analyses were carried out according to standard 
procedures. Briefly, stained cells were acquired using CyAn ADP (at least 100,000 events).  
To avoid false positive result, debris was first gated out, and a Near IR stain (Thermofisher 
Scientific) was used to remove dead cells. Thereafter, another gate was drawn to remove 
doublet cells. Subsequent gate was placed only on CD206 positive cells, and the geometric 
mean fluorescent intensity of the markers (CD80, CD86, CD40, MHCI and MHCII) were 
compared among the different treatment conditions in the overlay. The analyses were 
107 
 
performed using Kaluza analysis software. 
4.2.6 Statistical analysis. 
The difference in cell surface marker expression was compared using one-way analysis of 
variance (ANOVA). Significance was considered if p< 0.05. The data were further 
















4.3.1 Pure p-HBAD-1 increases IL-10 production in non-primed bDCs stimulated 
with LPS or bPPD compared to IFN- primed bDCs  
In addition to pro-inflammatory cytokine production, DCs infected with mycobacteria also 
produce the anti-inflammatory cytokine interleukin 10 (IL-10) [153]. To determine 
whether p-HBAD-1 affects anti-inflammatory cytokine production, the production of IL-
10 in unprimed and IFN- primed bDCs was assessed. The quantification of IL-10 revealed 
that LPS or bPPD induced IL-10 production in non-primed bDCs compared to non-treated 
cells. Interestingly, when p-HBAD-1 was added in non-primed bDCs treated with either 
LPS or bPPD, it stimulated a significant increase in IL-10 outputs over that induced by 
IFN- primed bDCs at 24 h of culture (Fig. 4.1). Considering that IL-10 production inhibits 
pro-inflammatory cytokine production. This suggests that the decreased pro-inflammatory 




Figure 4.1: Production of IL-10 by IFN- primed and non-primed bDCs stimulated with LPS and 
bPPD in the presence of p-HBAD-1. Bovine dendritic cells were primed with rIFN-  (100 ng/mL) for 2 h 
before stimulation with LPS (1 µg/mL), bPPD (1 µg/mL) in the presence of p-HBAD-1 (200 μM/mL) for 24 
h. The production of IL-10 was determined by ELISA, and the result obtained was compared with non-
primed bDCs. In all experiments, untreated cells served as a negative control. Results are presented as mean 
+/- SEM of signal from replicate wells and are representative of 3 independent experiments (*, p <0.05; **, 
p <0.01; ***, p <0.001).  
 
4.3.2 Pure p-HBAD-1 decreases the expression of co-stimulatory molecules in non-
primed bDCs induced by LPS unlike in IFN- primed and similarly treated bDCs 
Antigen-presenting cells respond to stimulation by expressing co-stimulatory molecules, 
which provide signal two required for optimal T-cells activation [414]. The expression of 
these molecules is increased in response to inflammatory stimuli or by engagement of 
pattern recognition receptors [415]. During the chronic phase of M. tuberculosis infection, 
it is known that co-stimulatory molecules (CD40, CD80 and CD86) are downregulated in 
































































mechanism reported to drive the downregulation of these molecules is the presence of the 
surface lipid trehalose 6,6′-dimycolate (TDM) [151]. Similar studies showed that distinct 
macrophage populations that were infected with wild-type M. tuberculosis did not express 
high levels of co-stimulatory molecules, while strains that were devoid of TDM strongly 
induced the expression of these molecules [416].  
Given that these co-stimulatory molecules play a significant role in the initiation 
and optimal sustenance of Th1 immune response, I hypothesized that p-HBAD-1 also 
dampens immune responses or induces immune tolerance in non-primed bDCs by altering 
the expression of these molecules. To confirm this hypothesis, non-primed and IFN- 
primed bDCs were stimulated with LPS in the presence of p-HBAD-1, and the cell 
responses were quantified and compared by the changes in expression of co-stimulatory 
molecules (CD40, CD80 and CD86) on CD206 positive cells using flow cytometry. 
Relative to no treatment, non-primed bDCs exposed to LPS resulted in the maturation of 
bDCs as manifested by significant up-regulation of CD40, CD80 and CD86 markers during 
24h culture.  In non-primed bDCs exposed to a combination of LPS and p-HBAD-I, LPS-
driven up-regulation of these co-stimulatory molecules was down-regulated by p-HBAD-
I. However, in IFN-γ primed bDCs exposed to LPS, p-HBAD-1 augments LPS-induced 
significant expression of CD40 and CD80; however, CD86 expression was not statistically 
significant.  The histogram plots (Figs 4.2A, C and E) and the corresponding bar chart (Figs 
4.2 B, D and F) indicate the expression of co-stimulatory molecules by CD206+ cells. Since 
the downregulation of co-stimulatory molecules is a characteristic marker of tolerogenic 


























































































Figure 4.2: p-HBAD-1 antagonizes the effects of LPS on bDCs maturation by decreasing the expression 
of co-stimulatory molecules compared to IFN- primed bDCs. Monocyte-derived bDCs were stained 
with specific antibodies (materials and methods) and assessed for the expression of co-stimulatory molecules 
by flow cytometry. Shown are histogram plots (A, C & E) and the corresponding bar chart (B, D & F) 
indicating the expression of co-stimulatory molecule markers by CD206+ cells. Results were expressed as 





















4.3.3 Pure p-HBAD-1 down-regulates the expression of antigen-presenting molecules 
in non-primed bDCs induced by LPS unlike IFN- primed and similarly treated bDCs  
To further understand the mechanism by which p-HBAD-I induces tolerogenic DCs, its 
effect on antigen-presenting molecules was investigated. Regulatory DCs are characterized 
by normal levels of expression of antigen-presenting molecules. Thus, no difference in the 
expression of MHC molecules in both immunogenic and tolerogenic DCs [164]. To 
evaluate whether p-HBAD-I induces immune tolerance by affecting MHC molecule 
expression, I performed Flow cytometry to detect MHC I and II expression following 
stimulation of non-primed and IFN- primed DCs with LPS. Results showed that LPS 
promotes bDCs maturation by up-regulating MHC-I and II molecules in non-primed bDCs 
compared to the levels observed in untreated cells. Surprisingly, no difference was seen in 
the expression of these molecules in both non-primed and IFN- primed bDCs treated with 
LPS in the presence of p-HBAD-I.  Shown are histogram plots (Figs. 4.3A and C) and the 
corresponding bar chart (Fig. 4.3B and D) indicating the expression of these MHC 
molecules by CD206+ cells.  Given that the expression of these molecules in both non-
primed and IFN- primed bDCs remain the same, this suggests that MHC molecules do not 























































Figure 4.3: p-HBAD-1 antagonizes the effects of LPS on bDCs maturation by decreasing the expression 
of antigen-presenting molecules. Monocyte-derived bDCs were stained with specific antibodies (materials 
and methods) and assessed for the expression of antigen-presenting molecules by flow cytometry. Shown are 
histogram plots (A & C) and the corresponding bar chart (B & D) indicating the expression of MHC 
molecules by CD206+ cells. Results were expressed as means ± SEMs. Results are representative of 3 







4.3.4 Pu e p HB   1 u  e u  tes the ex  ess  n     C SI N  n n n    me    Cs 
un  ke IFN     me  
The interaction between mycobacteria and macrophages has been extensively investigated, 
and the mannose receptor has been demonstrated to act as receptors on macrophages for 
mycobacteria detection [417]. However, Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin (DC-SIGN) has been implicated in the interaction of 
mycobacteria with DCs, and this receptor has a high affinity for mannose-containing 
carbohydrates [418]. It has been reported that DCs activation by ManLAM via DC-SIGN 
impairs maturation and induces the production of interleukin 10, resulting in immune 
tolerance [160]. Based on its carbohydrate recognition profile and its ability to induce 
immune tolerance, I hypothesized that p-HBAD-1 targets DC-SIGN to induce immune 
tolerance in non-primed bDCs. Following stimulation of non-primed and IFN- primed 
bDCs with LPS in the presence of p-HBAD-1, the results showed that p-HBAD-1 up-
regulates DC-SIGN expression in non-primed bDCs. However, the opposite effect was 
seen in IFN- primed bDCs, with p-HBAD-1 down-regulating DC-SIGN expression (Fig. 


















Figure 4.4:  Expression of DC-SIGN in non-primed and rIFN- primed bDCS stimulated with LPS 
in the presence of p-HBAD-1.  Bovine dendritic cells were primed with rIFN- (100 ng/mL) for 2 h before 
stimulation with LPS (1 µg/mL) in the presence of p-HBAD-I (200 μM/mL). Cell lysate was collected at 
different time points and assessed for expression of DC-SIGN (A) by Western blot, and the result generated 
was compared with non-primed bDCs. The same blots were stripped with stripping buffer and re-probed 










Several factors, including DCs phenotype, antigen detection receptors, DCs maturation 
state, and exposure to microbial and soluble inflammatory factors, play a crucial role in the 
induction of regulatory DCs.  Regulation of DCs activation makers by mycobacteria helps 
them evade host immune response and establish infection [419]. Several studies have 
shown that different mycobacterial components block antigen-presenting capacity by 
inhibiting the expression of antigen presentation molecules [420-422]. In addition, a recent 
study showed that Di-O-Acyl-trehalose promotes a tolerogenic profile in murine DCs 
activated with mycobacterial antigens, resulting in low expression of DCs activation 
markers [55].   
We previously showed that p-HBAD-1 blocks the production of pro-inflammatory 
cytokines in non-prime bDCs, suggesting induction of immune tolerance.  This chapter 
confirms immune tolerance by showing increased IL-10 production in non-primed bDCs, 
with the opposite effect seen in IFN- primed bDCs. Previous studies established that IL-
10 blocks the protective pro-inflammatory response in M. tuberculosis-infected antigen-
presenting cells [356, 423]. Hence, increased IL-10 production might be associated with 
the decreased production of pro-inflammatory cytokines in non-primed bDCs. 
Furthermore, we showed that p-HBAD-1 only suppresses the expression of co-stimulatory 
molecules in non-primed bDCs, resulting in impaired dendritic cell function. The inhibitory 
effect on co-stimulatory molecules was reversed in IFN- primed bDCs, leading to 
enhanced antigen presentation to naïve T-cells and increased immune response. However, 
MHC I and MHC II expression were similar in both non-primed and IFN- primed bDCs. 
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This observation is consistent with the earlier report demonstrating that tolerogenic DCs 
poorly express costimulatory molecules compared to immunogenic DCs, but the 
expression of MHC molecule is comparable in both immunogenic and tolerogenic DCs 
[424]. Thus, these results demonstrate that p-HBAD-1 might induce tolerance in non-
primed bDCs by inhibiting secondary signals initiated by co-stimulatory molecules, 
thereby dampening DCs maturation and efficient antigen presentation required for optimal 
T-cells activation. Thus, by the lack of co-stimulatory molecules, non primed DCs are not 
to provide T cells with the necessary signal two required for optimal T cell activation. 
However, in IFN- primed bDCs, p-HBAD-1 does not induce a tolerogenic response. 
Further confirmation of tolerogenic DCs in non-primed bDCs was seen in increased 
expression of DC-SIGN known induction of immune tolerance following recognition of 
carbohydrate antigen. In conclusion, p-HBAD-1 released by M. bovis targets  DC-SIGN in 











In previously published studies of M. tuberculosis mutants deficient in the biosynthesis of 
p-HBADs, the mutants were found to grow similarly to the wild-type strain in both 
macrophages and C57BL/6 mice. However, the mutants induced a more severe and diffuse 
inflammation in the lungs compared to the wild-type strain [68]. Using in vitro studies, I 
have shown that pure p-HBAD-1 exhibits a dual role in non-primed and IFN- primed 
bDCs, with p-HBAD-1 inducing tolerogenic and immunogenic phenotypes, respectively. 
To further confirm the role of M. bovis derived p-HBAD-1 in bTB pathogenesis, it is 
important to assess the role of p-HBAD-1 by comparing M. bovis WT & mutant strains.  To 
achieve this, I developed the genetic tools needed to generate M. bovis mutants devoid of 











CHAPTER 5.  Generation of M. bovis mutant 
5.1 Introduction 
Genetic manipulation of virulent mycobacteria is complicated due to its slow growth rate 
(>24 hour doubling time), high level of illegitimate recombination, pathogenicity (requires 
working in a biosafety level three laboratory), and low uptake of DNA [426]. Several 
techniques for generating mutants that were designed to prevent a high level of illegitimate 
recombination have been described [273].  Thus, the use of counter-selectable genetic 
markers and long linear dsDNA substrates inhibit illegitimate recombination [426, 427].  
Here, I attempted generating M. bovis mutant (lacking p-HBAD-1) via chorismate pyruvate 
ligase (CPL) gene disruption by homologous recombination. The CPL gene (600 base-pair 
length) encodes the enzyme that produces p-HBAD-1  [67]. The synthesis of p-HBADs is 
thought to proceed from p-hydroxybenzoic acid [67]. CPL produces p-hydroxybenzoic 
acid from chorismate and it is the sole enzymatic source of this product [67]. The purpose 
of generating M. bovis mutant is to enable future studies to understand the role of p-HBAD-
1 in bovine TB pathogenesis by comparing M. bovis WT & mutant strains.  
5.1.1 Generation of M. bovis mutant via gene disruption by homologous 
recombination. 
The ability to select genes to knock-out from the mycobacterial genome has greatly 
improved the understanding of mycobacteria.  Here, the  CPL gene is disrupted by the 
insertion of a hygromycin-resistance gene cassette in-frame [425].  A suicide delivery 
system (containing the mutated CPL gene and selection markers) was used to deliver the 
mutated CPL gene into M. bovis genomic DNA.  The disrupted version of the CPL gene 
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replaces the wild-type version through a two-step homologous recombination process.  
Selection involves selecting a single cross over event (SCOs) followed by a double cross 
over (DCOs). Single cross-over events occur during the first recombination and involve 
integrating suicide delivery plasmid DNA bearing the mutated CPL gene into M. bovis 
chromosome. The SCOs contain both WT and mutated CPL genes. In contrast, DCOs 
(originating from the second recombination) occur when the mutated CPL gene replaces 
the M. bovis WT CPL gene. Thus the DCOs either contain WT or mutated CPL gene [425]. 
The four major steps involved in the generation of mutated CPL gene include:- generation 
and cloning of mutated CPL gene into p2NIL vector, construction of suicide delivery 
plasmid DNA, transformation of suicide delivery plasmid DNA bearing the mutated CPL 
gene to M. bovis and selection of the mutant strain using a 2-step process. 
 
5.1.1.1 Generation and cloning of mutated CPL gene into p2NIL vector 
The amplified CPL gene was first mutated by insertion of hygromycin-resistant gene 
cassettes before cloning into a p2NIL vector as outlined in the scheme below (Fig. 5.1).
 
Figure 5.1 Steps in amplification of mutated CPL gene 
 
5.1.1.2 C nst u t  n    su    e  e   e y    sm    N  
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A marker gene cassette (required for selection) obtained from the pGOAL17 vector 
following digestion with PacI enzyme was cloned into the p2NIL with mutated CPL gene 
to create a suicide delivery plasmid DNA (Fig. 5.2). The resultant suicide delivery plasmid, 
which is a non-replicative vector [428], contains a kanamycin-resistant gene (from p2NIL 
vector), hygromycin-resistant gene (from mutated CPL gene), and gene cassette 
(containing LacZ and sacB selection makers).  
 
 
Figure 5.2 Steps in construction of suicide delivery plasmid DNA 
5.1.1.3. T  ns   m t  n    su    e  e   e y    sm    N   e   n  the mut te  CP  
 ene t  M. bovis 
The suicide delivery plasmid DNA containing the mutated CPL gene was transformed or 
introduced to M. bovis, where the mutated version of the CPL gene replaces the wild-type 
version by a two-step homologous recombination process. Since the suicide delivery 
plasmid bears kanamycin and hygromycin resistant genes, as well as cassette (lacZ/SacB) 
gene, transformation into M. bovis was done in a 7H10 agar plate containing kanamycin, 
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hygromycin and X-gal  
5.1.1.4 Selection of mutant strain using a 2-step process 
5.1.1.4.1 Single cross over events (SCOs) 
Since M. bovis cannot survive independently in hygromycin and kanamycin antibiotics, it 
has to integrate with suicide vector bearing these antibiotic-resistant cassette genes. Thus, 
suicide delivery plasmid DNA carrying the mutated CPL gene integrates into M. bovis 
chromosome following transformation. Hence, the first recombination event gave rise to 
SCOs containing two copies of the gene (both mutant and wild type) and the suicide vector 
integrated into the chromosome. The blue colonies, which are the SCOs containing mutant 
and WT gene, as well as the vector, were selected because they were hygromycin and 
kanamycin resistant (Fig. 5.3).  
 
Figure 5.3 Steps involved in selecting single cross over events (SCOs) 
5.1.1.4.2 Double cross over events (DCOs) 
Here, the mutated CPL gene bearing the hygromycin-resistance gene replaces the WT CPL 
gene. Thus, a second recombination event gives rise to DCOs that are either WT or mutant 
genes. Briefly, the bluish SCOs were streaked on 7H10 agar media without antibiotics to 
allow for second recombination events (eliminate suicide vector bearing kanamycin and 
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lacZ/SacB gene). Thereafter the DCOs were selected by re-suspending SCOs to 7H9 media 
before plating it out on an agar plate containing X-gal with or without sucrose. Potential 
DCOs, which are white colonies (loss of LacZ gene) and sucrose resistant (Loss of SacB 
gene), were selected because they lost the selection markers. To confirm if the potential 
DCOs have lost kanamycin-resistant gene associated with the SCOs, DCOs were tested for 
kanamycin sensitivity by plating on agar plates with or without kanamycin. DCOs colonies 
that are sensitive to kanamycin were selected, and the mutant was further confirmed by 
doing colony PCR using kanamycin sensitive colonies (Fig. 5.4).  
 









5.2 Materials and Methods 
5.2.1 PCR amplification of CPL gene 
PCR amplification of the mutated CPL gene was performed in a total volume of 100 ul 
containing oligonucleotide primers, Phusion polymerase enzyme, dNTPs, DMSO, Phusion 
buffer, M. bovis AF2122 strain template, and sterile water. Following amplification, an 
aliquot was run in 0.8% agarose gel to confirm successful amplification. The amplified 
CPL gene was purified using an EZ-10 spin column PCR product purification kit, and the 
concentration of DNA was determined using NanoDrop® ND-1000 Spectrophotometer.  
Below is the PCR mixture setup and cycling program.  
Reaction Mixture Concentration 
Sterile dH20  
5 x phusion buffer 1 x phusion buffer 
10mM  dNTPs 200µM 
100% DMSO 6% 
100µM Forward primer 1µM 
100µM Reverse primer 1µM 
90ng/ml gDNA (M . bovis strain) 450ng 
2000 U/ml Phusion polymerase 2 units 
Total volume = 100 µl  




Step Time Temperature Cycles 
Initial denaturation 2 minutes 98 °C 1X 
Denaturation 30 seconds 98 °C 30X 
Annealing 1 minute 57 °C 30X 
Extension 1.5 minutes 72 °C 30X 
Final extension 7 minutes 72 °C 1X 
Storage Infinity 18 °C Infinity 
Table.5. 2: PCR cycling program used to amplify the CPL gene using Phusion polymerase 
 
5.2.2 Digestion of vector and insert 
In a 50 µl volume, confirmation of successful cloning of mutated CPL gene to p2NIL was 
done using single and double digestion with BamHI and HindIII. For the construction of 
suicide delivery plasmid DNA, P2NIL with mutated CPL gene and pGOAl17 was digested 
using PacI enzyme. Also, confirmation of suicide delivery plasmid DNA generation was 
done by digestion with Sal1 enzyme. Digestion reactions were gently mixed, spun down in 
microcentrifuge and incubated at 37°C overnight. 5μl volume of digested sample was run 
in agarose gel to confirm the success of digestion. 
Reaction Mixture p2NIL with Mutated CPL gene 
Sterile dH20  
10 X 2.1 NEBuffer 1X 
DNA 4 µg 
20,000 U/ml HindDIII 60 unit 
20,000 U/ml BamHI 100 unit 
Total volume =50 µl  




Reaction Mixture p2NIL with Mutated CPL gene 
Sterile dH20  
10X 2.1 NEBuffer 1X 
DNA 4 µg 
20,000 U/ml HindDIII 60 unit 
Total volume = 50 µl  
Table 5. 4: Set up for single digestion of P2NILvector with mutated CPL gene using HindIII 
Reaction Mixture p2NIL with mutated CPL gene pGOAL17 
Sterile dH20   
10 X CutSmart Buffer 1X 1X 
Vector  4 µg 
DNA Insert 4 µg  
10,000 U/ml PacI 100 unit 100 unit 
Total volume = 50 µl   
Table 5. 5: Construction of suicide delivery plasmid DNA. Set up for single digestion of  P2NILvector 
with mutated CPL gene and pGOAL17 using PacI 
 
Reaction Mixture Suicide delivery plasmid p2NIL with mutated 
CPL gene 
Sterile dH20   
10 X CutSmart Buffer 1X 1X 
   
Vector  4 µg 
DNA Insert 4 µg  
   
20,000 U/ml SalI 100 unit 100 unit 
Total volume = 50 µl   
Table 5. 6: Set up for single digestion of suicide delivery plasmid and P2NILvector with mutated CPL 





5.2.3 Ligation of the insert to vector using T4 DNA ligase enzyme 
The mutated CPL gene was ligated into p2NIL at a ratio of 1:10 using T4 DNA ligase. For 
suicide delivery plasmid generation, p2NIL with mutated CPL was ligated to gene cassette 
using T4 DNA ligase at a ratio of 1:30. Ligation reactions were incubated overnight at 16 
degrees and heat shock at 65 degrees for 10 minutes. 
Reaction Mixture Volume 
Sterile dH20  
10 x T4 buffer 1X 
p2NIL vector 15ng 
Mutated CPL gene 150ng 
400,000 U/ml T4 DNA ligase 1 µl 
Total Volume 20 µl 
Table 5. 7: Set up for ligation reaction of mutated CPL gene with p2NIL 
Reaction Mixture Volume 
Sterile dH20  
10 x T4 buffer 1X 
p2NIL with mutated CPL gene 15ng 
Cassette gene 410ng 
400,000 U/ml T4 DNA ligase 1 µl 
Total Volume 20 µl 




Following ligation of mutated CPL gene to p2NIL, the ligation mixture was transformed 
to E. coli Top 10 cells. Same E. coli Top 10 cells were also used in transformation using a 
ligation mixture containing cassette gene and p2NIL with mutated CPL. Briefly, frozen 
competent E. coli Top 10 cells were removed from the –80 °C freezer and thawed on ice 
at room temperature. 50 μl of the cells and 10 μl of the ligation mixture were dispensed 
into sterile microcentrifuge tubes chilled on ice. The tube was incubated on ice for 35 
minutes. The cells were heat-shocked at 42°C for 45 seconds in a water bath, then incubated 
in ice for 2 minutes. 500 µl of pre-warmed LB media were dispensed in the tube, and the 
mixture was incubated at 37°C in a shaking incubator (200 rpm) for 60 minutes. 250 μl 
was transferred to the center of an agar plate containing kanamycin (50 µg/ml), and a sterile 
spreader sealed in a flame was used to spread the solution over the entire surface of the 
plate. The plate was inverted and incubated overnight at 37 °C. After overnight incubation 
at 37 °C, the plate was examined for the presence of kanamycin-resistant colonies and 
stored at 4 °C.  
5.2.5 UV irradiation of suicide delivery plasmid DNA and electroporation into 
electrocompetent M. bovis 
Following plasmid purification of suicide delivery plasmid DNA, an aliquot of suicide 
delivery plasmid DNA was subjected to UV energy for a few minutes. UV treatment can 
cause the incorporation of point mutations on the treated DNA. Thereafter, 
electrocompetent M. bovis was prepared using an established protocol[429].  Briefly, M. 
bovis was grown in 30 mL of Middlebrook 7H9 liquid media to the mid-logarithmic phase 
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of growth (OD600nm ~ 0.5 to 0.7). Then, 5ug of UV treated and non-treated suicide delivery 
plasmid DNA was electroporated into electrocompetent M. bovis and incubated for 24h.  
The entire transformation mix was plated out onto 7H10 plates containing kanamycin, 

















5.3.1 Mutated CPL gene of fragment size 2.1kb amplified from pUC19 vector 
PCR was used to amplify the mutated CPL gene bearing the hygromycin-resistant gene 
cassette from the pUC19 vector.  PCR product was confirmed via gel electrophoresis. 
Result showed a correct fragment size of 2.1kb CPL gene (Fig. 5.5).  
 
Figure 5.5: Amplified mutated CPL gene of fragment size 2.1kb 
5.3.2 Mutated CPL gene of fragment size 2.1kb amplified from p2NIL vector 
following digestion with HindIII enzyme 
Amplified mutated CPL gene and P2NIL vector were first digested and purified with 
HindIII (Shown in Tables 3 & 4). Thereafter mutated CPL gene was cloned into HindIII 
sites of p2NIL vector to generate p2NIL with mutated CPL.  Following transformation into 







for screening by PCR using CPL primers. PCR products were analyzed on a 0.8% agarose. 
Results showed 2 positive clones with a fragment size of 2.1kb, which correspond to the 
mutated CPL gene (Fig. 5.6).  
 
Figure 5.6: Amplified mutated CPL gene from 2 positive clones 
 
5.3.3 Confirmation of p2NIL with mutated CPL gene from 2 positive clones using 
HindIII and BamHI enzymes 
To further confirm the 2 positive clones obtained following transformation, single and 
double digestion using HindIII and BamHI was used to digest p2NIL with mutated CPL 
gene. For clone 1, uncut or single digestion of the p2NIL construct gave a correct size 
fragment of 6.8kb (correspond to p2NIL with mutated CPL gene). However, double 
digestion of the same construct gave a 2 sized fragment of 4.7kb and 2.1kb, which 
correspond to p2NIL and mutated CPL gene, respectively. A similar observation was seen 
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with clone 2 with double digestion resulting in 2 fragments compared to single digestion. 
This data showed successful cloning of the mutated CPL gene into p2NIL vector (Fig. 5.7). 
 
Figure 5.7: Confirmation of P2NIL with mutated CPL gene from 2 positive clones using HindIII and BamHI 
enzymes 
 
5.3.4 Confirmation of pGOAL17 gene cassette of fragment size 6.3kb following 
digestion with PacI enzyme 
To construct the suicide delivery plasmid DNA, PacI enzyme was used to digest pGOAL17 
(to release the cassette gene) and p2NIL construct. The digested product was confirmed 
using gel electrophoresis. Result showed pGOAL17 gene cassette of fragment size 6.3kb 




Figure 5.8: Digestion of pGOAL17 and p2NIL construct with Pacl enzyme 
 
5.3.5 C n   m t  n    su    e  e   e y    sm   N   y    est  n w th S   1 enzyme  
The fragment containing the cassette gene (6.3kb size) from pGOAL-17 was gel purified 
and cloned into PacI site of the p2NIL construct. Following transformation in the Top 10 
cells, one positive clone was obtained. The positive clone was confirmed by digesting with 
Sal-1 enzyme, and it gave the correct one-size fragment of 13.8kb of suicide delivery 
plasmid DNA.  However, Sal-1 digestion of the p2NIL construct, which is a negative clone, 
gave a fragment size of 6.8kb. This suggests that the positive clone possesses suicide 




Figure 5.9: Confirmation of suicide delivery plasmid DNA by digestion with Sal-1 enzyme 
 
5.3.6 Se e t  n     s n  e    ss   e  e ents (SCOs) 
The suicide delivery plasmid was transformed into M. bovis, plated in a 7H10 agar plate 
containing the ampicillin, hygromycin, and x-gal selective markers, followed by incubation 
at 37℃.M. bovis transformed with suicide delivery plasmid DNA was not successful. Thus 








Homologous recombination occurs between two copies of identical or highly-homologous 
sequences and is mediated by RecA [430]. Although homologous recombination is 
relatively straightforward in Mycobacterium smegmatis, it proved far more challenging to 
perform in slow-growing mycobacteria, and the reasons for this remain largely unknown. 
However, several strategies have been used to overcome this challenge. These include the 
use of long flanking regions [431, 432], UV-treated DNA substrates [433], counter-
selectable markers [434], development of improved delivery strategies such as 
temperature-sensitive plasmids, and use of suicide (non-replicating) plasmids [434, 435]. 
In my attempt to generate M. bovis mutant using homologous recombination, some of the 
above strategies were used, and I successfully cloned and prepared plasmid constructs 
required to disrupt the gene encoding a key enzyme involved in p-HBAD synthesis in M. 
bovis. This will be used in future efforts to generate an M. bovis mutant deficient in p-
HBAD-1 for detailed studies. Thus,  naïve and BCG vaccinated mice will be challenged 
with M. bovis mutant lacking p-HBAD-1, and the pro-inflammatory response, bacterial 




CHAPTER 6: General discussion and conclusions 
The overarching goal of this research work was to understand the pathogenesis of bTB by 
assessing the immunoregulatory role of M. bovis derived p-HBAD-1 on bDCs. 
The cell envelope of all the members of M. tuberculosis complex is decorated with glycan 
and glycolipids that are involved in host-pathogen interaction and disease pathogenesis. 
Interaction of M. t tuberculosis cell envelope-derived glycolipids and glycan with DCs alter 
their cytokine production and antigen presentation efficiency [55]. However, there is 
limited information on the immunogenicity of M. bovis cell wall antigen. To fill in the 
knowledge gap, I hypothesize that M. bovis cell envelope distinct antigenic components 
induce differential pro-inflammatory responses in bDCs. This was tested by comparing the 
stimulatory effects of bPPD, CWL and CSSE on bDCs in vitro.  Results showed that  M. 
bovis-derived CSSE is a poor immune stimulator of bDCs [296]. Given that the CSSE 
fraction of M. tuberculosis has been found to be enriched in p-HBADs which suppress host 
immune response [46]. Therefore, to identify the particular molecules contributing to the 
low immune-stimulatory effect of CSSE, and we proposed that M. bovis CSSE fraction 
contains p-HBAD-1, which was confirmed via Thin-Layer Chromatography. Further 
assessment of the role of p-HBAD-1 on bDCs showed a varying effect in non-primed and 
IFN- primed bDCs.  
In non-primed bDCs, p-HBAD-1 blocks the production of pro-inflammatory cytokines 
induced by LPS, bPPD and CWL. The reduction in IL-12 and TNF- production in non-
primed bDCs is consistent with the previous observation from M. t tuberculosis derived p-
HBADs, which was reported to suppress cytokine production in bone marrow-derived 
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macrophages [404].   This suggests that activation machinery in non-primed bDCs has been 
altered by M. bovis derived p-HBAD-I.  Thus, the attenuated production of IL-12 and TNF-
 in non-primed bDCs would interfere with the activation of Th1 cell immunity (protective 
immune response), thereby tilting the immunological balance towards Th2 immune 
response [436].  
On the contrary, p-HBAD-1 strongly promotes LPS/bPPD‐stimulated IL-12 and TNF- 
production in IFN‐γ primed bDCs. This interesting observation could be related to the 
priming of DCs with rIFN-. A vital pathway for IL-12 maximal output is the requirement 
for priming of DCs and macrophages with IFN- [406]. During infection, NK cells, 
activated Th1 lymphocytes, and cytotoxic T lymphocytes (CTLs) are the principal source 
of  IFN-γ, which serve as a positive feedback mechanism for robust IL-12 production, and 
DCs are responsive to IFN- as they express IFN‐γR [437]. IFN- produced by these cells 
have a combined effect with TLR ligation to enhance DCs activation and function [406]. 
Another study reported that priming APCs with IFN-γ triggers subsequent TLRs 
inflammatory response to release high levels of pro-inflammatory cytokines [406].  
In mycobacterial infection, it has been demonstrated that in the absence of IFN-, DCs 
infected with M. tuberculosis ligand produce high levels of IL-10 and IL-23, but a small 
amount of IL-12. However, priming DCs with IFN- restores their ability to produce IL-
12 efficiently and block IL-10 production [438]. Given that IFN- priming of DCs 
promotes the maximal output of pro-inflammatory cytokines, this suggests that the 
increased pro-inflammatory response in IFN- primed bDCs is IFN‐γ dependent, which 
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supplies a positive feedback signal to bDCs. 
To reveal the molecular basis by which p-HBAD-1 mediated its effects on bDCs functions, 
we analyzed the expression of TLR 2 and 4, as well as its downstream signaling pathway. 
In non-primed bDCs, we observed that the decrease in pro-inflammatory cytokine 
production is associated with decreased expression of TLR2 and 4 and the downstream 
surface membrane signaling pathway. In contrast, increased cytokine production in IFN- 
primed bDCs is mediated via endosomal and surface membrane TLRs.  
To further understand the molecular mechanism regulating cytokine production in non-
primed and IFN- primed bDCs, the effect of p-HBAD-1 to NF-B on activation was 
determined. Following initiation of the TLR signaling pathway, many signaling proteins 
are recruited, leading to the activation of a key NF-кB transcription factor. Previous studies 
showed that the anti-inflammatory effect of various mycobacterial components is due to 
their effect on NF-B phosphorylation. For example, Liu et al. showed that M. tb 
recombinant leucine-responsive regulatory protein (rLrp) inhibits LPS-induced TNF-α, IL-
6, and IL-12 production by blocking the nuclear translocation of NF-κB [439]. 
Furthermore, mycobacterial glycolipid (PGL-1 and PGL-tb) produced by M. tb clinical 
isolates were reported to block TLR2 agonist-driven activation of NF-κB and cytokine 
production [58, 440], as well as decreased TRIF-dependent  TLR4 signaling in 
macrophages resulting in limited pro-inflammatory responses [441]. In line with this, we 
observed that p-HBAD-1 blocks the phosphorylation of NF-кB in non-primed bDCs unlike 
in IFN- primed. Given that NF-B activation regulates pro-inflammatory cytokine 
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production, this suggests that the cytokine inhibitory effect of p-HBAD-1 in non-primed 
bDCs could be related to decrease activation of NF-B. 
Induction of the proinflammatory phenotype in DCs by mycobacterial infection is 
accompanied by the regulatory response, including SOCs protein expression. The SOCs 
family of inhibitors has received a lot of attention in relation to DCs. For instance, the 
expression of SOCs protein has been shown to be up-regulated in DCs infected with M. tb 
[442]. Specifically, DCs overexpressing SOCs3 exhibited a tolerogenic phenotype that 
showed a low level of expression of IL-12 but a high level of IL-10 [443].  
It has been well established that SOCs proteins diminish the JAK/STAT signaling pathway 
and can inhibit various cytokines, resulting in the inhibition of DCs activation [444]. 
However, a more recent report shows that the function of SOCs1 and 3 goes beyond IFN-
 related JAK/STAT signaling. Thus, another report demonstrated that  SOCs1 protein 
negatively regulates TLR-related NF-B activation pathways by mediating the degradation 
of adaptor protein mal, which is involved in TLR 2 and 4 signaling [445]. Furthermore, 
various reports have demonstrated an interaction between SOCs1 with NF-B p65 protein 
[446, 447]. The inhibitory effect of SOCs protein in NF-B was reported to be due to 
specific translocation of SOCS1 protein into the nucleus, where it interacts with the NF-
κB p65 subunit within the nucleus, resulting in ubiquitination and degradation, thus 
limiting NF-κB function as a transcription factor [448]. Thus, it is possible that in non-
primed bDCs, p-HBAD-I inhibits activation of NF-κB by induction of SOCS1 and 3, which 
either block the initial steps in TLR signaling or translocate to the nucleus and cause its 
degradation. Further studies are vital to determine the mechanism through which p-HBAD-
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1 regulates NF-κB phosphorylation in both IFN- primed and non-primed bDCs. 
Another immunoregulatory feature of DCs is the secretion of IL-10 in the course of 
inflammatory responses [449]. Interleukin-10 is a potent anti-inflammatory cytokine that 
has been shown to directly or indirectly affect multiple cell types, including DCs, 
macrophages, and T-cells [450]. The dominant function of IL-10 is to deactivate DCs and 
macrophages, resulting in decreased Th1 cytokine production [451], which may have far-
reaching consequences on both innate and adaptive immunity in vivo. Increased IL-10 
production following infection with many intracellular pathogens is associated with 
decreased resistance to infection [449]. In mycobacterial infection, IL-10 inhibits the 
production of pro-inflammatory cytokines in M. tb infected macrophages, resulting in the 
prevention of reactive nitrogen/oxygen intermediates released by macrophages [452]. In 
this study, p-HBAD-1 induced higher levels of IL-10 production in non-primed bDCs 
stimulated with LPS and bPPD, compared to IFN- primed bDCs. Therefore, it could be 
that increased IL-10 released by non-primed bDCs is responsible for the downregulation 
of IL-12 and TNF- production, thereby tilting Th1 immune response towards non-
protective Th2 response.  
Characteristic immunoregulatory factors associated with tolerogenic DCs include 
increased anti-inflammatory and decreased pro-inflammatory cytokines production. Since 
p-HBAD-1 promotes proinflammatory response in IFN- primed DCs, and the opposite 
effect was seen in non-primed bDCs. This suggests that p-HBAD-1 might be inducing a 
tolerogenic and immunogenic response in non-primed and IFN- primed bDCs, 
respectively.  It has been established that immunogenic DCs are known for high expression 
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of costimulatory molecules, which promote optimal T-cell activation [453], while 
tolerogenic DCs weakly express costimulatory molecules that impair T-cell proliferation 
[453]. In addition,  both immunogenic and tolerogenic DCs are known to express common 
markers, such as MHC Class I and II molecules [453].  Consistent with these studies, our 
results confirmed the tolerogenic effect of p-HBAD-1 in non-primed bDCs, with results 
depicting decreased expression of co-stimulatory, which was reversed in IFN- primed 
bDCs.  
Recognition receptors expressed by DCs play a role in the induction of either tolerance or 
immunogenic response. While TLR 2/4 recognizes protein or lipid antigen and induces an 
immunogenic response, DC-SIGN only recognizes carbohydrate antigen and induces a 
tolerogenic response in DCs [454]. Therefore, further confirmation of tolerogenic 
phenotype in non-primed bDCs suggests that p-HBAD-1 might be targeting DC-SIGN to 
induce immune tolerance. This data is consistent with the earlier observation in DCs where 
ManLAM suppresses activation of DCs by targeting DC-SIGN [64].   
In summary, this study showed that p-HBAD-1 might have a dual function. Based on these 
findings, I proposed a model for the dual role of p-HBAD-1 in bDCs and the mechanism 
through which it mediates its immune suppressive effect. In non-primed bDCs, p-HBAD-
1 inhibits the pro-inflammatory response by blocking TLRs/NF-B signaling pathways.  
This inhibitory effect is associated with the increased feedback inhibition exerted by IL-10 
and SOCs proteins. This data suggest a tolerogenic response confirmed by reduced 
expression of co-stimulatory molecules and increased expression of DC-SIGN. Thus, in 
non-primed bDCs, M. bovis evade host immune response by releasing p-HBAD-1, which 
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suppresses host immune response, thereby increasing the chance of survival and 
pathogenesis. 
 On the contrary, p-HBAD-1 does the opposite in IFN- primed bDCs by promoting a 
robust pro-inflammatory response. The mechanism underlying IFN- mediated priming 
includes enhanced TLRs 2 and 4 expressions, which promote TLRs signaling and 
activation of NF-B resulting in enhanced production of pro-inflammatory cytokines. IFN-
 achieved these by inactivating feedback inhibition induced by regulatory proteins (IL-10 
and SOCS1/3) and increasing the expression of activation markers required for optimal T-
cell activation. Thus in IFN- primed bDCs, p-HBAD-1 induces an excessive pro-












Theoretically, DCs found in various locations in and around the granuloma may be serving 
very different purposes. These immune cells exist at different maturation phases in the 
infected lung, with both matured and immature DCs responding differently to IFN- 
resulting in IFN- and non-primed bDCs, respectively. The dual effect exerted by M. bovis 
derived p-HBAD-1 on IFN- primed and non-primed bDCs enable it to adapt within the 
host cell by balancing their ability to induce a protective immune response and immune 
tolerance mechanism. If the bacterium is not well adapted in the host, it can kill the host 
via its virulence factors, or the bacteria can be eliminated by the host response. Through p-
HBAD-1, M. bovis maintain balance in host protective response and tolerance, thereby 
allowing M. bovis to adapt and survive in the dormant phase of chronic infection.  
In the context of M. tb infection, during the early phase of infection, no IFN- is produced 
due to the lack of M. bovis specific T- cells resulting generation of non-primed bDCs that 
causes immune tolerance. Previous studies showed that delay in T- cell priming by bDCs 
leads to latent mycobacterial infection [455].  Thus, the non-primed DCs with reduced 
proinflammatory cytokine production (IL-12) caused a delay in T- cell priming, which 
promotes latency. Within the granuloma, following the onset of adaptive immunity, bDCs 
localized in T-cell and NK- cell zone transforms to IFN- primed bDCs while bDCs 
localized in non-T-cell zone converts to non-primed bDCs, which maintains granuloma by 
inducing an immunogenic and tolerogenic response, respectively. Collectively, this study 
points to a novel effect of p-HBAD-1 as an immunoregulatory molecule (Fig. 6.1). 
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CHAPTER 7. Limitations 
The utilization of an in vitro model is the major limitation of this study because some of 
the results generated in vitro might not always correlate with the in vivo results, leading to 
over-interpretation of the results and erroneous conclusions.  
The growing field of immunometabolism has demonstrated how metabolic cellular 
reactions and processes not only provide a means to generate ATP and biosynthetic 
precursors, but are also a way of controlling immunity and inflammation. Metabolic 
reprogramming of immune cells is crucial for both inflammatory as well as anti-
inflammatory responses. Activation of DCs or macrophages with a range of stimuli, 
including LPS [456] and TLR3 ligand poly (I:C) [457], induces a metabolic switch from 
OXPHOS to glycolytic pathway, in a phenomenon similar to the Warburg effect. 
Therefore, it would have been fascinating to determine in detail whether p-HBAD-1 affects 
the metabolic reprogramming of DCs following LPS/bPPD stimulation of non-primed and 
IFN- primed bDCs. Specifically, it would be necessary to determine whether p-HBAD-1 
promotes Warburg metabolism effect on cytokine production by altering glycolytic 
pathway.  
Furthermore, we showed that p-HBAD-1 treatment upregulates the expression of  SOCs1 
and 3 in bDCs treated with either LPS/bPPD. The data would have been strengthened if we 
knocked down SOCs1 and 3 by siRNA to definitively determine whether phosphorylation 
of MAPKs and NF-B proteins and subsequent cytokine production in LPS/bPPD-treated 
cells following p-HBAD-1 treatment are rescued. Also, it would have been interesting to 
look for the expression of other intracellular regulators of cytokine production in DCS like 
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Toll interacting protein (TOLLIP) and whether their activation is upregulated upon p-
HBAD-1 treatment.   
This study also demonstrated that p-HBAD-1 promotes a tolerogenic phenotype in non-
primed bDCs activated with either LPS/bPPD. Besides low expression of costimulatory 
molecules and upregulation of anti-inflammatory cytokines, Indoleamine 2, 3 
dioxygenases (IDO), which is the immune-regulatory enzyme that participates in 
immunological tolerance, was not determined. In addition, the ability to expand regulatory 
T lymphocytes (a distinctive feature of tolerogenic DCs) was not determined. Thus, this 
study would have been strengthened by assessing whether p-HBAD-I induced non-primed 
bDCs to trigger activation of IDO and proliferation of regulatory T lymphocytes. 
Granulomas limit bacterial growth in various ways, including oxygen and nutrient 
deprivation, acidic pH, and production of host factors such as nitric oxide. Dormancy 
survival regulator (DosR) is a transcription factor that plays a role in gene regulation and 
is strongly induced during hypoxia. Thus, DosR plays a key regulatory role in the 
adaptation of bacilli to survival under hypoxic conditions. It would have been interesting 
to determine the transcriptional behavior of genes involved in the p-HBAD-1 biosynthesis 
in a hypoxic condition. Specifically, it would be necessary to determine whether the M. 
bovis grown in hypoxic conditions induces the production of p-HBAD-1. This can be 
achieved by extracting p-HBAD-1 from the culture filtrate of  M. bovis grown in hypoxic 





Determine how p-HBAD-1 regulates SOCs1 and 3 protein expressions or enhance MAPKs/  
NFkB phosphorylation 
The expression of SOCs1 and 3 proteins were higher in non-primed compared to IFN- 
primed bDCs. This suggests that p-HBAD-1 might act as a negative regulator of SOCs 
proteins in IFN- primed bDCs.   Also, this indicates a direct or indirect association 
between SOCs proteins and p-HBAD-1. Thus, it could be that IFN- priming of bDCs 
enables binding of p-HBAD-I to SOCs protein, thereby preventing their expression by 
directly or indirectly affecting the stability of SOCs proteins or enhancing their 
degradation. To determine whether p-HBAD-1 directly interacts with SOCs protein in 
bDCs, immunoprecipitation followed by western blotting or CHIP assays could be used. 
 
Phosphorylation of intracellular signaling protein (MyD88) involved in TLR4 signaling in 
p-HBAD-1 treated non-primed and IFN- primed bDCs needs to be further investigated. 
 The response of bDC to LPS/bPPD in the presence of p-HBAD-1 is greatly influenced by 
the MyD88-dependent signaling pathway (Akira et al., 2004). The TIRAP–MyD88 
dependent pathway plays a key role in regulating early NF-B activation and pro-
inflammatory cytokine production such as IL-12. Activation of MyD88 adaptor molecule 
results in recruitment and activation of the downstream proteins involved in LPS-TLR4 
signaling. Thus, further investigation of MyD88 protein, which is the first protein recruited 
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during LPS/bPPD-TLR4 signaling, is necessary. This could be achieved using Western 
blotting technique. 
Determine whether bDCs treated with p-HBAD-1 promote the expansion of regulatory T 
lymphocytes. 
 Tolerogenic DCs play essential roles in immune-related diseases and induce immune 
tolerance by shaping T-cell responses. The ability to expand regulatory T-cells is a 
distinctive feature of tolerogenic DCs [157]. Since the above findings are suggestive of a 
tolerogenic profile for non-primed bDCs treated with p-HBAD-1, it will be imperative to 
further investigate whether p-HBAD-1 treated non-primed bDCs triggered the proliferation 
of CD4+C25+FoxP3+ T lymphocytes. Thus, examining whether non-primed bDCs treated 
with p-HBAD-1 induce T-reg cell proliferation via mixed lymphocyte reaction (MLR) 
could be done using BrdU ELISA  
Using CRISPR-CAS 9 to generate a mutant that lacks p-HBAD-1AD-1: Following 
mutation of the CPL gene, the absence of p-HBAD-1 will be determined using TLC. 
Thereafter mice (naïve and BCG immunized) will be challenged with M. bovis WT and 
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